{"docstore/data": {"f1376409-62d5-4a48-bfc2-f6919d3130da": {"__data__": {"id_": "f1376409-62d5-4a48-bfc2-f6919d3130da", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a903647e-f527-4bce-acb1-29f0dee53783", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022. ", "original_text": "On the basis of U.S. "}, "hash": "4f5bfb1cf05f87659c7e1025136f9ef4b4dabaaf05c467f019884c6a50fe25d7", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion. ", "start_char_idx": 0, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a903647e-f527-4bce-acb1-29f0dee53783": {"__data__": {"id_": "a903647e-f527-4bce-acb1-29f0dee53783", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1376409-62d5-4a48-bfc2-f6919d3130da", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bde513f5f03c169d53af79467988893981b03fc63df188a8a668ac4f9e9b6e3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60912c69-6218-41c7-aaf3-002514baea26", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter. "}, "hash": "95fe72070f158ce5851a538016cc1b7389e41a8929cdda91c27ffc5f2dd2a2fb", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 542, "end_char_idx": 563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60912c69-6218-41c7-aaf3-002514baea26": {"__data__": {"id_": "60912c69-6218-41c7-aaf3-002514baea26", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a903647e-f527-4bce-acb1-29f0dee53783", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34f2536f60cdadf4d509487625fbfdf724ddbf0f76a9c35189d8f76e9a30e106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36c74af9-a578-4373-aced-70467b2edbec", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n"}, "hash": "8bf44e651a8ab635460ce7404417311f5132468c707414296de267df8dcce37f", "class_name": "RelatedNodeInfo"}}, "text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter. ", "start_char_idx": 563, "end_char_idx": 736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36c74af9-a578-4373-aced-70467b2edbec": {"__data__": {"id_": "36c74af9-a578-4373-aced-70467b2edbec", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60912c69-6218-41c7-aaf3-002514baea26", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d42e830e59c6d223d45eb13fb0429bfc3e12b850f89cab795f63932add441686", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a2cc351-a57d-4ace-b88a-e1338051ea30", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2022. "}, "hash": "9cf62b188f2623376855ef3ab5a42ef8a1f633b74c4f0a99953474a77a34210a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n", "start_char_idx": 736, "end_char_idx": 921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a2cc351-a57d-4ace-b88a-e1338051ea30": {"__data__": {"id_": "5a2cc351-a57d-4ace-b88a-e1338051ea30", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2022. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36c74af9-a578-4373-aced-70467b2edbec", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3750184e2b481caa6acfee8fbda7f922986d54a350e2c78376bff90c4599c8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4ed20b7-50a5-4f89-84a4-0185ecb2625c", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. "}, "hash": "1c8b33758f45fe84c3757609a006ac06ff7dd50bb66835bd82df67ff692239c6", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is updating its outlook for fiscal year 2022. ", "start_char_idx": 921, "end_char_idx": 985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4ed20b7-50a5-4f89-84a4-0185ecb2625c": {"__data__": {"id_": "d4ed20b7-50a5-4f89-84a4-0185ecb2625c", "embedding": null, "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a2cc351-a57d-4ace-b88a-e1338051ea30", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2022. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c308696e350b3f148d79a48fccf3d25e36ff9330a24bf56b61de762467d59073", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fd20d5f-1621-4b4f-ab57-b11a3cac7397", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n"}, "hash": "39424b7521b3644003afc2d3524c746677be655160445c2b0de1dfac4eecba09", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "start_char_idx": 985, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fd20d5f-1621-4b4f-ab57-b11a3cac7397": {"__data__": {"id_": "1fd20d5f-1621-4b4f-ab57-b11a3cac7397", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4ed20b7-50a5-4f89-84a4-0185ecb2625c", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a535997eed95f90ca67c34545a6d0d3ce2994e0a83ed50869f517eefbff67ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47cf6cb5-c6f5-43cd-8b92-0b06693083bc", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n", "original_text": "\"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n"}, "hash": "4a9c1c0a962e26d5b6795e460f15ffc1f02bb3494241064a29b50980b2211bd8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n", "start_char_idx": 1109, "end_char_idx": 1231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47cf6cb5-c6f5-43cd-8b92-0b06693083bc": {"__data__": {"id_": "47cf6cb5-c6f5-43cd-8b92-0b06693083bc", "embedding": null, "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n", "original_text": "\"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fd20d5f-1621-4b4f-ab57-b11a3cac7397", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2bed505b58bce6c30217f19f920b4d9029c1152cdaf72c46a2ae9a6467971e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b71f098-9369-4e32-adb7-7fc2796626d0", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "\"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr. "}, "hash": "fd58a532335e113cbaab0ec6f7a73a6d25fb8a10fe8ef8858d88d3a08dcde8f0", "class_name": "RelatedNodeInfo"}}, "text": "\"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1231, "end_char_idx": 1553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b71f098-9369-4e32-adb7-7fc2796626d0": {"__data__": {"id_": "4b71f098-9369-4e32-adb7-7fc2796626d0", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "\"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47cf6cb5-c6f5-43cd-8b92-0b06693083bc", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n", "original_text": "\"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f3960369c347f79c3d3d26d5dae03106a49c2c695a9fdf7a20aec8da3715707", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48107d5d-81f2-4dd2-aca4-2c5face58097", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "Collis continued. "}, "hash": "e783a2314fd2a877bac77cf3417afbfff3882b835361d14b19ed5093010e4a8a", "class_name": "RelatedNodeInfo"}}, "text": "\"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr. ", "start_char_idx": 1553, "end_char_idx": 1773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48107d5d-81f2-4dd2-aca4-2c5face58097": {"__data__": {"id_": "48107d5d-81f2-4dd2-aca4-2c5face58097", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b71f098-9369-4e32-adb7-7fc2796626d0", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "\"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cd35f6cf7dbf3f40a12e9b207df51e7cee90c071b388f109e04c407eeac5193", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61c8d977-2276-40ca-bd05-0259ac3251de", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "\"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n"}, "hash": "aa84d2b6d2272045420fff7619510060e8a9ce44b7baeafb3ae907c58e839596", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1773, "end_char_idx": 1791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61c8d977-2276-40ca-bd05-0259ac3251de": {"__data__": {"id_": "61c8d977-2276-40ca-bd05-0259ac3251de", "embedding": null, "metadata": {"window": "\"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "\"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48107d5d-81f2-4dd2-aca4-2c5face58097", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.80 to $11.05 to a range of $10.90 to $11.10.\n \"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41c75cf67dfb86e661bdd8ec4f6e413647e77a0d2095826f4e7c8c602e0d5f18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac2b8d21-8cde-47c0-a84c-dc396cbd16e9", "node_type": "1", "metadata": {"window": "\"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1"}, "hash": "a5ca410cd4a6e24c5c380caa1984073ef1c2521eda22542f83ed6e3d8fe04b4a", "class_name": "RelatedNodeInfo"}}, "text": "\"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n", "start_char_idx": 1791, "end_char_idx": 2094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac2b8d21-8cde-47c0-a84c-dc396cbd16e9": {"__data__": {"id_": "ac2b8d21-8cde-47c0-a84c-dc396cbd16e9", "embedding": null, "metadata": {"window": "\"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e4519c1dc2e9dd993e1ec8535f24e4f9c150587d7091217079a71336893bdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61c8d977-2276-40ca-bd05-0259ac3251de", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen delivered another quarter of strong results, and we have raised our full year outlook, driven by our team\nmembers' continued strong execution, our differentiated solutions, and the resilience of our businesses,\" said Steven H. Collis,\nChairman, President & Chief Executive Officer of AmerisourceBergen.\n \"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "\"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ebe6be2adb9f1b7096a5c15b520d4caae1912819ccfd669f9897e1749495f38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e888d6ae-a6bb-4743-93c1-6276b456ccdd", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S. ", "original_text": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "ee5fd4ed800e1c548742e8bfbe806512581d410b23d7021aee45dfaea0a641f2", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "start_char_idx": 2094, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e888d6ae-a6bb-4743-93c1-6276b456ccdd": {"__data__": {"id_": "e888d6ae-a6bb-4743-93c1-6276b456ccdd", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S. ", "original_text": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac2b8d21-8cde-47c0-a84c-dc396cbd16e9", "node_type": "1", "metadata": {"window": "\"As a global healthcare solutions leader, driven by our 42,000 team members, we continue to deliver on our strategic imperatives\nand further strengthen our value proposition to our upstream and downstream partners,\" Mr.  Collis continued.  \"We remain guided\nby our purpose of being united in our responsibility to create healthier futures - and inspired by the importance of our role at the\ncore of the global pharmaceutical supply chain, supporting pharmaceutical innovation and facilitating access to critical medications\naround the world.\"\n Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "original_text": "Third Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $60.1B $60.1B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.3B\nOperating Income $487M $756M\nInterest Expense, Net $53M $53M\nEffectiv e Tax Rat e 23.7% 20.2%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $407M $555M\n1", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1478e834886ca6368a2acbc5526cf518c1a18933be11f63daf0b001ba47c7098", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41ff12a5-d804-4c9d-be01-ce7aa020028e", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "39bef6742175191e83ba4cd0d5ad1a1ac4d36705cba2a0f18ed41468053536b4", "class_name": "RelatedNodeInfo"}}, "text": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41ff12a5-d804-4c9d-be01-ce7aa020028e": {"__data__": {"id_": "41ff12a5-d804-4c9d-be01-ce7aa020028e", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e888d6ae-a6bb-4743-93c1-6276b456ccdd", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S. ", "original_text": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f1638a68417de2c6004a6daa195964a893230234846b1762500c84b3d5f4666", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6284bb7b-7d00-4181-a24b-53bb61ef5f5f", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n"}, "hash": "b08a6831f4c63c3beb543f5032f24262335d7f909510e6f3e6ecbeead5aef9d5", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 206, "end_char_idx": 298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6284bb7b-7d00-4181-a24b-53bb61ef5f5f": {"__data__": {"id_": "6284bb7b-7d00-4181-a24b-53bb61ef5f5f", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41ff12a5-d804-4c9d-be01-ce7aa020028e", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac0adee00beec0accea4babc505b8f730fac2ef256c92384b4de83973707c8ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53658c5a-d2f3-4a5b-b1fb-9679c4025082", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S. "}, "hash": "191f6e4df71c568e71f358a4c81201a888ba04c6d740d31a414ae88f02c952da", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n", "start_char_idx": 298, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53658c5a-d2f3-4a5b-b1fb-9679c4025082": {"__data__": {"id_": "53658c5a-d2f3-4a5b-b1fb-9679c4025082", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6284bb7b-7d00-4181-a24b-53bb61ef5f5f", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e936985b74d590979fb8e5320e78a63c2fd75942695100f203cc9b35970daaae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfcdce41-9dda-4320-8705-cf5abbce8edb", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter. ", "original_text": "Healthcare Solutions\nrevenue.\n"}, "hash": "810fa3def909330cd484cb374ffedf49ae981896d0f337983b4da4636a2d1855", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S. ", "start_char_idx": 520, "end_char_idx": 902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfcdce41-9dda-4320-8705-cf5abbce8edb": {"__data__": {"id_": "bfcdce41-9dda-4320-8705-cf5abbce8edb", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter. ", "original_text": "Healthcare Solutions\nrevenue.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53658c5a-d2f3-4a5b-b1fb-9679c4025082", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18a6a043ba5dd2abc078039ba50b37507e1cb88438d0891434815dd427ca6d1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "026cf758-3c32-4623-b161-cbd12a658a87", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. "}, "hash": "a602d60a939f00587dc08856cbec2371a39b98f5a958552ab100a64d5b2866af", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nrevenue.\n", "start_char_idx": 902, "end_char_idx": 932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "026cf758-3c32-4623-b161-cbd12a658a87": {"__data__": {"id_": "026cf758-3c32-4623-b161-cbd12a658a87", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfcdce41-9dda-4320-8705-cf5abbce8edb", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter. ", "original_text": "Healthcare Solutions\nrevenue.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b55918f055981c3bfde0469f55ee51a0fa1d62f4e9672a309537bd160b59f1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "453c436f-ab52-46fd-acaa-72487c0b22a0", "node_type": "1", "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter. ", "original_text": "Healthcare Solutions.\n"}, "hash": "4a8d5e1df734bc760c08cf7e4d9b11f8ae1c0cf7a6a70a58e9f41193aae65706", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "start_char_idx": 932, "end_char_idx": 1295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "453c436f-ab52-46fd-acaa-72487c0b22a0": {"__data__": {"id_": "453c436f-ab52-46fd-acaa-72487c0b22a0", "embedding": null, "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter. ", "original_text": "Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "026cf758-3c32-4623-b161-cbd12a658a87", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8aa9be1440ae25d1894516f2bae451890e1f68ff461bcbd74bf6adc43ad0c58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab055769-4aac-4a42-b35d-24bd2dc85394", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n", "original_text": "The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter. "}, "hash": "8710c750b544451e9e5c80951a752804e4ebe9ed6e0daf0df77dd6929b5c7200", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions.\n", "start_char_idx": 1295, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab055769-4aac-4a42-b35d-24bd2dc85394": {"__data__": {"id_": "ab055769-4aac-4a42-b35d-24bd2dc85394", "embedding": null, "metadata": {"window": "Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n", "original_text": "The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "453c436f-ab52-46fd-acaa-72487c0b22a0", "node_type": "1", "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter. ", "original_text": "Healthcare Solutions.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19abf7239b9794c1321b558f5c5881317a55c333d455a5e12f53dfed0af6fbdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2849634-6cfc-496b-ae6e-02babf2f21ba", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit. ", "original_text": "Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n"}, "hash": "2f75b4040efc64212c99edcfd4322781efa3ceec48584d34a0612d791ee2d4af", "class_name": "RelatedNodeInfo"}}, "text": "The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter. ", "start_char_idx": 1317, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2849634-6cfc-496b-ae6e-02babf2f21ba": {"__data__": {"id_": "a2849634-6cfc-496b-ae6e-02babf2f21ba", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit. ", "original_text": "Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab055769-4aac-4a42-b35d-24bd2dc85394", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n", "original_text": "The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d8e4cc7fe386165f5c80eb5394a1adb97e1f562196b68e9bb2fee5939755b34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad9ac889-dab6-432a-b1ac-74209b10ca80", "node_type": "1", "metadata": {"window": "Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter. "}, "hash": "b9d5b2186e425bbeef160eb8c41941b09a1673b4814d866ed7e0cbd488c94129", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n", "start_char_idx": 1677, "end_char_idx": 1794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad9ac889-dab6-432a-b1ac-74209b10ca80": {"__data__": {"id_": "ad9ac889-dab6-432a-b1ac-74209b10ca80", "embedding": null, "metadata": {"window": "Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2849634-6cfc-496b-ae6e-02babf2f21ba", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2022 was $2.0 billion, a 6.7 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in International Healthcare Solutions, which was\nlargely driven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit. ", "original_text": "Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72cea1231e741b1b03708c735f5992613e189c5cb7ac59bb868cdf58d6b7c58c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f3151ec-24eb-4b48-a92e-b7651dfe3ec3", "node_type": "1", "metadata": {"window": "The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n"}, "hash": "b2074233f63bf9be8538927c977034c3abff12e2cd4e78ecaf0cd64df412e2ac", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter. ", "start_char_idx": 1794, "end_char_idx": 2285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f3151ec-24eb-4b48-a92e-b7651dfe3ec3": {"__data__": {"id_": "3f3151ec-24eb-4b48-a92e-b7651dfe3ec3", "embedding": null, "metadata": {"window": "The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad9ac889-dab6-432a-b1ac-74209b10ca80", "node_type": "1", "metadata": {"window": "Healthcare Solutions.\n The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56a72628d385b9c8d44ea0304cfab83e6c9855ed283a91c05ebb6164f54d529a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb448d88-0bfe-4a8c-ace7-c53ec5794d6c", "node_type": "1", "metadata": {"window": "Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022. ", "original_text": "Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit. "}, "hash": "d8427825bb24fb20f07839fcbe26f019cc4b5855900c977b121a52efdc9980a5", "class_name": "RelatedNodeInfo"}}, "text": "The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n", "start_char_idx": 2285, "end_char_idx": 2461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb448d88-0bfe-4a8c-ace7-c53ec5794d6c": {"__data__": {"id_": "bb448d88-0bfe-4a8c-ace7-c53ec5794d6c", "embedding": null, "metadata": {"window": "Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022. ", "original_text": "Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f3151ec-24eb-4b48-a92e-b7651dfe3ec3", "node_type": "1", "metadata": {"window": "The increase in gross profit was partially offset by a decrease in gains related to antitrust litigation settlements, a LIFO\nexpense in the current year period versus a LIFO credit in the previous fiscal year period, and the Turkey foreign exchange\nremeasurement expense due to its economy now being considered highly inflationary in the current year quarter.  Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ed362c407f2bb5c9cbe308585541bb770a7b3b7023047f38ecd62356db4eb82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e832744a-6f2c-4019-b8b9-20ec54fa0ebe", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n", "original_text": "Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n"}, "hash": "a94cc0f8682236da497fe155a9fb0461d87b70a0f163fb1ffe3b00f302566429", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit. ", "start_char_idx": 2461, "end_char_idx": 2721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e832744a-6f2c-4019-b8b9-20ec54fa0ebe": {"__data__": {"id_": "e832744a-6f2c-4019-b8b9-20ec54fa0ebe", "embedding": null, "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n", "original_text": "Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb448d88-0bfe-4a8c-ace7-c53ec5794d6c", "node_type": "1", "metadata": {"window": "Gross profit\nas a percentage of revenue was 3.36 percent, a decrease of 18 basis points from the prior year quarter.\n Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022. ", "original_text": "Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1be11af99de2a3836f2bc7ace36c8ce061563841b95977f468ae7c3c47bb530", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68291281-5c35-4128-85b2-a17d0934b946", "node_type": "1", "metadata": {"window": "The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter. ", "original_text": "Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "01e77fead36519a5e2616950751358e0c7b4fd3000609a8051efb69ff9253402", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n", "start_char_idx": 2721, "end_char_idx": 2890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68291281-5c35-4128-85b2-a17d0934b946": {"__data__": {"id_": "68291281-5c35-4128-85b2-a17d0934b946", "embedding": null, "metadata": {"window": "The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter. ", "original_text": "Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e832744a-6f2c-4019-b8b9-20ec54fa0ebe", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2022, operating expenses were $1.5 billion, a 20.6 percent increase\ncompared to the same period in the previous fiscal year, primarily as a result of increases in distribution, selling, and\nadministrative expenses and depreciation and amortization expense compared to the prior year quarter, largely due to the\nJune 2021 acquisition of Alliance Healthcare, and a goodwill impairment charge related to Profarma in the current year\nquarter.  The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n", "original_text": "Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0e01e6698032cf70e97bd58067dba2dbec6b7228f9f81d1bb43ba02167c7426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26bc811a-7026-4400-85a6-49bb30a1b111", "node_type": "1", "metadata": {"window": "Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022. "}, "hash": "8f748c7305b6e139c8fb2df9f1e5962a667a7e7ad98b0c2a623468217e4e7ade", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 2890, "end_char_idx": 3140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26bc811a-7026-4400-85a6-49bb30a1b111": {"__data__": {"id_": "26bc811a-7026-4400-85a6-49bb30a1b111", "embedding": null, "metadata": {"window": "Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68291281-5c35-4128-85b2-a17d0934b946", "node_type": "1", "metadata": {"window": "The increase in operating expenses was partially offset by a reduction of opioid legal settlement accruals as the prior\nyear quarter included a $124.3 million expense accrual.\n Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter. ", "original_text": "Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87524065136e1deb4a25b7acdff19c137e45896dd8986e6d50da68c7927eca51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89665b11-691c-4dc1-b5fe-c6a9d954a976", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc. ", "original_text": "This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n"}, "hash": "a55b76161672be60b30ebe22b7eb9468415c09bb2006dbe14fc8c29a73546225", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022. ", "start_char_idx": 3140, "end_char_idx": 3239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89665b11-691c-4dc1-b5fe-c6a9d954a976": {"__data__": {"id_": "89665b11-691c-4dc1-b5fe-c6a9d954a976", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc. ", "original_text": "This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26bc811a-7026-4400-85a6-49bb30a1b111", "node_type": "1", "metadata": {"window": "Operating Income:  In the third quarter of fiscal 2022, operating income was $487.3 million, a 21.5 percent decrease compared\nto the same period in the previous fiscal year due to the increase in operating expenses and partially offset by higher gross\nprofit.  Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "383165ae9ebc33e337a1d4a2df0109c03c074d08cb914fb7cfaa923c1b9b660f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbc1f0f2-87bf-45d1-92e3-b6c25d8e6759", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter. "}, "hash": "34830408ecab416c183813ce48a847b7c37a2ce8482725187a2b52faa542133c", "class_name": "RelatedNodeInfo"}}, "text": "This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n", "start_char_idx": 3239, "end_char_idx": 3363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbc1f0f2-87bf-45d1-92e3-b6c25d8e6759": {"__data__": {"id_": "dbc1f0f2-87bf-45d1-92e3-b6c25d8e6759", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89665b11-691c-4dc1-b5fe-c6a9d954a976", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.81 percent in the third quarter of fiscal 2022, a decrease of 35\nbasis points when compared to the prior year quarter.\n Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc. ", "original_text": "This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6da582ee10b67967abda4e6ea3302dde473d0f328fc08768a405f4f8b9c0d4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1b99932-ef6d-45e5-8b63-c8fb74f3069b", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n"}, "hash": "146bc1b14f63ce364df8d49ed554fa2ba3f5817279aaa715a91acf0008a88f5b", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter. ", "start_char_idx": 3363, "end_char_idx": 3553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1b99932-ef6d-45e5-8b63-c8fb74f3069b": {"__data__": {"id_": "c1b99932-ef6d-45e5-8b63-c8fb74f3069b", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbc1f0f2-87bf-45d1-92e3-b6c25d8e6759", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the third quarter of fiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b354bd4ce9b39d575f990be104e6808d2086f51389c7c6bfa84acb7bc1361fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f30c214d-8715-4fd1-b5b2-32a5fdd0cb57", "node_type": "1", "metadata": {"window": "This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc. "}, "hash": "6f4862884cfb70d9ce422ad767b679aa84483ce477ecb8accbfbf44569313a16", "class_name": "RelatedNodeInfo"}}, "text": "The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n", "start_char_idx": 3553, "end_char_idx": 3668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f30c214d-8715-4fd1-b5b2-32a5fdd0cb57": {"__data__": {"id_": "f30c214d-8715-4fd1-b5b2-32a5fdd0cb57", "embedding": null, "metadata": {"window": "This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1b99932-ef6d-45e5-8b63-c8fb74f3069b", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the third quarter of fiscal 2022.  This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c481fd30fba371877a92811b858a0f0057777267d6621b015a2f4a4392486cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afc2ab63-0334-4ad8-95ba-59f438f4d763", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "(\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n"}, "hash": "686dc5c08a2b7f09a40ebadd95c62556928faee02800d7d6b0e825710a01975b", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc. ", "start_char_idx": 3668, "end_char_idx": 4067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afc2ab63-0334-4ad8-95ba-59f438f4d763": {"__data__": {"id_": "afc2ab63-0334-4ad8-95ba-59f438f4d763", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "(\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f30c214d-8715-4fd1-b5b2-32a5fdd0cb57", "node_type": "1", "metadata": {"window": "This compares to 48.5 percent in\nthe prior year quarter, which was negatively impacted by tax reform in the United Kingdom.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52126c3a02bcf0d4d686aaf65e8eb898bd60a9455302cd73f73e9cd6ba312950", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5f87745-10df-4b61-bbdf-8a119c272e0b", "node_type": "1", "metadata": {"window": "The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "a91922147da154b866e90ad1c9447633cd72d0837fac18c8a9e8a6861d3f6008", "class_name": "RelatedNodeInfo"}}, "text": "(\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n", "start_char_idx": 4067, "end_char_idx": 4173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5f87745-10df-4b61-bbdf-8a119c272e0b": {"__data__": {"id_": "b5f87745-10df-4b61-bbdf-8a119c272e0b", "embedding": null, "metadata": {"window": "The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afc2ab63-0334-4ad8-95ba-59f438f4d763", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.92 in the third quarter of fiscal 2022, a 37.1 percent increase\ncompared to $1.40 in the previous fiscal year\u2019s third quarter.  The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "(\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a775a8bffb7c5061f2b30bb055f2e7dbfba6070a7afc28c0bfe22a6ce76711bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0e9cf2b-31b9-4fa3-ac11-d5c47ebb6ff5", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "In the third quarter of fiscal 2022, revenue was\n2"}, "hash": "2fa5f400f97e27a85eedd737bc67ede6ae98f9263e2c9300314671252ff36280", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 4173, "end_char_idx": 4290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0e9cf2b-31b9-4fa3-ac11-d5c47ebb6ff5": {"__data__": {"id_": "c0e9cf2b-31b9-4fa3-ac11-d5c47ebb6ff5", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "In the third quarter of fiscal 2022, revenue was\n2", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa40c07bccb6dcc74799e655d35bdfb2cb4e1a4d627d100f37c85caa86ed3f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5f87745-10df-4b61-bbdf-8a119c272e0b", "node_type": "1", "metadata": {"window": "The increase was primarily due to the lower effective tax rate,\noffset in part by the decline in operating income.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce48fa67efc0921e5e3cc98e29f691b953d97a5434c7fcb3fa84111aff1d47c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f0672f0-3098-4286-bfea-e83b05852650", "node_type": "1", "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions. ", "original_text": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S. "}, "hash": "d78e9a6fa237e468bef5bcace368f650c8427a0db2163ca2fa55766d6299dca1", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter of fiscal 2022, revenue was\n2", "start_char_idx": 4290, "end_char_idx": 4340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f0672f0-3098-4286-bfea-e83b05852650": {"__data__": {"id_": "5f0672f0-3098-4286-bfea-e83b05852650", "embedding": null, "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions. ", "original_text": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0e9cf2b-31b9-4fa3-ac11-d5c47ebb6ff5", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2022 were 211.7\nmillion, an increase of 2.8 million shares, or 1.4 percent versus the prior fiscal year third quarter resulting from stock option\nexercises, restricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to\nWalgreens Boots Alliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare, partially offset by share\nrepurchases.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2022, revenue was\n2", "original_text": "In the third quarter of fiscal 2022, revenue was\n2", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80bbdd5fea2901b946c874afff14d82be461c1c94efb8e9294ad808ae07101b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ceb99d52-6419-4e57-ba68-225ee03f6aaf", "node_type": "1", "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n", "original_text": "Healthcare Solutions revenue.\n"}, "hash": "b34a8313c11493006898abc23c67d8fdc0472bdb8e05ea9f82eea6cd16a82a51", "class_name": "RelatedNodeInfo"}}, "text": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S. ", "start_char_idx": 0, "end_char_idx": 294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ceb99d52-6419-4e57-ba68-225ee03f6aaf": {"__data__": {"id_": "ceb99d52-6419-4e57-ba68-225ee03f6aaf", "embedding": null, "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n", "original_text": "Healthcare Solutions revenue.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f0672f0-3098-4286-bfea-e83b05852650", "node_type": "1", "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions. ", "original_text": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d80e134da6c21982906a1e334454e3952149425eb33186c61ffaa15860c6e19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37684366-b73f-49d9-bf83-60a6a1850c90", "node_type": "1", "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S. "}, "hash": "4e1f4bbe1edd442020a1b4541a2c7aa087faac7b7f5c068c473b7dc008815719", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue.\n", "start_char_idx": 294, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37684366-b73f-49d9-bf83-60a6a1850c90": {"__data__": {"id_": "37684366-b73f-49d9-bf83-60a6a1850c90", "embedding": null, "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ceb99d52-6419-4e57-ba68-225ee03f6aaf", "node_type": "1", "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n", "original_text": "Healthcare Solutions revenue.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c15496beb1c821e242c761722d110ca79f60c0ac40e45d66dd8b0ed692d2344f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d85016d-8324-4a10-83f1-75f35fdfc26d", "node_type": "1", "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. "}, "hash": "3cba910ac33aeb95e9c5cb2c6645e87a5f659b9e9e24b8856ad5e6326b66616f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S. ", "start_char_idx": 324, "end_char_idx": 665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d85016d-8324-4a10-83f1-75f35fdfc26d": {"__data__": {"id_": "7d85016d-8324-4a10-83f1-75f35fdfc26d", "embedding": null, "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37684366-b73f-49d9-bf83-60a6a1850c90", "node_type": "1", "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "791546d58385ceda91966f750233fd53a1d831244f825fa0d2ce7d38da806ee4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd105971-9c67-4a0b-b6c9-731cc9778848", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S. ", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n"}, "hash": "83b447b8ffbd43c8e83a165812d3cc80edd44d3773f16deabad2b0c59da0ff44", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions. ", "start_char_idx": 665, "end_char_idx": 687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd105971-9c67-4a0b-b6c9-731cc9778848": {"__data__": {"id_": "bd105971-9c67-4a0b-b6c9-731cc9778848", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S. ", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d85016d-8324-4a10-83f1-75f35fdfc26d", "node_type": "1", "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57ddfc36f08c7b19d03f321d77ed640ad14aacd9a4111b48a8429ab818093d8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35b584be-a08e-4e1a-b89c-13be314137a2", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "5cea15d7c93938ef599b2bd2ddec237e51c39a0624817accae899ed0861b1cfb", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n", "start_char_idx": 687, "end_char_idx": 1006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35b584be-a08e-4e1a-b89c-13be314137a2": {"__data__": {"id_": "35b584be-a08e-4e1a-b89c-13be314137a2", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd105971-9c67-4a0b-b6c9-731cc9778848", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S. ", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c9fa184d0104a870dabd5d4b673feffe5125ca11b3eac30fd65493da1a8e9ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dfe9750-da1b-4f1b-9f88-34f9a0ef8ce8", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n", "original_text": "Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year. "}, "hash": "1698f7101b469e47d384e02907717b701f84d92e543925ded50e629160cf1d43", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 1006, "end_char_idx": 1361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dfe9750-da1b-4f1b-9f88-34f9a0ef8ce8": {"__data__": {"id_": "0dfe9750-da1b-4f1b-9f88-34f9a0ef8ce8", "embedding": null, "metadata": {"window": "Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n", "original_text": "Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35b584be-a08e-4e1a-b89c-13be314137a2", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67dd63015c809dbca3b60b8b747cbcc57f517cec8ec09fe605c5434409c466e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1c52f43-6050-4893-9762-a8b80ec363a5", "node_type": "1", "metadata": {"window": "Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S. "}, "hash": "aa3428a7c479c16415b12d5630cf3c3c0434216130482db77fce026872f0bf93", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year. ", "start_char_idx": 1361, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1c52f43-6050-4893-9762-a8b80ec363a5": {"__data__": {"id_": "c1c52f43-6050-4893-9762-a8b80ec363a5", "embedding": null, "metadata": {"window": "Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dfe9750-da1b-4f1b-9f88-34f9a0ef8ce8", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n", "original_text": "Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c13c171cc939c31a3b51f9d2d3990388d4b98dd18ad0f549b14834296ae3bb87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6967086-0a0f-4889-b94f-965752571813", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions' operating income.\n"}, "hash": "ec024c053ecbff36161d5b4ca2227abee21f5a54e7a5c5714ee5532856dddc58", "class_name": "RelatedNodeInfo"}}, "text": "The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S. ", "start_char_idx": 1550, "end_char_idx": 1695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6967086-0a0f-4889-b94f-965752571813": {"__data__": {"id_": "e6967086-0a0f-4889-b94f-965752571813", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions' operating income.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1c52f43-6050-4893-9762-a8b80ec363a5", "node_type": "1", "metadata": {"window": "Adjusted gross\nprofit as a percentage of revenue was 3.44 percent in the fiscal 2022 third quarter, an increase of 39 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare and fees earned from\nthe distribution of government-owned COVID-19 treatments.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c79e780452b104a4bbd4078b8bd21b159e564bf592230fab3bac18890975b333", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83ffc80c-32e5-4814-a942-4c0f028fe911", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n"}, "hash": "b98821bec256f0ef5ae74e27fe2b69683e88e929896703d855ce94d3a40691dc", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions' operating income.\n", "start_char_idx": 1695, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83ffc80c-32e5-4814-a942-4c0f028fe911": {"__data__": {"id_": "83ffc80c-32e5-4814-a942-4c0f028fe911", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6967086-0a0f-4889-b94f-965752571813", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 31.5 percent\nincrease, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation expense\ncompared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions' operating income.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dd85bf31d9a52e4d9bfe4c9936b1599024c59ea06420cf8e1c9e3bec7953072", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05c78100-06e7-43c1-8383-399e0107d7c7", "node_type": "1", "metadata": {"window": "The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "0081141e161b697e82b9e3e429e6a87d5aa9818ecbc11b3abbe825975671d7ec", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n", "start_char_idx": 1735, "end_char_idx": 2051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05c78100-06e7-43c1-8383-399e0107d7c7": {"__data__": {"id_": "05c78100-06e7-43c1-8383-399e0107d7c7", "embedding": null, "metadata": {"window": "The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83ffc80c-32e5-4814-a942-4c0f028fe911", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the third quarter of fiscal 2022, adjusted operating income was $756.2 million, a 19.9 percent\nincrease compared to the same period in the prior fiscal year.  The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3839bd2f6df1ce15990db18194249d31b22fa8b73b6bc88bf6d05e3da4f936db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ad8e704-2f6a-40b9-a3a0-aeeb49aa144d", "node_type": "1", "metadata": {"window": "Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "abff6878c8cc1f24416da58c261764c8e51a245ce428fc0d25988bdc539bb5be", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 2051, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ad8e704-2f6a-40b9-a3a0-aeeb49aa144d": {"__data__": {"id_": "0ad8e704-2f6a-40b9-a3a0-aeeb49aa144d", "embedding": null, "metadata": {"window": "Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05c78100-06e7-43c1-8383-399e0107d7c7", "node_type": "1", "metadata": {"window": "The increase was due to a 74.8 percent increase in operating\nincome within International Healthcare Solutions and a 9.5 percent increase in U.S.  Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4f72d17287224b3ec73adf5cded0841846a22a08147781aaa2929d31d9968fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa08710d-7155-4945-a2fc-a3c0e30d3f86", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n"}, "hash": "f969e45d1676203bfd858c713c9680675af0c595fe558e1340199b519181791a", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 2150, "end_char_idx": 2376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa08710d-7155-4945-a2fc-a3c0e30d3f86": {"__data__": {"id_": "aa08710d-7155-4945-a2fc-a3c0e30d3f86", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ad8e704-2f6a-40b9-a3a0-aeeb49aa144d", "node_type": "1", "metadata": {"window": "Healthcare Solutions' operating income.\n Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0eadc64d8fb5d82266c30887e4fa91eedcb4e13bec2fd5bda05ebfd4b3ab1bbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9cd7057-3830-421b-9499-4bda9d0b41b5", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n"}, "hash": "2ef0f0b4b666af700aa1700d8b056fc7f7f95d00684bc3e67c79c3ce3dae895a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n", "start_char_idx": 2376, "end_char_idx": 2544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9cd7057-3830-421b-9499-4bda9d0b41b5": {"__data__": {"id_": "c9cd7057-3830-421b-9499-4bda9d0b41b5", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa08710d-7155-4945-a2fc-a3c0e30d3f86", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.26 percent in the fiscal 2022 third quarter, an increase of 8 basis\npoints when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare acquisition and fees\nearned from the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83da7eb96d90e87d8009d433e6e16e83342bf1492b15ec72ae04622ea7470c47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03431f43-51f6-4445-9055-219e8dcb6ad3", "node_type": "1", "metadata": {"window": "In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "4f3cf87a56a4f820f3eca398eceba27e5b9fe7f028887381bf5b16ff6ba829b9", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n", "start_char_idx": 2544, "end_char_idx": 2752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03431f43-51f6-4445-9055-219e8dcb6ad3": {"__data__": {"id_": "03431f43-51f6-4445-9055-219e8dcb6ad3", "embedding": null, "metadata": {"window": "In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9cd7057-3830-421b-9499-4bda9d0b41b5", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c278648d383317957b124b3be2d1f2058c8793db7c64ff4d669fa66a5ebfb51a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "174beec3-145f-404a-b5c9-6eabafe33511", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n"}, "hash": "b34b58aa54e861411eda4bcdf39474308105166331ce7b875efcbeac98dad9ab", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 2752, "end_char_idx": 2862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "174beec3-145f-404a-b5c9-6eabafe33511": {"__data__": {"id_": "174beec3-145f-404a-b5c9-6eabafe33511", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03431f43-51f6-4445-9055-219e8dcb6ad3", "node_type": "1", "metadata": {"window": "In the third quarter of\nfiscal 2022, net interest expense of $52.9 million was up 3.0 percent versus the prior year quarter primarily due to an increase\nin debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36dec1499366013413b0202e975c85d39dc5fd6cf175e7442cbc4eb2168ef4a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad340b6c-b061-4935-bc86-a27b06084a62", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. "}, "hash": "d1913a4336f55f2dce371b3bad3121a1b377f13a3802990cc129f75cac851eb2", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n", "start_char_idx": 2862, "end_char_idx": 3303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad340b6c-b061-4935-bc86-a27b06084a62": {"__data__": {"id_": "ad340b6c-b061-4935-bc86-a27b06084a62", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "174beec3-145f-404a-b5c9-6eabafe33511", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.2 percent for the third quarter of fiscal 2022 compared to\n21.0 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c51c439c95a3d51cbf3760c952a74712d77749ea531b44803a24e0ece387bb59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c39e2ab-7ca2-4a78-91e3-152f68894c1a", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. "}, "hash": "6a47d427a267d4d989c82f0562b4214c39e3308c37659b55139ca8af6d30cab2", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "start_char_idx": 3303, "end_char_idx": 3429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c39e2ab-7ca2-4a78-91e3-152f68894c1a": {"__data__": {"id_": "4c39e2ab-7ca2-4a78-91e3-152f68894c1a", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad340b6c-b061-4935-bc86-a27b06084a62", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.62 in the third quarter of fiscal 2022, a 21.3\npercent increase compared to $2.16 in the previous fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5524033dba1fc1f29295e308e070d5368d7fbace0636ecac214773eccbf0ec30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f4a0df9-f463-465c-892d-29edaef39f69", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. "}, "hash": "812bb42911564eccf37116e8d25b655c2b611314badd352a1d4613f9d9d322e9", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "start_char_idx": 3429, "end_char_idx": 3549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f4a0df9-f463-465c-892d-29edaef39f69": {"__data__": {"id_": "6f4a0df9-f463-465c-892d-29edaef39f69", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c39e2ab-7ca2-4a78-91e3-152f68894c1a", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cd1faaebcc47897dbc7e2e94049292f7947160d95b1c78c433e615fbdeeba1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12b534bb-64fb-4f1a-96be-682487c02960", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. "}, "hash": "21ecaa49aa0217fdb67ba48b3d10bd220b3e99fc08eddf8c340742014e98dd21", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "start_char_idx": 3549, "end_char_idx": 3610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12b534bb-64fb-4f1a-96be-682487c02960": {"__data__": {"id_": "12b534bb-64fb-4f1a-96be-682487c02960", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f4a0df9-f463-465c-892d-29edaef39f69", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2022 were 211.7 million, an increase of 2.8 million shares,\nor 1.4 percent versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the\nJune 2021 issuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare, partially offset by share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "282bcf81be6f52c951fddbf67a86757935573cbdf3a6de0c6e5b5660716d2f06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37279452-189a-4e1f-a239-c94bae076420", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. "}, "hash": "5dae5527e9e3701399753bbec2b2aa418ef09f171e511691ad195148caaa6f6b", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 289, "end_char_idx": 294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37279452-189a-4e1f-a239-c94bae076420": {"__data__": {"id_": "37279452-189a-4e1f-a239-c94bae076420", "embedding": null, "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12b534bb-64fb-4f1a-96be-682487c02960", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3da82c7f160f3142b7e6820d1e6911624a424cc0dde8264703facc55a163a807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b06cca55-88f4-4b89-bccb-b2cefe12cff8", "node_type": "1", "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). "}, "hash": "0dd428584cceeb713b1481c5c8554f5e6715efe7aee30e364b9dd6e70c0df116", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "start_char_idx": 3615, "end_char_idx": 3789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b06cca55-88f4-4b89-bccb-b2cefe12cff8": {"__data__": {"id_": "b06cca55-88f4-4b89-bccb-b2cefe12cff8", "embedding": null, "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37279452-189a-4e1f-a239-c94bae076420", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbb8066d5e20f5767300026ce89f8a556a12569f2bb879163421081f10cae0b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a9b8daf-a385-4d71-965a-92f1c870696b", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n"}, "hash": "3ee9ff73c15d6ab1dd1a66868c0c969c128db5b63532542c2db349c4bfbd18d2", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "start_char_idx": 3789, "end_char_idx": 3952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a9b8daf-a385-4d71-965a-92f1c870696b": {"__data__": {"id_": "3a9b8daf-a385-4d71-965a-92f1c870696b", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b06cca55-88f4-4b89-bccb-b2cefe12cff8", "node_type": "1", "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc33370db9b615e196623c7f7296f20ca8c8a356fb7a3bb6b020fbde906f0b20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2163abfd-09ef-414d-afdb-3ed680a8241d", "node_type": "1", "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n", "original_text": "U.S. "}, "hash": "327ae2c4eddc6d27c01a56afdebcda95f2fe980fce6fded647b442f2a812eb61", "class_name": "RelatedNodeInfo"}}, "text": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "start_char_idx": 3952, "end_char_idx": 4070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2163abfd-09ef-414d-afdb-3ed680a8241d": {"__data__": {"id_": "2163abfd-09ef-414d-afdb-3ed680a8241d", "embedding": null, "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a9b8daf-a385-4d71-965a-92f1c870696b", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f85ca7f524f15ee2fb61ee425a1a8df4a29220a7d2138ff505062f159872ff38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29736fdf-b1aa-4321-861b-f30a5bb9fab2", "node_type": "1", "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Healthcare Solutions\nU.S. "}, "hash": "605bdcbd3d9499dcca64d9db00cd4ef4f93887dec3ea2e43fc4b1ec34e5f56fa", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 289, "end_char_idx": 294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29736fdf-b1aa-4321-861b-f30a5bb9fab2": {"__data__": {"id_": "29736fdf-b1aa-4321-861b-f30a5bb9fab2", "embedding": null, "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2163abfd-09ef-414d-afdb-3ed680a8241d", "node_type": "1", "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c86da15a45021b83c9bb0907f64db6d1cb7f6013bc663ae8615fb3e4143d68c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cf609ca-0ddd-4662-8bad-5cbae2fbd242", "node_type": "1", "metadata": {"window": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. "}, "hash": "fbaaae12e7d51aafd04d18843efe9a6e88738d814e96d65c8e9cce8274021496", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nU.S. ", "start_char_idx": 4075, "end_char_idx": 4101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cf609ca-0ddd-4662-8bad-5cbae2fbd242": {"__data__": {"id_": "2cf609ca-0ddd-4662-8bad-5cbae2fbd242", "embedding": null, "metadata": {"window": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29736fdf-b1aa-4321-861b-f30a5bb9fab2", "node_type": "1", "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90625fd7b40e549b9dcc070071b0f8e6681fe65c3b9ac04a38fd315e04cb339e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4ed3bf8-7f3e-47c3-a8d9-0da01d862bc2", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n"}, "hash": "2f6cbedbacccdb96249e62de87c00372a5a74675f6c00b386892456212705e84", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "start_char_idx": 4101, "end_char_idx": 4437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4ed3bf8-7f3e-47c3-a8d9-0da01d862bc2": {"__data__": {"id_": "f4ed3bf8-7f3e-47c3-a8d9-0da01d862bc2", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cf609ca-0ddd-4662-8bad-5cbae2fbd242", "node_type": "1", "metadata": {"window": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9313817c6dafdfd5e1964ccd5eadb182ca92ef4f38a623e8938577eabc8bcd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44c5ff7e-cbcc-4e5c-9a0f-8678b05416ab", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "3"}, "hash": "e0d726987f330a1b850e5a5441e4ef210bb5df2d5462c6b7007299ec88c6fdde", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n", "start_char_idx": 4437, "end_char_idx": 4779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44c5ff7e-cbcc-4e5c-9a0f-8678b05416ab": {"__data__": {"id_": "44c5ff7e-cbcc-4e5c-9a0f-8678b05416ab", "embedding": null, "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "3", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b3c2c318953e69175b97226b8062e82b1724287a9c1ad902b15c7dffe661c5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4ed3bf8-7f3e-47c3-a8d9-0da01d862bc2", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0905ff3a1963a2a96747a4506733fa859099c75f39c9c2c71705206c1c453b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8332c56-a46c-46a2-8bc7-ae1f1eeb96f4", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. "}, "hash": "a603612231af7fbb617b4fbb766ed031b1a52f3ba1d74aeab17c0b6059e3dbd7", "class_name": "RelatedNodeInfo"}}, "text": "3", "start_char_idx": 106, "end_char_idx": 107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8332c56-a46c-46a2-8bc7-ae1f1eeb96f4": {"__data__": {"id_": "a8332c56-a46c-46a2-8bc7-ae1f1eeb96f4", "embedding": null, "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44c5ff7e-cbcc-4e5c-9a0f-8678b05416ab", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $53.4 billion in the third quarter of fiscal 2022, an increase of 6.0 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $579.9 million in the third\nquarter of fiscal 2022 was up 9.5 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned from the distribution of government-owned COVID-19 treatments and gross profit on sales to specialty\nphysician practices.\n 3", "original_text": "3", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9371c3ccc69c3c6ea56490b6a231b353d8ad1d0b39b2607b3f414ee3f465bd71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7d34fd3-6d9d-403d-ab75-e455ab7cbea3", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S. ", "original_text": "Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n"}, "hash": "36991dd064489f7e4069708ec74d3df465857bcd36343bdfef4ea0517b29e0b4", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. ", "start_char_idx": 0, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7d34fd3-6d9d-403d-ab75-e455ab7cbea3": {"__data__": {"id_": "b7d34fd3-6d9d-403d-ab75-e455ab7cbea3", "embedding": null, "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S. ", "original_text": "Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8332c56-a46c-46a2-8bc7-ae1f1eeb96f4", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c79d86df9021aab21b3176a656ba4001f0b24b9eb834321f96539f9f5572777f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d408751e-1b7a-45ce-aa3d-b805b9abfd12", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study. ", "original_text": "Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n"}, "hash": "6966d1b20d56463c1b25e59ba92382b8693360327a4bc6f97ffba938dc30d382", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n", "start_char_idx": 278, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d408751e-1b7a-45ce-aa3d-b805b9abfd12": {"__data__": {"id_": "d408751e-1b7a-45ce-aa3d-b805b9abfd12", "embedding": null, "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study. ", "original_text": "Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7d34fd3-6d9d-403d-ab75-e455ab7cbea3", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S. ", "original_text": "Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82979d95d3bf767042d75c03e97f45ee50e36d3329e59b34036acef671e463f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c225d553-0c54-4cfc-83c1-a97258fe9a75", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. "}, "hash": "b575640341fce1e911987bbfcf371267a3fe3ff52905360a4051c32918429a53", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n", "start_char_idx": 505, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c225d553-0c54-4cfc-83c1-a97258fe9a75": {"__data__": {"id_": "c225d553-0c54-4cfc-83c1-a97258fe9a75", "embedding": null, "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d408751e-1b7a-45ce-aa3d-b805b9abfd12", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study. ", "original_text": "Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f04140b267c0ca2b86a717d8bc5fcdb820b7c2955e862ad4c9a8dcafcbc1fbcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a46fb5d-8310-4c76-83db-808ef8816903", "node_type": "1", "metadata": {"window": "Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n", "original_text": "Power 2022 U.S. "}, "hash": "b973e790f06c19eba0637a06cfe7cfa3ad501b54d209af299e0e71e9173dd0d9", "class_name": "RelatedNodeInfo"}}, "text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "start_char_idx": 746, "end_char_idx": 938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a46fb5d-8310-4c76-83db-808ef8816903": {"__data__": {"id_": "2a46fb5d-8310-4c76-83db-808ef8816903", "embedding": null, "metadata": {"window": "Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n", "original_text": "Power 2022 U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c225d553-0c54-4cfc-83c1-a97258fe9a75", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fc375161fa71be80a2864d5e9126347a4392f211bc2cffdc954bf6331c8c306", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "292163f3-b5a9-415d-b50f-6516aa61c094", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n", "original_text": "Pharmacy Study. "}, "hash": "f53818122ae58ef1ca5b1ceb6157be7d0fb443f534fe0b46014d041b3b166c29", "class_name": "RelatedNodeInfo"}}, "text": "Power 2022 U.S. ", "start_char_idx": 938, "end_char_idx": 954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "292163f3-b5a9-415d-b50f-6516aa61c094": {"__data__": {"id_": "292163f3-b5a9-415d-b50f-6516aa61c094", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n", "original_text": "Pharmacy Study. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a46fb5d-8310-4c76-83db-808ef8816903", "node_type": "1", "metadata": {"window": "Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n", "original_text": "Power 2022 U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d214f8991424e1bb0e9a769b7d0674c100dda5b32b0de8185c954b40ae8bff4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "578fc715-f349-48a8-89dc-a6971caf9f2f", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices. ", "original_text": "This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n"}, "hash": "b1c1c27a61cceb89c66e8916d2a3a84d5d366d671c4025fc8ff02f4272464c71", "class_name": "RelatedNodeInfo"}}, "text": "Pharmacy Study. ", "start_char_idx": 954, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "578fc715-f349-48a8-89dc-a6971caf9f2f": {"__data__": {"id_": "578fc715-f349-48a8-89dc-a6971caf9f2f", "embedding": null, "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices. ", "original_text": "This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "292163f3-b5a9-415d-b50f-6516aa61c094", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n", "original_text": "Pharmacy Study. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "871d0a0f85381b3c1acda986825ae9e7589e3aeb3c91a5125731ce6f6093fdd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8226e07a-5fad-4ee5-8037-e65d960b6b41", "node_type": "1", "metadata": {"window": "Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n", "original_text": "Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n"}, "hash": "558a870b8430e8b5ceb96a7489fe4d6077107dd8b9c2fe85851c9c6324722b1f", "class_name": "RelatedNodeInfo"}}, "text": "This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n", "start_char_idx": 970, "end_char_idx": 1116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8226e07a-5fad-4ee5-8037-e65d960b6b41": {"__data__": {"id_": "8226e07a-5fad-4ee5-8037-e65d960b6b41", "embedding": null, "metadata": {"window": "Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n", "original_text": "Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "578fc715-f349-48a8-89dc-a6971caf9f2f", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices. ", "original_text": "This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6eb7fc95cc8fdbab35c883c4639dcf5fe6dd06de395b0130da5efff1381f6e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26ed6df1-1717-4c66-9cea-99238cb91550", "node_type": "1", "metadata": {"window": "Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n", "original_text": "Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n"}, "hash": "9e546d382c9ddcb82b0cb2fc64d06585b8c329b260edb5102a9ae83db26f2d11", "class_name": "RelatedNodeInfo"}}, "text": "Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n", "start_char_idx": 1116, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26ed6df1-1717-4c66-9cea-99238cb91550": {"__data__": {"id_": "26ed6df1-1717-4c66-9cea-99238cb91550", "embedding": null, "metadata": {"window": "Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n", "original_text": "Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8226e07a-5fad-4ee5-8037-e65d960b6b41", "node_type": "1", "metadata": {"window": "Power 2022 U.S.  Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n", "original_text": "Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f564d2bba3694704eb07ee122d353305fa3ea12e528d87bc7d748dcf1f1e01e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83f0561c-41fc-4a97-844d-9d1d9a0f6120", "node_type": "1", "metadata": {"window": "This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S. ", "original_text": "AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices. "}, "hash": "b8431e6aaff42525f811110fabc141a679ae466251c5d5a9bd5dcee9f1d2f1db", "class_name": "RelatedNodeInfo"}}, "text": "Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n", "start_char_idx": 1236, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83f0561c-41fc-4a97-844d-9d1d9a0f6120": {"__data__": {"id_": "83f0561c-41fc-4a97-844d-9d1d9a0f6120", "embedding": null, "metadata": {"window": "This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S. ", "original_text": "AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26ed6df1-1717-4c66-9cea-99238cb91550", "node_type": "1", "metadata": {"window": "Pharmacy Study.  This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n", "original_text": "Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3866a171b796b2ab4f030a9cdf1953c5daad7247af29d86dd29f0f688302a42f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7acd524a-c0fc-45fb-a0cf-4d2247a721a6", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n", "original_text": "Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n"}, "hash": "d91ca8357f312c9f23df30dc4844522f058a86a19a40dec755de5677e2808968", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices. ", "start_char_idx": 1433, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7acd524a-c0fc-45fb-a0cf-4d2247a721a6": {"__data__": {"id_": "7acd524a-c0fc-45fb-a0cf-4d2247a721a6", "embedding": null, "metadata": {"window": "Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n", "original_text": "Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83f0561c-41fc-4a97-844d-9d1d9a0f6120", "node_type": "1", "metadata": {"window": "This marks\nthe eleventh time that Good Neighbor Pharmacy has earned the achievement in the last 13 years and the network's sixth\nconsecutive win.\n Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S. ", "original_text": "AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13ca54a1af817ebb65205a84229b33c2ea44b38accaaf2614c1038b6a19e8085", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b090702d-78fa-4c66-b308-fdb9159ce81b", "node_type": "1", "metadata": {"window": "Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases. ", "original_text": "Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n"}, "hash": "63a81908317c2ba18b4b121fa3669b56bf289582ea17a0bf3d7d2ce270ff2e6c", "class_name": "RelatedNodeInfo"}}, "text": "Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n", "start_char_idx": 1610, "end_char_idx": 1764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b090702d-78fa-4c66-b308-fdb9159ce81b": {"__data__": {"id_": "b090702d-78fa-4c66-b308-fdb9159ce81b", "embedding": null, "metadata": {"window": "Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases. ", "original_text": "Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7acd524a-c0fc-45fb-a0cf-4d2247a721a6", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy celebrated its fortieth anniversary and hosted ThoughtSpot, its annual conference and tradeshow.\n Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n", "original_text": "Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8d5b064013e96aa843501747acf7b5ab7d7bba2f2d41fca4af3efea32c14aad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a957d5d-1ee8-4ceb-8a3e-0ff1cad1d85b", "node_type": "1", "metadata": {"window": "AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n", "original_text": "AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S. "}, "hash": "1b374efa81b9cec5160dc7964e4520f185b525fa63127738ba9d68b261111347", "class_name": "RelatedNodeInfo"}}, "text": "Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n", "start_char_idx": 1764, "end_char_idx": 1999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a957d5d-1ee8-4ceb-8a3e-0ff1cad1d85b": {"__data__": {"id_": "9a957d5d-1ee8-4ceb-8a3e-0ff1cad1d85b", "embedding": null, "metadata": {"window": "AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n", "original_text": "AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b090702d-78fa-4c66-b308-fdb9159ce81b", "node_type": "1", "metadata": {"window": "Nearly 5,000 independent pharmacy owners and advocates participated in the event, which included continuing education\nsessions and certification programs, networking events and business resources.\n AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases. ", "original_text": "Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad717ec26d5149208c24b7b33f8343bf96bdbb6876ed54edda6a370ed6a3dd0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7e65ac2-ab26-4797-8bd5-5716faf4ea54", "node_type": "1", "metadata": {"window": "Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity. ", "original_text": "and its emergency\nresponse and recovery efforts worldwide.\n"}, "hash": "b31c6512c7c7a8b85f32c22b9333b65815f8b4d6eee77e72cc9443caef93b589", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S. ", "start_char_idx": 1999, "end_char_idx": 2219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7e65ac2-ab26-4797-8bd5-5716faf4ea54": {"__data__": {"id_": "b7e65ac2-ab26-4797-8bd5-5716faf4ea54", "embedding": null, "metadata": {"window": "Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity. ", "original_text": "and its emergency\nresponse and recovery efforts worldwide.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a957d5d-1ee8-4ceb-8a3e-0ff1cad1d85b", "node_type": "1", "metadata": {"window": "AmerisourceBergen launched Clinical Trial Navigator, a solution suite that assists with biopharmaceutical clinical trial\nrecruitment within community-based specialty practices.  Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n", "original_text": "AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80bf5545919ae58cfe287cb96babed93753cc61550fa03fe07720d4f654eddb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "723a026b-862c-4e5f-9098-14cb27942489", "node_type": "1", "metadata": {"window": "Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n", "original_text": "The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases. "}, "hash": "ea4cb2d19edca46dd92e56c48149972224ff08f2c2a378b5c6d485a7d515147d", "class_name": "RelatedNodeInfo"}}, "text": "and its emergency\nresponse and recovery efforts worldwide.\n", "start_char_idx": 2219, "end_char_idx": 2278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "723a026b-862c-4e5f-9098-14cb27942489": {"__data__": {"id_": "723a026b-862c-4e5f-9098-14cb27942489", "embedding": null, "metadata": {"window": "Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n", "original_text": "The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7e65ac2-ab26-4797-8bd5-5716faf4ea54", "node_type": "1", "metadata": {"window": "Clinical Trial Navigator unites oncology practices and their patients\nwith trials through digital selection, patient identification and enrollment tools.\n Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity. ", "original_text": "and its emergency\nresponse and recovery efforts worldwide.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34ad10d03c4851e7253f95cbb99b21fd62778005286a767d86e900a5d42dc6ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae7b22b6-3df5-4524-af1c-3ce55b56adcb", "node_type": "1", "metadata": {"window": "AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n"}, "hash": "81a1ca0aaf4494b267bbea4c0ffad093db3be3ddd13d47f87fae9b8f67aad65f", "class_name": "RelatedNodeInfo"}}, "text": "The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases. ", "start_char_idx": 2278, "end_char_idx": 2483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae7b22b6-3df5-4524-af1c-3ce55b56adcb": {"__data__": {"id_": "ae7b22b6-3df5-4524-af1c-3ce55b56adcb", "embedding": null, "metadata": {"window": "AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "723a026b-862c-4e5f-9098-14cb27942489", "node_type": "1", "metadata": {"window": "Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to\nAmerisourceBergen in recognition of the Company's commitment to increasing access to healthcare around the world.\n AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n", "original_text": "The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aab0b71c140193c2df4ab1ea2630d6fa7ccc55fcf354fca74a23ade8bd9bddb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fe54f1e-e522-4464-be44-992ca879dca6", "node_type": "1", "metadata": {"window": "and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity. "}, "hash": "28c50946b84a330b4ff63cdaeac0a00466aa14b8f5aab3c42b408d927278b0af", "class_name": "RelatedNodeInfo"}}, "text": "The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n", "start_char_idx": 2483, "end_char_idx": 2662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fe54f1e-e522-4464-be44-992ca879dca6": {"__data__": {"id_": "9fe54f1e-e522-4464-be44-992ca879dca6", "embedding": null, "metadata": {"window": "and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae7b22b6-3df5-4524-af1c-3ce55b56adcb", "node_type": "1", "metadata": {"window": "AmerisourceBergen and the AmerisourceBergen Foundation have supported Americares since 1997, providing both product\ndonations and financial contributions to support the organization\u2019s ongoing health programs in the U.S.  and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a3ea76ae5b9154f38e63f4013e3591363498ff397c6bc9cb50e9bfefacac7a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b41d7d83-bdde-4857-8edf-d357cdf76a02", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count. ", "original_text": "The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n"}, "hash": "a2c14b5a9455c6a2bb818906bf68b3c1d4e698d16935901ace6e58091c244461", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity. ", "start_char_idx": 2662, "end_char_idx": 2876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b41d7d83-bdde-4857-8edf-d357cdf76a02": {"__data__": {"id_": "b41d7d83-bdde-4857-8edf-d357cdf76a02", "embedding": null, "metadata": {"window": "The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count. ", "original_text": "The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fe54f1e-e522-4464-be44-992ca879dca6", "node_type": "1", "metadata": {"window": "and its emergency\nresponse and recovery efforts worldwide.\n The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63bbd77b2205823153c4b28cd56796c0ab63b9ed7cf9d19502111f99ec85c1bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4214caaf-5ee9-409a-a291-9048b867dcf0", "node_type": "1", "metadata": {"window": "The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "6708cdf869ec89f7d750b2c9cb8700db7aedb42a59336fed7ea946950dbbea00", "class_name": "RelatedNodeInfo"}}, "text": "The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n", "start_char_idx": 2876, "end_char_idx": 3006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4214caaf-5ee9-409a-a291-9048b867dcf0": {"__data__": {"id_": "4214caaf-5ee9-409a-a291-9048b867dcf0", "embedding": null, "metadata": {"window": "The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b41d7d83-bdde-4857-8edf-d357cdf76a02", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation committed funds to the United Nations Foundation's Shot@Life campaign to support\nvaccine equity, protecting the world's most vulnerable children from devastating diseases.  The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count. ", "original_text": "The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "216c660839190204c9ba5327a34d9c6db2da7373117b3046c8d0f695c03cd715", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff7a88b4-b4ca-4062-a6e6-b19261e05b42", "node_type": "1", "metadata": {"window": "AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "d29bcdbcf3b0b3bd7174a95f5c0cef499932c90003e87844abd278ccdadaa245", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 3006, "end_char_idx": 3250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff7a88b4-b4ca-4062-a6e6-b19261e05b42": {"__data__": {"id_": "ff7a88b4-b4ca-4062-a6e6-b19261e05b42", "embedding": null, "metadata": {"window": "AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4214caaf-5ee9-409a-a291-9048b867dcf0", "node_type": "1", "metadata": {"window": "The funding will be used towards\nvaccine inventions in marginalized populations and will specifically support vaccine delivery, transportation logistics and\ncommunity engagement.\n AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "023046fdff550ad1981b933d63f59378d18eb6963b2ba378041557cd193b77ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a5274b-c82d-4995-b2cd-811955bd85a9", "node_type": "1", "metadata": {"window": "The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count. "}, "hash": "2829afbbfc238cb324241c7245c8ab0b1df53de47df0ca8473e0d0b4fbcaadfc", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 3250, "end_char_idx": 3382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a5274b-c82d-4995-b2cd-811955bd85a9": {"__data__": {"id_": "52a5274b-c82d-4995-b2cd-811955bd85a9", "embedding": null, "metadata": {"window": "The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff7a88b4-b4ca-4062-a6e6-b19261e05b42", "node_type": "1", "metadata": {"window": "AmerisourceBergen published its first Diversity, Equity and Inclusion Summary Report, which captures progress and provides\ntransparency on core Diversity, Equity and Inclusion measurements for workforce diversity.  The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caf59df40167590a298d1d776139fcec10bf482348a9250e0ed36502e519a7f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee48edc2-528c-46ca-b3d2-0b3aca3b1fed", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations. "}, "hash": "78dfce44be1f924c775c99d645b8ba6ef44ba221916320d27891b03696ddb42c", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count. ", "start_char_idx": 3382, "end_char_idx": 3640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee48edc2-528c-46ca-b3d2-0b3aca3b1fed": {"__data__": {"id_": "ee48edc2-528c-46ca-b3d2-0b3aca3b1fed", "embedding": null, "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a5274b-c82d-4995-b2cd-811955bd85a9", "node_type": "1", "metadata": {"window": "The report aligns with the\nCompany's Diversity, Equity and Inclusion strategy focused on people, culture, progress and community.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a7c35fb84e86ab482a0f654d8fcef08181a1d69ac2bf5c00b8e8e9f2b129e71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "060e63ca-ac8b-47db-b45b-88c819093634", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n"}, "hash": "f4b70eddc5832bc67a5379db5d9f85d50fa09e9b481d871af545c518d06d3a68", "class_name": "RelatedNodeInfo"}}, "text": "The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations. ", "start_char_idx": 3640, "end_char_idx": 3811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "060e63ca-ac8b-47db-b45b-88c819093634": {"__data__": {"id_": "060e63ca-ac8b-47db-b45b-88c819093634", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee48edc2-528c-46ca-b3d2-0b3aca3b1fed", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d9e4fcfb3dc0a39169ba22dbc0f9fe94d4370e01c4f2469d61c8897226eacfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b63f17d-8772-4c9f-be18-bc966e1cadd9", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "Additional expectations now include:\n4"}, "hash": "3a3fc3c3085dba4d91ad461f7d36e0631c58a70ae3f8c722fd274a34d578243e", "class_name": "RelatedNodeInfo"}}, "text": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n", "start_char_idx": 3811, "end_char_idx": 3964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b63f17d-8772-4c9f-be18-bc966e1cadd9": {"__data__": {"id_": "4b63f17d-8772-4c9f-be18-bc966e1cadd9", "embedding": null, "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "Additional expectations now include:\n4", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3091f7860c98a926802fabcfe6bf0e554d07d796dde17f1720e7b80761f62f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "060e63ca-ac8b-47db-b45b-88c819093634", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af1f5139f10b87a6b1610c6872c55413eb598586e98ee592df3a346e0cbd4318", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6df9099b-4a07-4077-86c9-41286fc8e6ba", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n", "original_text": "U.S. "}, "hash": "129ad2e4134f9ae264aaf3b3c5e1eb569fa8dcca53df37a13abbd8f6673a1432", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\n4", "start_char_idx": 3964, "end_char_idx": 4002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6df9099b-4a07-4077-86c9-41286fc8e6ba": {"__data__": {"id_": "6df9099b-4a07-4077-86c9-41286fc8e6ba", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n", "original_text": "U.S. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b63f17d-8772-4c9f-be18-bc966e1cadd9", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses and a lower average diluted share count.  The company's previously communicated expectations for COVID\ncontributions remain generally unchanged, with the June quarter contribution being in line with expectations.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to\n$11.05.\n Additional expectations now include:\n4", "original_text": "Additional expectations now include:\n4", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4435489abe0abeb0cf71d491c219d6d4caf8fb047393c9a354b7c177f544af0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c58afb8-fa1a-45db-a71a-484d7cfac58e", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n", "original_text": "Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n"}, "hash": "fa123884a44234b12d1ae152396d662f717b36f17c651ae42f012b5e8120fa51", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 0, "end_char_idx": 5, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c58afb8-fa1a-45db-a71a-484d7cfac58e": {"__data__": {"id_": "0c58afb8-fa1a-45db-a71a-484d7cfac58e", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n", "original_text": "Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6df9099b-4a07-4077-86c9-41286fc8e6ba", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n", "original_text": "U.S. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e81a7b53630e629e978c8c0968ef67fad0ab32b6ea3d5afc9da354ace74744ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1347ac50-3e34-4b24-bc62-7448a98a0062", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n"}, "hash": "4f9963c9509757b8b5cb1d625a6256c916d88b19f0e4570106a89d6b5a5bf1a9", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n", "start_char_idx": 5, "end_char_idx": 543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1347ac50-3e34-4b24-bc62-7448a98a0062": {"__data__": {"id_": "1347ac50-3e34-4b24-bc62-7448a98a0062", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c58afb8-fa1a-45db-a71a-484d7cfac58e", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n", "original_text": "Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79f5bf2606af362a0a331fd43bfbe26943d40058026d431a7c17e9a3f1506629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13288cc8-18be-4e39-99c2-e5a0d251bc43", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n"}, "hash": "aeb2f2ab4aa9916393b8b0ac8e332a4862428ba0920d8b7e2a98e4ca99c78ebf", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "start_char_idx": 543, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13288cc8-18be-4e39-99c2-e5a0d251bc43": {"__data__": {"id_": "13288cc8-18be-4e39-99c2-e5a0d251bc43", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1347ac50-3e34-4b24-bc62-7448a98a0062", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022. ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61be83d42d0b5eacb46319cd7622bb9ccc6b51a47f1f12387e5e3e10ca01a12a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71737c57-3d01-4825-977b-bfafb1b04d9f", "node_type": "1", "metadata": {"window": "Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims. ", "original_text": "Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n"}, "hash": "687c530ae852940e77a9add5aecb122ca0ff824533bf52b306b1ca0ca83d8f46", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n", "start_char_idx": 671, "end_char_idx": 883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71737c57-3d01-4825-977b-bfafb1b04d9f": {"__data__": {"id_": "71737c57-3d01-4825-977b-bfafb1b04d9f", "embedding": null, "metadata": {"window": "Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims. ", "original_text": "Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13288cc8-18be-4e39-99c2-e5a0d251bc43", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c4594beca94c1b8a225321d3cbe39fcdae8ed09f194a87fdc3383513fc48ee0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "232cdd59-b151-4df7-af7e-f1bb37c81e77", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual. ", "original_text": "The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022. "}, "hash": "57622972d59f1266927acd8ed43aed000f7474011a8f4b16540e39f5a1e6f657", "class_name": "RelatedNodeInfo"}}, "text": "Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n", "start_char_idx": 883, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "232cdd59-b151-4df7-af7e-f1bb37c81e77": {"__data__": {"id_": "232cdd59-b151-4df7-af7e-f1bb37c81e77", "embedding": null, "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual. ", "original_text": "The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71737c57-3d01-4825-977b-bfafb1b04d9f", "node_type": "1", "metadata": {"window": "Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims. ", "original_text": "Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6e31ccbf1c1cdefbf8e2f782f9736aefda02c4d81865de7a601101b9236ead8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24bffac4-e532-4bc5-ad73-ccd8c3df529c", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n", "original_text": "The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n"}, "hash": "2827f86be9be7ccd31938a2b18690746603e9e1598e34c54cb16147be1ad655a", "class_name": "RelatedNodeInfo"}}, "text": "The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022. ", "start_char_idx": 1289, "end_char_idx": 1425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24bffac4-e532-4bc5-ad73-ccd8c3df529c": {"__data__": {"id_": "24bffac4-e532-4bc5-ad73-ccd8c3df529c", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n", "original_text": "The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "232cdd59-b151-4df7-af7e-f1bb37c81e77", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual. ", "original_text": "The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3216142c0c96d1d8672002dd99f88b53d7cbf0af47ce5b748f3a861170364ec8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecb7c3f7-a18a-4c52-a165-084fc372dd61", "node_type": "1", "metadata": {"window": "Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims. "}, "hash": "8e6440726152ab84d1c8ecdf4533023edcec27c6f3fad1a47a5483618ea6ef8a", "class_name": "RelatedNodeInfo"}}, "text": "The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n", "start_char_idx": 1425, "end_char_idx": 1582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecb7c3f7-a18a-4c52-a165-084fc372dd61": {"__data__": {"id_": "ecb7c3f7-a18a-4c52-a165-084fc372dd61", "embedding": null, "metadata": {"window": "Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24bffac4-e532-4bc5-ad73-ccd8c3df529c", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n", "original_text": "The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7c66d035725bb2b5f0c7c604b8c4a472c7df61b57aef50abe9af998b07e3149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62ca346f-aa6a-4099-ba96-fd93f6d87c1e", "node_type": "1", "metadata": {"window": "The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022. ", "original_text": "The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual. "}, "hash": "5f509deff072ced26c2840cc791f0a84e98f7023f9d0cc6e2611e15f855a482b", "class_name": "RelatedNodeInfo"}}, "text": "On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims. ", "start_char_idx": 1582, "end_char_idx": 1821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62ca346f-aa6a-4099-ba96-fd93f6d87c1e": {"__data__": {"id_": "62ca346f-aa6a-4099-ba96-fd93f6d87c1e", "embedding": null, "metadata": {"window": "The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022. ", "original_text": "The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecb7c3f7-a18a-4c52-a165-084fc372dd61", "node_type": "1", "metadata": {"window": "Opioid Litigation\nOn June 27, 2022, AmerisourceBergen and the two other national pharmaceutical distributors entered into an agreement with the\nState of Oklahoma and participating subdivisions to resolve opioid-related claims, consistent with Oklahoma's allocations under the\ncomprehensive settlement agreement to settle the vast majority of opioid lawsuits filed by state and local governmental entities.\n The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17863f97116c94d8e73bf9a9fa653c90788f855988c187842855e918abfd8178", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c81d5fd8-cb3c-44ed-add8-83c3e5e5c2c2", "node_type": "1", "metadata": {"window": "The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n"}, "hash": "ad87f0f46e7597c6875a9e68cdb39ee2ef8541500004aec56dae140c5111bbed", "class_name": "RelatedNodeInfo"}}, "text": "The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual. ", "start_char_idx": 1821, "end_char_idx": 1953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c81d5fd8-cb3c-44ed-add8-83c3e5e5c2c2": {"__data__": {"id_": "c81d5fd8-cb3c-44ed-add8-83c3e5e5c2c2", "embedding": null, "metadata": {"window": "The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62ca346f-aa6a-4099-ba96-fd93f6d87c1e", "node_type": "1", "metadata": {"window": "The agreement includes certain contingencies, including attaining the required rate of subdivision participation by September 23,\n2022.  The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022. ", "original_text": "The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bf700774bd0196e4e98a34fabecbce1566bed530e8b5a2210b5a2d936ef988e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cde92c4-9043-4e46-9b76-1e8f06ed57b9", "node_type": "1", "metadata": {"window": "On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "60c70204edd39453a1953f7c5a4088b5e63a0d52d3b059d40fbbd3290dc58de3", "class_name": "RelatedNodeInfo"}}, "text": "The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n", "start_char_idx": 1953, "end_char_idx": 2053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cde92c4-9043-4e46-9b76-1e8f06ed57b9": {"__data__": {"id_": "4cde92c4-9043-4e46-9b76-1e8f06ed57b9", "embedding": null, "metadata": {"window": "On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c81d5fd8-cb3c-44ed-add8-83c3e5e5c2c2", "node_type": "1", "metadata": {"window": "The Oklahoma settlement agreement brings the number of States with whom the Company has recently settled opioid-\nrelated claims to 48 of 49 eligible states.\n On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aadf74eccdaef17e166c913491436ba45d90f404a73342ad2ffebb98b444d3dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f81c59c4-e1af-4a6a-8335-1b3949685daf", "node_type": "1", "metadata": {"window": "The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on August 3, 2022. "}, "hash": "203eff8ec596c037ce8e697d08c84d161a316ab548f558eda46e30a3ec64d5b9", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 2053, "end_char_idx": 2168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f81c59c4-e1af-4a6a-8335-1b3949685daf": {"__data__": {"id_": "f81c59c4-e1af-4a6a-8335-1b3949685daf", "embedding": null, "metadata": {"window": "The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on August 3, 2022. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cde92c4-9043-4e46-9b76-1e8f06ed57b9", "node_type": "1", "metadata": {"window": "On July 31, 2022, the Company and the two other distributors reached an agreement to pay up to $400 million in a settlement with\nWest Virginia subdivisions (excluding Cabell County and City of Huntington) to resolve opioid-related claims.  The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "804a767d1f9fd95899dd2e69f1f425e3fc7cedf98f47c6739047bbcf2d9cf508", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "133dfc7b-2ebe-4c3c-883a-c6b203e08c03", "node_type": "1", "metadata": {"window": "The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "8e06adf5f5b1c4833caa7958ab632c75c87070b35589b38475830b3db66bcd96", "class_name": "RelatedNodeInfo"}}, "text": "ET on August 3, 2022. ", "start_char_idx": 2168, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "133dfc7b-2ebe-4c3c-883a-c6b203e08c03": {"__data__": {"id_": "133dfc7b-2ebe-4c3c-883a-c6b203e08c03", "embedding": null, "metadata": {"window": "The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f81c59c4-e1af-4a6a-8335-1b3949685daf", "node_type": "1", "metadata": {"window": "The Company\u2019s 31.0%\nshare of the $400 million settlement amount is a component of its overall $6.4 billion total liability accrual.  The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on August 3, 2022. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "262e4ed52680bfb3305635cc9ef9bea712fc395b0c5c7bf0e1deb10f53e81771", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fe3470c-84e5-4389-828a-09a5da90eaf9", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. "}, "hash": "f4100a2df6c131cee7d15ac1097c35866edbf090deb2b5648ad97023cc49a6db", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 2190, "end_char_idx": 2307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fe3470c-84e5-4389-828a-09a5da90eaf9": {"__data__": {"id_": "7fe3470c-84e5-4389-828a-09a5da90eaf9", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "133dfc7b-2ebe-4c3c-883a-c6b203e08c03", "node_type": "1", "metadata": {"window": "The agreement is subject\nto certain contingencies, including the rate of subdivision participation.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "add5ec89313fa2333039bf7fc558dbf0b03d5f4fd5ca245d000cbf589dcb1e11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dddf706-c501-43d6-af04-d05cf2b4ccc1", "node_type": "1", "metadata": {"window": "ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. "}, "hash": "f110b5353c32b5daa7644f5fdcc69d15774738ea97f30d750dbfdd31842fa1d7", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "start_char_idx": 2307, "end_char_idx": 2546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dddf706-c501-43d6-af04-d05cf2b4ccc1": {"__data__": {"id_": "6dddf706-c501-43d6-af04-d05cf2b4ccc1", "embedding": null, "metadata": {"window": "ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fe3470c-84e5-4389-828a-09a5da90eaf9", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7215cba655b86256713e7a8426c9c9d4c4785e2b1bd7dfeb39f189b2b3db96e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed13e6f2-fb77-4a97-a673-a43605c5ed5e", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 620948. "}, "hash": "4fc3b0c553d3993fe204f9585a7d8ebe8368d005c7b85d146e864412b6f783db", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "start_char_idx": 2546, "end_char_idx": 2613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed13e6f2-fb77-4a97-a673-a43605c5ed5e": {"__data__": {"id_": "ed13e6f2-fb77-4a97-a673-a43605c5ed5e", "embedding": null, "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 620948. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dddf706-c501-43d6-af04-d05cf2b4ccc1", "node_type": "1", "metadata": {"window": "ET on August 3, 2022.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56a327a24a7ea0c4d3d8dad7826b7d9ddf5a6b21f05e5825b177107a874f4d67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67daff0f-83b9-4a8c-ab22-c177cf9552d5", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . "}, "hash": "4c3c7d1c31ef5da44031608d98f9f11229d07cd542badce1282814ebd77bc60b", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 620948. ", "start_char_idx": 2613, "end_char_idx": 2658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67daff0f-83b9-4a8c-ab22-c177cf9552d5": {"__data__": {"id_": "67daff0f-83b9-4a8c-ab22-c177cf9552d5", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed13e6f2-fb77-4a97-a673-a43605c5ed5e", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 620948. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca877572d164d226d15daaaebfd27888f4d1ad71daa22eed9a72bc445aeeb62a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b52e2b9-2310-4f24-a554-fd5889ad1f9f", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n"}, "hash": "29c837cc534a68ac1420a6697e7d7d0ddf52b99af695d792b800cc5b3862d7c6", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "start_char_idx": 2658, "end_char_idx": 2755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b52e2b9-2310-4f24-a554-fd5889ad1f9f": {"__data__": {"id_": "9b52e2b9-2310-4f24-a554-fd5889ad1f9f", "embedding": null, "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67daff0f-83b9-4a8c-ab22-c177cf9552d5", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35766e52c798ac432895d025329ac650c35c50111523e141d3d83a1185a5d851", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b985de3-9c7c-45c7-8d43-34c8da777df2", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "31c53a642620b01b01f569091823278a4d46593f1559d8ad65414b092453863f", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "start_char_idx": 2755, "end_char_idx": 2878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b985de3-9c7c-45c7-8d43-34c8da777df2": {"__data__": {"id_": "3b985de3-9c7c-45c7-8d43-34c8da777df2", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b52e2b9-2310-4f24-a554-fd5889ad1f9f", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10568bb534ccc17d665a88eeae4317772ad252b8c7431ed9c9bd4b5f4a1dc5c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4be52beb-db88-46c1-9b18-47449ef7a60a", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "46c89cbd30b0ddceb6dd6ebb0c164a2549cd67c6833ed2db1d25c53da0d0351b", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 2878, "end_char_idx": 2948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4be52beb-db88-46c1-9b18-47449ef7a60a": {"__data__": {"id_": "4be52beb-db88-46c1-9b18-47449ef7a60a", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b985de3-9c7c-45c7-8d43-34c8da777df2", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 620948.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b4155a1d66370c61b3d0d4e1282826c0d69e2536858b98f5fdc4e77c1e7e668", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d887cd66-efe0-40ed-8222-8072021950a4", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "1f656ca1db59cc5e0eef313bc40fbc4cebef02af39e5a0f3865a418178f24ec6", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 2948, "end_char_idx": 3118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d887cd66-efe0-40ed-8222-8072021950a4": {"__data__": {"id_": "d887cd66-efe0-40ed-8222-8072021950a4", "embedding": null, "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4be52beb-db88-46c1-9b18-47449ef7a60a", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e49e004c4c9c8698f83fcebdaf52947dc4f4422eae3b12f7aaf68624732e4a6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b5dca8b-ee1a-492e-96cd-233251be8b5a", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n", "original_text": "To access the telephone replay from within the U.S. "}, "hash": "d12064b664cd833e7865e88add6a5b56b0d6544b7b0f91257f316640778216a1", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 3118, "end_char_idx": 3260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b5dca8b-ee1a-492e-96cd-233251be8b5a": {"__data__": {"id_": "1b5dca8b-ee1a-492e-96cd-233251be8b5a", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d887cd66-efe0-40ed-8222-8072021950a4", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "316861550a6520af45bb9ec2d501d3612e733e0fab7e4e3b60b10024aa5ec3e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00f14fcb-6fd7-4be8-a811-f9baf5582b39", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "4b7d22bc3ccc2d7a492c94147cf4bb8c38f3ffc430915a07b8a3da571794f7b6", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S. ", "start_char_idx": 3260, "end_char_idx": 3312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00f14fcb-6fd7-4be8-a811-f9baf5582b39": {"__data__": {"id_": "00f14fcb-6fd7-4be8-a811-f9baf5582b39", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b5dca8b-ee1a-492e-96cd-233251be8b5a", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ccafca8cfce10d80d079335e5e6c802d1408f2efced9d15503f284825289946", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1590fccf-45e7-4cd9-9179-3c75103a0728", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. "}, "hash": "3d5d202235cb2790eff37a73eaac609d6f46e8ae0f6eee614680a34bc27e7190", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 3312, "end_char_idx": 3345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1590fccf-45e7-4cd9-9179-3c75103a0728": {"__data__": {"id_": "1590fccf-45e7-4cd9-9179-3c75103a0728", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00f14fcb-6fd7-4be8-a811-f9baf5582b39", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd48b7a72400832808ca1b139818326ab761d894cd81e9030c98b3526cf1f2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1360ac08-61bb-4232-8011-c5384836bd47", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "The access code for the replay is 958171.\n"}, "hash": "282fccfcff42ea3ab0901343fc358d284b8d3170b29cd381f4a0e0bed2aa9398", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "start_char_idx": 3345, "end_char_idx": 3413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1360ac08-61bb-4232-8011-c5384836bd47": {"__data__": {"id_": "1360ac08-61bb-4232-8011-c5384836bd47", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "The access code for the replay is 958171.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1590fccf-45e7-4cd9-9179-3c75103a0728", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ab4ad4ee3f3a52b80a0052d739432c90c2eafabf76dfd266625182117bd3d3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b730e2f-c1e9-40ab-a9b3-95887ce8dd92", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5"}, "hash": "bddedb2770a4c404d12a64e36299bd7147481b1d74288623ea046315413a10c5", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 958171.\n", "start_char_idx": 3413, "end_char_idx": 3455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b730e2f-c1e9-40ab-a9b3-95887ce8dd92": {"__data__": {"id_": "3b730e2f-c1e9-40ab-a9b3-95887ce8dd92", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "17c1b134-bef7-4067-9464-18c8c23ac74f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "855c8998ba67bdf8a314fef2169f65c086d6243fa2c4cdff8ce93fabb015712a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1360ac08-61bb-4232-8011-c5384836bd47", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "The access code for the replay is 958171.\n", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83304ba33acd07d9e879c707db084985c6050f9365022f8d2b31bedcf989a1b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f15d240-5bdf-4c76-972c-71e71a9afc96", "node_type": "1", "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n"}, "hash": "c97f8d693c6707cc669d22c43c1000084b70867e8a6d5c88057f708ee5b951ad", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "start_char_idx": 3455, "end_char_idx": 3582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f15d240-5bdf-4c76-972c-71e71a9afc96": {"__data__": {"id_": "0f15d240-5bdf-4c76-972c-71e71a9afc96", "embedding": null, "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b730e2f-c1e9-40ab-a9b3-95887ce8dd92", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 958171.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\n5", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46830ecb51bb3a40d6f4fde2e4c906d3f31409d78648dffaa2792eb447ef76d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8822e284-b228-41bd-b36a-925751260669", "node_type": "1", "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. "}, "hash": "e1dcc28670a863070afedae4a941ce30b8aa028cd016a93dbd0e9dfbf9881cb0", "class_name": "RelatedNodeInfo"}}, "text": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n", "start_char_idx": 0, "end_char_idx": 111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8822e284-b228-41bd-b36a-925751260669": {"__data__": {"id_": "8822e284-b228-41bd-b36a-925751260669", "embedding": null, "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f15d240-5bdf-4c76-972c-71e71a9afc96", "node_type": "1", "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d95a863fb44dde3c514c41428d02fb7e1a03432970ffe665941f71d7f54acfe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e6645ab-30e2-4254-9f7a-0b6c9de809ee", "node_type": "1", "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. "}, "hash": "07f38b1d809914e9fe0d6cbb43ba84eee4b28ef08ff64b15f70c6b3e99cbd8f1", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "start_char_idx": 111, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e6645ab-30e2-4254-9f7a-0b6c9de809ee": {"__data__": {"id_": "8e6645ab-30e2-4254-9f7a-0b6c9de809ee", "embedding": null, "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8822e284-b228-41bd-b36a-925751260669", "node_type": "1", "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "550ce7e33a80c77f9a49e0816ec36dba1fadface34f95a61f9b0c42526480dce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59d898ac-1ea9-479a-bf65-d9c7da5420be", "node_type": "1", "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "1034fd322d52ffd928786f535e81b02806f2de1a6aac639d620b66ca1aa06a83", "class_name": "RelatedNodeInfo"}}, "text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "start_char_idx": 324, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59d898ac-1ea9-479a-bf65-d9c7da5420be": {"__data__": {"id_": "59d898ac-1ea9-479a-bf65-d9c7da5420be", "embedding": null, "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e6645ab-30e2-4254-9f7a-0b6c9de809ee", "node_type": "1", "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03f21df3ac4baa138332f1997f9bd594d4c52bc789b0256ca41135c749a759f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66078c83-a361-4718-b80a-2a92b1bb6b22", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. "}, "hash": "471dda7ef54f4c64e2f6f6f35a695165434c08aa84bcdb705e3daba79f878f4a", "class_name": "RelatedNodeInfo"}}, "text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 559, "end_char_idx": 674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66078c83-a361-4718-b80a-2a92b1bb6b22": {"__data__": {"id_": "66078c83-a361-4718-b80a-2a92b1bb6b22", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59d898ac-1ea9-479a-bf65-d9c7da5420be", "node_type": "1", "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e7952ec11adbd2a6340dbe62635442994755b22ecd9353c0547cc86cde222fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e4eadab-b898-4d05-a960-a118843eefed", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "9bb62e2069f5311d0d0d3bb854959c34e9ac900cd914497645aad14163d3aa6f", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "start_char_idx": 674, "end_char_idx": 772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e4eadab-b898-4d05-a960-a118843eefed": {"__data__": {"id_": "4e4eadab-b898-4d05-a960-a118843eefed", "embedding": null, "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66078c83-a361-4718-b80a-2a92b1bb6b22", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7693df8ce3c998bb5ac5f6121d494371cc40ccef2f2975cf4b27eec11f2bc772", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b33de3b-72bb-4245-a36b-0545170d4207", "node_type": "1", "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). "}, "hash": "519ea6af9047378d7f1e64cc1f0e93dd4289316483de7f060df4cc67de4d4d9e", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 772, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b33de3b-72bb-4245-a36b-0545170d4207": {"__data__": {"id_": "0b33de3b-72bb-4245-a36b-0545170d4207", "embedding": null, "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e4eadab-b898-4d05-a960-a118843eefed", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a11e85aaf0e3ab5f484f767a042d43fece09d75742f239541ec08edadfa1d1e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be8c30f9-7588-4c81-bdc5-68687052d4df", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. "}, "hash": "3aea88350904576b30362e1c98d81d3e5cf3d54a6ed685e427d7476efa7d4a7e", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "start_char_idx": 819, "end_char_idx": 1166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be8c30f9-7588-4c81-bdc5-68687052d4df": {"__data__": {"id_": "be8c30f9-7588-4c81-bdc5-68687052d4df", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b33de3b-72bb-4245-a36b-0545170d4207", "node_type": "1", "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a1d49b6ac0844faa34f94218b9425da9e3f694e85a50159591ab7f01df534a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53f1b40c-91c2-40b5-9a72-4ca4eb021b0a", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "e9b61f44dfab74df3782271734d85a41fb48723044f7cdc2eb1a909c07eb4d85", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "start_char_idx": 1166, "end_char_idx": 1515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53f1b40c-91c2-40b5-9a72-4ca4eb021b0a": {"__data__": {"id_": "53f1b40c-91c2-40b5-9a72-4ca4eb021b0a", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be8c30f9-7588-4c81-bdc5-68687052d4df", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdf5860d3b7e548bc5cf31331ecaf0707bbf15db00054d797cf85fef5bd0c4e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce2b1630-9eec-4681-95dd-9f6d5b1e0335", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. "}, "hash": "d5e219b296c97f46da241b69598ccf8803809450c0240980802909360120ca2a", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 1515, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce2b1630-9eec-4681-95dd-9f6d5b1e0335": {"__data__": {"id_": "ce2b1630-9eec-4681-95dd-9f6d5b1e0335", "embedding": null, "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53f1b40c-91c2-40b5-9a72-4ca4eb021b0a", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7db9ee6c285a7c6cb4896f88988cb58aac635679ca6ab4f9f7fd2d490371f2aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a47a0ee-7a9d-43bb-86b1-2056aff1e51c", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. "}, "hash": "6c192acda1d32e9d64a0d6613aac404ef20153673db256b00baded0981d8e11f", "class_name": "RelatedNodeInfo"}}, "text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "start_char_idx": 1677, "end_char_idx": 1876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a47a0ee-7a9d-43bb-86b1-2056aff1e51c": {"__data__": {"id_": "6a47a0ee-7a9d-43bb-86b1-2056aff1e51c", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce2b1630-9eec-4681-95dd-9f6d5b1e0335", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4615387d0b37aef36516995dee51889f4c5da5a911bc449cfd1c03d847569a7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1287924-bff3-4b71-90b3-2a9966fae016", "node_type": "1", "metadata": {"window": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n"}, "hash": "0fe20621200d81d7eda59a0d08a5c76274f781fff32ef682cc58d67efdb2982e", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "start_char_idx": 1876, "end_char_idx": 5464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1287924-bff3-4b71-90b3-2a9966fae016": {"__data__": {"id_": "b1287924-bff3-4b71-90b3-2a9966fae016", "embedding": null, "metadata": {"window": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a47a0ee-7a9d-43bb-86b1-2056aff1e51c", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c122b8efb0f4f346808c6c4e354a656e90a8f72c67a6b79ddc1972bb3132ce88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "433ed539-4ad9-4a50-a677-3ea08191666e", "node_type": "1", "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6"}, "hash": "ca0b5e0bd8b5687548b5c2f8c465c9cafb2296d0194e362ff20f1705cc0df2d3", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "start_char_idx": 5464, "end_char_idx": 5675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "433ed539-4ad9-4a50-a677-3ea08191666e": {"__data__": {"id_": "433ed539-4ad9-4a50-a677-3ea08191666e", "embedding": null, "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa96497e9647e32dca0b419b86a6a5acc78de82841e8cf3484892adee8646e32", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1287924-bff3-4b71-90b3-2a9966fae016", "node_type": "1", "metadata": {"window": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09a9d7692377e4db9e1b06ff914ae2b58357358a9a0f4cbf66481c51d9c7ea51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ef64117-75f7-4454-b719-13774022523e", "node_type": "1", "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. "}, "hash": "c9b0c020f096ee11b716d763be647b1020b4a83084cdc596978e63f38238df46", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "start_char_idx": 5675, "end_char_idx": 5941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ef64117-75f7-4454-b719-13774022523e": {"__data__": {"id_": "8ef64117-75f7-4454-b719-13774022523e", "embedding": null, "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b47b6f6a-7bf4-4739-8ffd-267bc91011b4", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79ed746b4dfc480bfbdb302769846feaf1286930e97ee11b2932c11c2b7d23a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "433ed539-4ad9-4a50-a677-3ea08191666e", "node_type": "1", "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\n6", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a4ba2ceb23ad082262fca8dbea98000b8cb4660466a8a88a1308019464df3e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a27c0bb2-5d3d-48b1-a6ea-6ee16e567af0", "node_type": "1", "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. "}, "hash": "cac329c5dd401b6783ce39989042f4e1b83b82d33ecda9a1ecc0c5f888974961", "class_name": "RelatedNodeInfo"}}, "text": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. ", "start_char_idx": 0, "end_char_idx": 1643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a27c0bb2-5d3d-48b1-a6ea-6ee16e567af0": {"__data__": {"id_": "a27c0bb2-5d3d-48b1-a6ea-6ee16e567af0", "embedding": null, "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b47b6f6a-7bf4-4739-8ffd-267bc91011b4", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79ed746b4dfc480bfbdb302769846feaf1286930e97ee11b2932c11c2b7d23a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ef64117-75f7-4454-b719-13774022523e", "node_type": "1", "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "095ec099a703ddf5cb3de256c9acf1536753d76dfab6e91803fb381d7022d435", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "975c835c-efa7-4a9c-811f-1105f4fbc6bd", "node_type": "1", "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n"}, "hash": "0f667e0f1a56d25038a97560574db60c83e899255ab894015d6896282c511bff", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 1643, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "975c835c-efa7-4a9c-811f-1105f4fbc6bd": {"__data__": {"id_": "975c835c-efa7-4a9c-811f-1105f4fbc6bd", "embedding": null, "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b47b6f6a-7bf4-4739-8ffd-267bc91011b4", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79ed746b4dfc480bfbdb302769846feaf1286930e97ee11b2932c11c2b7d23a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a27c0bb2-5d3d-48b1-a6ea-6ee16e567af0", "node_type": "1", "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34bafcc215343bfdcb69ad607695ad9a86fbf8de66c2cf25948ffc0cfceed704", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9b46e1f-2f14-46da-9021-8547a79f1994", "node_type": "1", "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7"}, "hash": "3bec661ee5cbda76d8fbb25216ff5349b163b8be8d9d364e2ac27068b9a52ebe", "class_name": "RelatedNodeInfo"}}, "text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "start_char_idx": 2058, "end_char_idx": 2207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9b46e1f-2f14-46da-9021-8547a79f1994": {"__data__": {"id_": "d9b46e1f-2f14-46da-9021-8547a79f1994", "embedding": null, "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b47b6f6a-7bf4-4739-8ffd-267bc91011b4", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79ed746b4dfc480bfbdb302769846feaf1286930e97ee11b2932c11c2b7d23a6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "975c835c-efa7-4a9c-811f-1105f4fbc6bd", "node_type": "1", "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1425433726f39033809745e0e95448ee928c4720fc0fb88a35c6c06ef904448", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b41c37c-6950-46d8-a7f4-18c06f0a6455", "node_type": "1", "metadata": {"window": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8", "original_text": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8"}, "hash": "a09e99a8578f38aeed2aef4006ee1acc315d24fd1cc3c36655f6499e4a1324eb", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "start_char_idx": 2207, "end_char_idx": 2846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b41c37c-6950-46d8-a7f4-18c06f0a6455": {"__data__": {"id_": "2b41c37c-6950-46d8-a7f4-18c06f0a6455", "embedding": null, "metadata": {"window": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8", "original_text": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8", "page_label": "8", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfca8351-6e90-402f-8ae5-18e43836680c", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e54f88673e23e590824e8d429220c6341f4493ff71f9a88595c0e5662a13fe1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9b46e1f-2f14-46da-9021-8547a79f1994", "node_type": "1", "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c809e05d79013b479139bef6a174e9cde311be4a0fef9948d1660d159268414", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5db8d93c-97fa-4d62-9f89-748fb8722730", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n", "original_text": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022. "}, "hash": "e28f78f7b3bc1d59569f819ee6c963c14a20d750bae1d9fb5ee1c4ac06419022", "class_name": "RelatedNodeInfo"}}, "text": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8", "start_char_idx": 0, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5db8d93c-97fa-4d62-9f89-748fb8722730": {"__data__": {"id_": "5db8d93c-97fa-4d62-9f89-748fb8722730", "embedding": null, "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n", "original_text": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022. ", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40392e94ec764a29082343afb09bdc76e322184f53cc6197450bdbcf5644946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b41c37c-6950-46d8-a7f4-18c06f0a6455", "node_type": "1", "metadata": {"window": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8", "original_text": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8", "page_label": "8", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "067462251e4e755739539e0b17015c50d90237d44d43cb486dc1816809610ae6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "256a1601-3baa-448a-98b1-42bcef1a8782", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n", "original_text": "Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n"}, "hash": "82cf727c6d62298105f7147bcc4d8c346a2dca3be657db67ab3f07f54ee42aa5", "class_name": "RelatedNodeInfo"}}, "text": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022. ", "start_char_idx": 0, "end_char_idx": 189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "256a1601-3baa-448a-98b1-42bcef1a8782": {"__data__": {"id_": "256a1601-3baa-448a-98b1-42bcef1a8782", "embedding": null, "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n", "original_text": "Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40392e94ec764a29082343afb09bdc76e322184f53cc6197450bdbcf5644946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5db8d93c-97fa-4d62-9f89-748fb8722730", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n", "original_text": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022. ", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffeed3b7e212e1fe00e8d830b3abd830e3a8f90eda8b970b416d885b66848718", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b93dcb9-0b97-4d92-8041-8c7023b40fed", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022. ", "original_text": "2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022. "}, "hash": "937bdcf1af85fdddf3c88bf88876d16523152c1f34d9c0ef28df63a9a67a6914", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n", "start_char_idx": 189, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b93dcb9-0b97-4d92-8041-8c7023b40fed": {"__data__": {"id_": "9b93dcb9-0b97-4d92-8041-8c7023b40fed", "embedding": null, "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022. ", "original_text": "2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022. ", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40392e94ec764a29082343afb09bdc76e322184f53cc6197450bdbcf5644946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "256a1601-3baa-448a-98b1-42bcef1a8782", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n", "original_text": "Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f747c657762dfa2ec985e45ce05039d2a55531f0f5b716a00cfb9828fb18f640", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e96a0e3-d536-4e4c-a80a-58d1a6e50e11", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n", "original_text": "Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n"}, "hash": "5c1ed264fa2f518e067954494db1cb3f6fb2aec1a19cef09742b9ae968d32b1d", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022. ", "start_char_idx": 335, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e96a0e3-d536-4e4c-a80a-58d1a6e50e11": {"__data__": {"id_": "8e96a0e3-d536-4e4c-a80a-58d1a6e50e11", "embedding": null, "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n", "original_text": "Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40392e94ec764a29082343afb09bdc76e322184f53cc6197450bdbcf5644946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b93dcb9-0b97-4d92-8041-8c7023b40fed", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022. ", "original_text": "2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022. ", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72be3dfa8265c071901c2e0bf6f52eabfb7a8fc7904102da27c9c89e8c61abbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0893809-3817-4952-87e1-c81b9066baa9", "node_type": "1", "metadata": {"window": "Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n"}, "hash": "b796590242635cd525057e5f6d9530dd63d4dfb78a14705e8721b9804f491963", "class_name": "RelatedNodeInfo"}}, "text": "Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n", "start_char_idx": 683, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0893809-3817-4952-87e1-c81b9066baa9": {"__data__": {"id_": "e0893809-3817-4952-87e1-c81b9066baa9", "embedding": null, "metadata": {"window": "Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40392e94ec764a29082343afb09bdc76e322184f53cc6197450bdbcf5644946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e96a0e3-d536-4e4c-a80a-58d1a6e50e11", "node_type": "1", "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n", "original_text": "Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b745316385b66e7455d3b179e32bb0ebb78de914d0b2e9e8ed1171f2b5306cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a64ebf5f-4fc1-434b-9e45-800ddecccf1c", "node_type": "1", "metadata": {"window": "2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022. "}, "hash": "97c067328e823bb6f6b81c0ae20be4d0fbae853df234a325249b0a5c81f10b10", "class_name": "RelatedNodeInfo"}}, "text": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n", "start_char_idx": 1122, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a64ebf5f-4fc1-434b-9e45-800ddecccf1c": {"__data__": {"id_": "a64ebf5f-4fc1-434b-9e45-800ddecccf1c", "embedding": null, "metadata": {"window": "2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022. ", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40392e94ec764a29082343afb09bdc76e322184f53cc6197450bdbcf5644946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0893809-3817-4952-87e1-c81b9066baa9", "node_type": "1", "metadata": {"window": "Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cb347a4c5ddf89b2e867bc9502e7604788061006de0ff1a05615f1bad2afcf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54de995a-d95a-406a-b821-92ce3ff90ced", "node_type": "1", "metadata": {"window": "Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n"}, "hash": "713b2862afa1c69fce3932c97523de37c92f983b66a76d8788bf9a64ccd3b93c", "class_name": "RelatedNodeInfo"}}, "text": "4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022. ", "start_char_idx": 1218, "end_char_idx": 1497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54de995a-d95a-406a-b821-92ce3ff90ced": {"__data__": {"id_": "54de995a-d95a-406a-b821-92ce3ff90ced", "embedding": null, "metadata": {"window": "Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40392e94ec764a29082343afb09bdc76e322184f53cc6197450bdbcf5644946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a64ebf5f-4fc1-434b-9e45-800ddecccf1c", "node_type": "1", "metadata": {"window": "2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022. ", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a914d28fa779a4a83a56e771f3378437fd082ab66fd491b53cf2e0a0e90c3a78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aac47b6c-fa75-408d-8c47-9c5b15c10fef", "node_type": "1", "metadata": {"window": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9"}, "hash": "b99a8bef9c74434605de4956d638e086b7daff9789964ddd97dfd138ec57454b", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n", "start_char_idx": 1497, "end_char_idx": 1649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aac47b6c-fa75-408d-8c47-9c5b15c10fef": {"__data__": {"id_": "aac47b6c-fa75-408d-8c47-9c5b15c10fef", "embedding": null, "metadata": {"window": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b40392e94ec764a29082343afb09bdc76e322184f53cc6197450bdbcf5644946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54de995a-d95a-406a-b821-92ce3ff90ced", "node_type": "1", "metadata": {"window": "Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d87453ac7f9eccef6f4f9fde7edd6c4a9cc4074b39633fc1c2e6598dfdc85f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c396bc-c7a4-43b9-b433-38aa0533f82d", "node_type": "1", "metadata": {"window": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10"}, "hash": "3c71f153d53812b5c82dff4ffb2bd8362ef1a8df6789bff0915497abdff003be", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "start_char_idx": 1649, "end_char_idx": 2096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c396bc-c7a4-43b9-b433-38aa0533f82d": {"__data__": {"id_": "57c396bc-c7a4-43b9-b433-38aa0533f82d", "embedding": null, "metadata": {"window": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3105b0d4-8518-4336-9440-5ee0a82312a9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "113f736ef7351dcb11d745a33fd98d8bdf819037a8086acce7ac931a6bd397a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aac47b6c-fa75-408d-8c47-9c5b15c10fef", "node_type": "1", "metadata": {"window": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, an $8.9 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nthree months ended June 30, 2022.  Includes a $6.2\u00a0million gain on the currency remeasurement of deferred tax assets\nrelating to Swiss tax reform in the three months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Nine \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$177,412,857 \u00a0\u00a0\u00a0 \u00a0$155,076,422 \u00a0\u00a0\u00a0 \u00a014.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0171,102,049 \u00a0\u00a0\u00a0 \u00a0\u00a0150,202,605 \u00a0\u00a0\u00a0 \u00a013.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a06,310,808 \u00a0\u00a03.56% \u00a0\u00a04,873,817 \u00a0\u00a03.14% \u00a029.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "123cb6b5a79e870f2f126991908abc4bbb63f6b5ca37548790db551e9dc7ff3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf5fe614-f3e2-456b-b6d3-15e98f2bb1df", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n", "original_text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022. "}, "hash": "7b3a5a71428b3cf6ee07565df77b90a2d976c4a8c27501cc7dea0d5834b8be3a", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "start_char_idx": 0, "end_char_idx": 1246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf5fe614-f3e2-456b-b6d3-15e98f2bb1df": {"__data__": {"id_": "bf5fe614-f3e2-456b-b6d3-15e98f2bb1df", "embedding": null, "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n", "original_text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022. ", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b97e7fe2da14869f7c46e38b1fec9ac6881902ac93cad4263fb28121d324594", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c396bc-c7a4-43b9-b433-38aa0533f82d", "node_type": "1", "metadata": {"window": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9aa1859c1c0dbe459fed775cbaab3076b9cd51c8680b7af1a3e4c8282a89b1ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d72eebe5-b86a-495a-807a-a9847dc030bd", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n", "original_text": "Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n"}, "hash": "585250dd8272f4bb5d68c65796111fe92f9855f23dde69a487d455d34d742165", "class_name": "RelatedNodeInfo"}}, "text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022. ", "start_char_idx": 0, "end_char_idx": 388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d72eebe5-b86a-495a-807a-a9847dc030bd": {"__data__": {"id_": "d72eebe5-b86a-495a-807a-a9847dc030bd", "embedding": null, "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n", "original_text": "Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b97e7fe2da14869f7c46e38b1fec9ac6881902ac93cad4263fb28121d324594", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf5fe614-f3e2-456b-b6d3-15e98f2bb1df", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n", "original_text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022. ", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e024fbd996a6004ce0eb213effceea47d8ac6751806de87b149e586875b72eff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d2833ba-cde8-47c9-b298-8f3065e22dc4", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022. ", "original_text": "2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022. "}, "hash": "187c3566e619f1057920da6287e11bee7efdc686d56201354461948f1346fcb2", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n", "start_char_idx": 388, "end_char_idx": 532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d2833ba-cde8-47c9-b298-8f3065e22dc4": {"__data__": {"id_": "3d2833ba-cde8-47c9-b298-8f3065e22dc4", "embedding": null, "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022. ", "original_text": "2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022. ", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b97e7fe2da14869f7c46e38b1fec9ac6881902ac93cad4263fb28121d324594", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d72eebe5-b86a-495a-807a-a9847dc030bd", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n", "original_text": "Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "587eec0aab106641c2a9bf3ee6c31d11e18088d005f3078a42c5a0f5870cae14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2ee3d02-14ee-4381-a5f0-4b5e0e6e01f9", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n", "original_text": "Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n"}, "hash": "27fa4cd58d00c1f45f14b262e2fb8a0ba68f93acf303d560b9ac168e2eaea8c8", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022. ", "start_char_idx": 532, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2ee3d02-14ee-4381-a5f0-4b5e0e6e01f9": {"__data__": {"id_": "e2ee3d02-14ee-4381-a5f0-4b5e0e6e01f9", "embedding": null, "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n", "original_text": "Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b97e7fe2da14869f7c46e38b1fec9ac6881902ac93cad4263fb28121d324594", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d2833ba-cde8-47c9-b298-8f3065e22dc4", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022. ", "original_text": "2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022. ", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "525040abda328f59fbf44ff5c57b232d51e4ebbbb3c8d555e4e6baa5b363da18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50ecd62d-972e-4d44-b180-7139553b4717", "node_type": "1", "metadata": {"window": "Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n"}, "hash": "bb0ba5b478be0afeb69a5c9155583aab494b588e2b2f64d568261ac08b24ea08", "class_name": "RelatedNodeInfo"}}, "text": "Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n", "start_char_idx": 952, "end_char_idx": 1390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50ecd62d-972e-4d44-b180-7139553b4717": {"__data__": {"id_": "50ecd62d-972e-4d44-b180-7139553b4717", "embedding": null, "metadata": {"window": "Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b97e7fe2da14869f7c46e38b1fec9ac6881902ac93cad4263fb28121d324594", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2ee3d02-14ee-4381-a5f0-4b5e0e6e01f9", "node_type": "1", "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n", "original_text": "Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "834f0042b12f182186a0a2e82ded4e269d1fb181a27e25a328c24c2f900c38e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01c0cb71-bbe4-471b-9366-0f2c85ea78bf", "node_type": "1", "metadata": {"window": "2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022. "}, "hash": "40f986d094abdf08fb8005350c73ebd8195844d256168e5e18c03970c1377807", "class_name": "RelatedNodeInfo"}}, "text": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n", "start_char_idx": 1390, "end_char_idx": 1485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01c0cb71-bbe4-471b-9366-0f2c85ea78bf": {"__data__": {"id_": "01c0cb71-bbe4-471b-9366-0f2c85ea78bf", "embedding": null, "metadata": {"window": "2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022. ", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b97e7fe2da14869f7c46e38b1fec9ac6881902ac93cad4263fb28121d324594", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50ecd62d-972e-4d44-b180-7139553b4717", "node_type": "1", "metadata": {"window": "Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdf21032ddd721b61640d20db99b10876c46d61228bf65d9784cbff092d50c88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d3ffaa2-a63e-4ef0-ab90-d6c54c32fad8", "node_type": "1", "metadata": {"window": "Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n"}, "hash": "05f099f303a43f45135838a3d9e57fcf480b1be038396636271db4046eb3eaba", "class_name": "RelatedNodeInfo"}}, "text": "4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022. ", "start_char_idx": 1485, "end_char_idx": 1762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d3ffaa2-a63e-4ef0-ab90-d6c54c32fad8": {"__data__": {"id_": "9d3ffaa2-a63e-4ef0-ab90-d6c54c32fad8", "embedding": null, "metadata": {"window": "Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b97e7fe2da14869f7c46e38b1fec9ac6881902ac93cad4263fb28121d324594", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01c0cb71-bbe4-471b-9366-0f2c85ea78bf", "node_type": "1", "metadata": {"window": "2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022. ", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29742b8c9bc4a56b91917dfa7b75ccf2c8c09eb3a2da9f5d110e595d2384fe0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccf6cb6a-9a37-4daf-b330-625fa5e0d2a2", "node_type": "1", "metadata": {"window": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11"}, "hash": "c5d89a5a7437e97fea50f08ab05e421375035194c47f585c7558f2764f094af8", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n", "start_char_idx": 1762, "end_char_idx": 1913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccf6cb6a-9a37-4daf-b330-625fa5e0d2a2": {"__data__": {"id_": "ccf6cb6a-9a37-4daf-b330-625fa5e0d2a2", "embedding": null, "metadata": {"window": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b97e7fe2da14869f7c46e38b1fec9ac6881902ac93cad4263fb28121d324594", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d3ffaa2-a63e-4ef0-ab90-d6c54c32fad8", "node_type": "1", "metadata": {"window": "Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n 3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50398ff5f6e88c7dba70c9c1f74b40fc9c7498ce447976c87bdb4ad511c20d85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9d88532-40c3-48f9-a9f4-b11318586b04", "node_type": "1", "metadata": {"window": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12", "original_text": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12"}, "hash": "7a36171a683cfc07f7a6dc9e1a5075a6e1c0f2d2d2a051322ee0031705eaecc7", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "start_char_idx": 1913, "end_char_idx": 2321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9d88532-40c3-48f9-a9f4-b11318586b04": {"__data__": {"id_": "a9d88532-40c3-48f9-a9f4-b11318586b04", "embedding": null, "metadata": {"window": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12", "original_text": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12", "page_label": "12", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b429cd82-4359-4aed-a8ea-b0f48fba2b9b", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8494813bf686451c1fee03baee41e3d764b7bbcca15a170557cbaa13caa29466", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccf6cb6a-9a37-4daf-b330-625fa5e0d2a2", "node_type": "1", "metadata": {"window": "3\u00a0The goodwill impairment is related to the Company's non-wholly-owned subsidiary in Brazil.\n\u00a0\n 4\u00a0Includes a $60.0 million gain on the sale of non-core businesses, a $6.3 million loss on the currency remeasurement of\ndeferred tax assets relating to Swiss tax reform, and Turkey foreign exchange remeasurement expense of $5.8 million in the\nnine months ended June 30, 2022.  Includes a $1.1\u00a0million loss on the currency remeasurement of deferred tax assets relating\nto Swiss tax reform in the nine months ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\n11", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce1df2392cec4db1c87094c962048eeae37a2f3e74b5b952e56c19c29f558122", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67721d3e-a1c2-431b-aa5d-ac761113e92e", "node_type": "1", "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "Non-GAAP\n% change\nvs. "}, "hash": "af0fb228dd918054c88ae796b6a44f18cbb0e56b418e74b07764a6042fa6e3ac", "class_name": "RelatedNodeInfo"}}, "text": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12", "start_char_idx": 0, "end_char_idx": 1251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67721d3e-a1c2-431b-aa5d-ac761113e92e": {"__data__": {"id_": "67721d3e-a1c2-431b-aa5d-ac761113e92e", "embedding": null, "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "Non-GAAP\n% change\nvs. ", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08edd3a91cf72a36813ac40fc40c823aa36e56a549574efc8b3579c4bf2f7672", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9d88532-40c3-48f9-a9f4-b11318586b04", "node_type": "1", "metadata": {"window": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12", "original_text": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12", "page_label": "12", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a52dbae91115cfa034eb93aba39779eb9c1e2ebd3e2decc735225ee905d6edbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72904d5c-b15c-4faa-b0f4-d7f7f438bec8", "node_type": "1", "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0"}, "hash": "cf226c84dcce8905e228aa109a4ec01127331e89d33d5610e37a933e178e68e4", "class_name": "RelatedNodeInfo"}}, "text": "Non-GAAP\n% change\nvs. ", "start_char_idx": 0, "end_char_idx": 22, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72904d5c-b15c-4faa-b0f4-d7f7f438bec8": {"__data__": {"id_": "72904d5c-b15c-4faa-b0f4-d7f7f438bec8", "embedding": null, "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08edd3a91cf72a36813ac40fc40c823aa36e56a549574efc8b3579c4bf2f7672", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67721d3e-a1c2-431b-aa5d-ac761113e92e", "node_type": "1", "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "Non-GAAP\n% change\nvs. ", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4835f81eca151f33d891d3bf58b6b047d913287450b6a270a9b9218cc5eae413", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d5b461a-3271-4d97-935c-a471129c273a", "node_type": "1", "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "984006e0413644649c58f5691921ab7b8ff7eb27d8d386884f37155ed3daebf5", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "start_char_idx": 22, "end_char_idx": 458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d5b461a-3271-4d97-935c-a471129c273a": {"__data__": {"id_": "0d5b461a-3271-4d97-935c-a471129c273a", "embedding": null, "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08edd3a91cf72a36813ac40fc40c823aa36e56a549574efc8b3579c4bf2f7672", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72904d5c-b15c-4faa-b0f4-d7f7f438bec8", "node_type": "1", "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b15c4eb96a4383f01ad21a9ef8f3f8b446437d649e9b497cdcc784670864895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6b4313c-fbc1-4662-b7ea-6a716d9536a3", "node_type": "1", "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13"}, "hash": "f70c4cf8fb77b04c62a5d700b092756302c224f42c8174f851257c5ae29ea5eb", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 458, "end_char_idx": 635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6b4313c-fbc1-4662-b7ea-6a716d9536a3": {"__data__": {"id_": "e6b4313c-fbc1-4662-b7ea-6a716d9536a3", "embedding": null, "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08edd3a91cf72a36813ac40fc40c823aa36e56a549574efc8b3579c4bf2f7672", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d5b461a-3271-4d97-935c-a471129c273a", "node_type": "1", "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac59c956a7437c50621061ec6603379e3269d8dbb2ea39b4fad88f1fa365e38f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d230fa4-278a-4ee2-a56f-1b0eee309acc", "node_type": "1", "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n"}, "hash": "669368859a45176e2ab7a301248a3a6534e57387a4f7b1cf6c2fa410b64238e0", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "start_char_idx": 635, "end_char_idx": 1177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d230fa4-278a-4ee2-a56f-1b0eee309acc": {"__data__": {"id_": "8d230fa4-278a-4ee2-a56f-1b0eee309acc", "embedding": null, "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2804764e-0d08-458a-b941-ec3b619cb0ba", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b2bb4a0541ab3111de035d9c0a5870a87af2ac33362a3852ed4ecd13e5ca436", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6b4313c-fbc1-4662-b7ea-6a716d9536a3", "node_type": "1", "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9330692397b1c430f20e62d540d93ae4854ef384498336b208503b57c78d61e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48714758-3b4d-420c-a446-7b1d469f7352", "node_type": "1", "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n"}, "hash": "54765c136315861d5e4392010fc9e9c52b0a609b267a0787cf592e902c44fb9e", "class_name": "RelatedNodeInfo"}}, "text": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n", "start_char_idx": 0, "end_char_idx": 1223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48714758-3b4d-420c-a446-7b1d469f7352": {"__data__": {"id_": "48714758-3b4d-420c-a446-7b1d469f7352", "embedding": null, "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2804764e-0d08-458a-b941-ec3b619cb0ba", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b2bb4a0541ab3111de035d9c0a5870a87af2ac33362a3852ed4ecd13e5ca436", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d230fa4-278a-4ee2-a56f-1b0eee309acc", "node_type": "1", "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d746b8400efa93980446874a93b6fd4e22c4d71b11c1e8009dccaafb1815e700", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11b1a9e1-10c4-448e-aca2-50a203f3643b", "node_type": "1", "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "14"}, "hash": "d5a6a7b7a5b3aa19c3f7ea300aae94e9037977f1cb62e7d0d37e6b7813986706", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n", "start_char_idx": 1223, "end_char_idx": 1297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11b1a9e1-10c4-448e-aca2-50a203f3643b": {"__data__": {"id_": "11b1a9e1-10c4-448e-aca2-50a203f3643b", "embedding": null, "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "14", "page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2804764e-0d08-458a-b941-ec3b619cb0ba", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b2bb4a0541ab3111de035d9c0a5870a87af2ac33362a3852ed4ecd13e5ca436", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48714758-3b4d-420c-a446-7b1d469f7352", "node_type": "1", "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efd9c82f74aafb19b16a34a2413f06e4138c8124decc8a9398c2ef6dfe88214b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74ab59e6-c45c-44e8-9883-ff2d66c406f6", "node_type": "1", "metadata": {"window": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "original_text": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "1d71a38f21f496ab8d9aaadf836424f77a12795c5052ba93a7eff7a4c34d0f19", "class_name": "RelatedNodeInfo"}}, "text": "14", "start_char_idx": 26, "end_char_idx": 28, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74ab59e6-c45c-44e8-9883-ff2d66c406f6": {"__data__": {"id_": "74ab59e6-c45c-44e8-9883-ff2d66c406f6", "embedding": null, "metadata": {"window": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "original_text": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd9c2d22-daf1-4438-92c9-2c5e663f9a3f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2667b36cd2b7168c594ed065cfd5488339b1848e6246edc43735e952367cac4c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11b1a9e1-10c4-448e-aca2-50a203f3643b", "node_type": "1", "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "14", "page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8375d4a08e7932aabcbd1aa9e864ceccfc7faccd8a52b973571740a47d9d8717", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "943cd21a-56ab-4d4e-a5fe-460dfd36b099", "node_type": "1", "metadata": {"window": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15"}, "hash": "4744b690b1916efe2c7f8c6b8959dccb213f9bde03881bb86e485e6ef05aa9ce", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "943cd21a-56ab-4d4e-a5fe-460dfd36b099": {"__data__": {"id_": "943cd21a-56ab-4d4e-a5fe-460dfd36b099", "embedding": null, "metadata": {"window": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "page_label": "15", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bd9c2d22-daf1-4438-92c9-2c5e663f9a3f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2667b36cd2b7168c594ed065cfd5488339b1848e6246edc43735e952367cac4c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74ab59e6-c45c-44e8-9883-ff2d66c406f6", "node_type": "1", "metadata": {"window": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "original_text": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53ba3b0976e8f4180671bbc88b84a7006f6c63f23a78aa2430654654a4a46b23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c405952f-34bc-4b6b-923c-c25fa9a2cf50", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. "}, "hash": "d9aed67b05366b8f2d4f8cd3d484f031546e0e9d6173cae8222769eaa184376f", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "start_char_idx": 179, "end_char_idx": 1370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c405952f-34bc-4b6b-923c-c25fa9a2cf50": {"__data__": {"id_": "c405952f-34bc-4b6b-923c-c25fa9a2cf50", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "16", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3be76cb-f655-46f6-be0f-bc2b34951518", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cf2ba7ca968f8bf378cdabe77646f79eed8e508e63707b7ba9266a78e08dd6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "943cd21a-56ab-4d4e-a5fe-460dfd36b099", "node_type": "1", "metadata": {"window": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "page_label": "15", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40f8af3815dae8797779d50e63c9fbf59a75ebda79eef780fc89adb03930171e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c985b6-049c-49ba-9dbd-9df197aabd9d", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "original_text": "prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16"}, "hash": "7c24c221fa9db3d501817961b8c2f0016d7b902b419adf46e3fa6a8b5a27a4fa", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "start_char_idx": 0, "end_char_idx": 768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c985b6-049c-49ba-9dbd-9df197aabd9d": {"__data__": {"id_": "57c985b6-049c-49ba-9dbd-9df197aabd9d", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "original_text": "prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "page_label": "16", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3be76cb-f655-46f6-be0f-bc2b34951518", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cf2ba7ca968f8bf378cdabe77646f79eed8e508e63707b7ba9266a78e08dd6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c405952f-34bc-4b6b-923c-c25fa9a2cf50", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "16", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fc44f2125c28a57dda2afbabe2bc6a20f5dc43e6b0853a6701348d928a551d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7c622d3-98d4-4b5b-8496-d934757d4524", "node_type": "1", "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n"}, "hash": "3d107e97852a490bee625d0d92e5dc8bf1a2dff654e4ebd1617a0473a2978817", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "start_char_idx": 768, "end_char_idx": 1027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7c622d3-98d4-4b5b-8496-d934757d4524": {"__data__": {"id_": "e7c622d3-98d4-4b5b-8496-d934757d4524", "embedding": null, "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73efb85c-f47a-44ee-bd17-6ce84ee08a14", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d751f186190f9138b7358a8798a5cb5ad8e4e53a1a4e9122ad0127f63890d778", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c985b6-049c-49ba-9dbd-9df197aabd9d", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "original_text": "prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "page_label": "16", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f69fc0f2e7283c4bb0dd69645a2dfd40056693f6a6f5392a714131a3359ea45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9987be0f-695b-4e3c-81c0-2330f8489afe", "node_type": "1", "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0"}, "hash": "a09bc0643f320f5d58d6429555eb83a31ddb295b677e273714ad468e40b95c81", "class_name": "RelatedNodeInfo"}}, "text": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n", "start_char_idx": 0, "end_char_idx": 184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9987be0f-695b-4e3c-81c0-2330f8489afe": {"__data__": {"id_": "9987be0f-695b-4e3c-81c0-2330f8489afe", "embedding": null, "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73efb85c-f47a-44ee-bd17-6ce84ee08a14", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d751f186190f9138b7358a8798a5cb5ad8e4e53a1a4e9122ad0127f63890d778", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7c622d3-98d4-4b5b-8496-d934757d4524", "node_type": "1", "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87c8010fcc93c677c01a003a65b57a75881320af480c8cf504c27249c36e945e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "660f6b69-2822-4b5a-a541-a5660695f751", "node_type": "1", "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "b2d0102c2e7c1a1b4c12be369811ceb3e2d2e6e8ab39efacc79a31a660fcb353", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "start_char_idx": 184, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "660f6b69-2822-4b5a-a541-a5660695f751": {"__data__": {"id_": "660f6b69-2822-4b5a-a541-a5660695f751", "embedding": null, "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73efb85c-f47a-44ee-bd17-6ce84ee08a14", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d751f186190f9138b7358a8798a5cb5ad8e4e53a1a4e9122ad0127f63890d778", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9987be0f-695b-4e3c-81c0-2330f8489afe", "node_type": "1", "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a135621245bd3fc8c3f16db47e179ac347a1b188a5688ad7d144803ff93d9d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7061d1a0-97af-4bd1-b23a-9cacf5cad9b1", "node_type": "1", "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17"}, "hash": "34d1e7e7b75814d0ff2ec43f3f42460c17d59cbd301a90812c44e062fffdc0ca", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 260, "end_char_idx": 437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7061d1a0-97af-4bd1-b23a-9cacf5cad9b1": {"__data__": {"id_": "7061d1a0-97af-4bd1-b23a-9cacf5cad9b1", "embedding": null, "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73efb85c-f47a-44ee-bd17-6ce84ee08a14", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d751f186190f9138b7358a8798a5cb5ad8e4e53a1a4e9122ad0127f63890d778", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "660f6b69-2822-4b5a-a541-a5660695f751", "node_type": "1", "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c7b496a75465e842a840e9dadb752582f7d44e49cd611f355b3166b2e967e81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b10782ed-de35-411d-acb5-49df0f9d0d92", "node_type": "1", "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n"}, "hash": "25007648c6c3a119f1ad91346eb42f10b2f1a7134f77ddad6b935827f01af8f3", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "start_char_idx": 437, "end_char_idx": 1423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b10782ed-de35-411d-acb5-49df0f9d0d92": {"__data__": {"id_": "b10782ed-de35-411d-acb5-49df0f9d0d92", "embedding": null, "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9829c99f-a04e-407c-9935-6fec97bb62ea", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f59182d4c293e8b001597a3d08b487f53e5f84324c08411dee41e73f9e0932e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7061d1a0-97af-4bd1-b23a-9cacf5cad9b1", "node_type": "1", "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25007871f9f2bdf6c0f05a4f055fe30a82494f7b3d8f21a649979841a45e5914", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "980461ff-52e3-493c-9a8c-dc68adaf1289", "node_type": "1", "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0"}, "hash": "a81f74aadc9a5f222a1daeac388c66368078e3721630e0c85698f7c779cf17b5", "class_name": "RelatedNodeInfo"}}, "text": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n", "start_char_idx": 0, "end_char_idx": 806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "980461ff-52e3-493c-9a8c-dc68adaf1289": {"__data__": {"id_": "980461ff-52e3-493c-9a8c-dc68adaf1289", "embedding": null, "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9829c99f-a04e-407c-9935-6fec97bb62ea", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f59182d4c293e8b001597a3d08b487f53e5f84324c08411dee41e73f9e0932e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b10782ed-de35-411d-acb5-49df0f9d0d92", "node_type": "1", "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6470aecc4ae06e3ee6eab377db7f6a77a36f8ea802a1bdbedcf8cf789d6f505d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62d566a0-688d-4083-a6b1-02004be6a552", "node_type": "1", "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "a84ade638d563463c652640a7bb94d32f4ddd529fea1fc1de77088e73b89376f", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "start_char_idx": 806, "end_char_idx": 1072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62d566a0-688d-4083-a6b1-02004be6a552": {"__data__": {"id_": "62d566a0-688d-4083-a6b1-02004be6a552", "embedding": null, "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9829c99f-a04e-407c-9935-6fec97bb62ea", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f59182d4c293e8b001597a3d08b487f53e5f84324c08411dee41e73f9e0932e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "980461ff-52e3-493c-9a8c-dc68adaf1289", "node_type": "1", "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a335d74ac3d71b56d4e7baa396e3a1ce8726797906e7f4aa5a74bf8fb348d812", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c437a22c-6975-4875-bfd4-cc9bc1b88740", "node_type": "1", "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18"}, "hash": "62b6f3a2c10a7fc40f07ba3b529c1ada1a13f8e8fd344b1eef386721231f40c9", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 1072, "end_char_idx": 1249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c437a22c-6975-4875-bfd4-cc9bc1b88740": {"__data__": {"id_": "c437a22c-6975-4875-bfd4-cc9bc1b88740", "embedding": null, "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9829c99f-a04e-407c-9935-6fec97bb62ea", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f59182d4c293e8b001597a3d08b487f53e5f84324c08411dee41e73f9e0932e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62d566a0-688d-4083-a6b1-02004be6a552", "node_type": "1", "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6145bddfdec5fce8f55e1c81466da7b3c44cd5527aaea491ad346c932d5608f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b45935b-531f-42ae-940b-d1870c64919a", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. "}, "hash": "ed613313a7f41e43591cf70ceabbab1c06c8124b0f6e8e159f0e8c102d04aafc", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "start_char_idx": 1249, "end_char_idx": 1309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b45935b-531f-42ae-940b-d1870c64919a": {"__data__": {"id_": "0b45935b-531f-42ae-940b-d1870c64919a", "embedding": null, "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26fe9012-9886-4bfe-9e07-2a2d8815347e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09c3ab8a0b5e0b16606401285d188f1812120abb2f5fa69f93eeb8978b23f329", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c437a22c-6975-4875-bfd4-cc9bc1b88740", "node_type": "1", "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa775eb2564bb8a886251f6940bf490bd8a255770e3128f08acc797d86ff2682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b454b7d8-fdeb-4ba8-9816-c8bf24f16355", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. "}, "hash": "48c4ee62a45fe25506cf7a70728f97bac2c442f21705c472c543303ccee1a15d", "class_name": "RelatedNodeInfo"}}, "text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "start_char_idx": 0, "end_char_idx": 95, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b454b7d8-fdeb-4ba8-9816-c8bf24f16355": {"__data__": {"id_": "b454b7d8-fdeb-4ba8-9816-c8bf24f16355", "embedding": null, "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26fe9012-9886-4bfe-9e07-2a2d8815347e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09c3ab8a0b5e0b16606401285d188f1812120abb2f5fa69f93eeb8978b23f329", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b45935b-531f-42ae-940b-d1870c64919a", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5baaabd385287713579e7c79f95f758b36ec8845ea03539d10f6f522f40b7e13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7159f84b-434e-4b21-8543-0e12ccccd01f", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19"}, "hash": "89f0c57e74e3063ce8507fc6e15dccaaf4470e816bf838c1a44dd5900c08113a", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "start_char_idx": 95, "end_char_idx": 395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7159f84b-434e-4b21-8543-0e12ccccd01f": {"__data__": {"id_": "7159f84b-434e-4b21-8543-0e12ccccd01f", "embedding": null, "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "26fe9012-9886-4bfe-9e07-2a2d8815347e", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09c3ab8a0b5e0b16606401285d188f1812120abb2f5fa69f93eeb8978b23f329", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b454b7d8-fdeb-4ba8-9816-c8bf24f16355", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "084fe957029471df74cfccb3026561a9890b16057c8deb219cf52cc794beaa6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "681b15af-3529-4336-8be3-32ef122ac854", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "94a228b179bcfc278e686df0c04661592469c7ab17ff17865d0a491ed12119f8", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "start_char_idx": 395, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "681b15af-3529-4336-8be3-32ef122ac854": {"__data__": {"id_": "681b15af-3529-4336-8be3-32ef122ac854", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3836303-9cf4-4bc8-a48e-9d167c85aa93", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edd796ef6af444acc29de121738d375bb91c58be2759e0d6094744bb8cb7113f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7159f84b-434e-4b21-8543-0e12ccccd01f", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07a43157aeb50f7fa23430e523e4b56346eb35ece2036e6ee6df2a9f563672f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7b28925-b5d8-4ed5-bd2f-43e332697f3b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "af686fd1b7fdbf539c5a14a3c06fb233b6717a1169c7e07af0bf9ceadc849e0f", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7b28925-b5d8-4ed5-bd2f-43e332697f3b": {"__data__": {"id_": "a7b28925-b5d8-4ed5-bd2f-43e332697f3b", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3836303-9cf4-4bc8-a48e-9d167c85aa93", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edd796ef6af444acc29de121738d375bb91c58be2759e0d6094744bb8cb7113f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "681b15af-3529-4336-8be3-32ef122ac854", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51b3f2af3870fbd5e5844d8a6e28f46b9db4684a7a627b35575a4fe9cef6e792", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8f8efb0-67ec-4957-a87f-c7144aac9a1d", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20"}, "hash": "32339278348fa250daef8eb5f36950a9bf346ec26b2a7599a2e00d284604e46d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 16, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8f8efb0-67ec-4957-a87f-c7144aac9a1d": {"__data__": {"id_": "c8f8efb0-67ec-4957-a87f-c7144aac9a1d", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3836303-9cf4-4bc8-a48e-9d167c85aa93", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edd796ef6af444acc29de121738d375bb91c58be2759e0d6094744bb8cb7113f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7b28925-b5d8-4ed5-bd2f-43e332697f3b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82daada52475e3d52d96528004b0d94c926d0c75286d80ff6df1c340eb7099c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43e64f46-ac7f-486d-a95f-54f81f6f95fe", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. "}, "hash": "4066542d87bf52e2949b36d5d6af76ae69b8ea6681cfd458187e7732e9d5a570", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "start_char_idx": 851, "end_char_idx": 926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43e64f46-ac7f-486d-a95f-54f81f6f95fe": {"__data__": {"id_": "43e64f46-ac7f-486d-a95f-54f81f6f95fe", "embedding": null, "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7ee99bb-dccc-489b-8b3e-724db5cfd5e8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3aae8f69a5b77dd62f6f9607ea81fe15176a2efa614f34785d9003bb86d8ea16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8f8efb0-67ec-4957-a87f-c7144aac9a1d", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9056a0e0e97bb5b9cbae436cadbc17b14ee6a3242cf66cee286733717830064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce7bb7a9-180a-4acf-8ab0-c48c06679df0", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. "}, "hash": "d153a0310a98a2dd90a3b4e773ab00b221be413be637e6947e7cd0066b3d9b48", "class_name": "RelatedNodeInfo"}}, "text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "start_char_idx": 0, "end_char_idx": 79, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce7bb7a9-180a-4acf-8ab0-c48c06679df0": {"__data__": {"id_": "ce7bb7a9-180a-4acf-8ab0-c48c06679df0", "embedding": null, "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7ee99bb-dccc-489b-8b3e-724db5cfd5e8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3aae8f69a5b77dd62f6f9607ea81fe15176a2efa614f34785d9003bb86d8ea16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43e64f46-ac7f-486d-a95f-54f81f6f95fe", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90229528ec83587fdd838f99a70ae00154822e3edb3874556e750f5ff3b02c29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58ad214b-c37b-4aae-9480-27541a1413e7", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21"}, "hash": "6c782aad1c3d7ded493e234b72bde3d12f6b96ee0675515ab58e2b7a1ef43032", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "start_char_idx": 79, "end_char_idx": 385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58ad214b-c37b-4aae-9480-27541a1413e7": {"__data__": {"id_": "58ad214b-c37b-4aae-9480-27541a1413e7", "embedding": null, "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7ee99bb-dccc-489b-8b3e-724db5cfd5e8", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3aae8f69a5b77dd62f6f9607ea81fe15176a2efa614f34785d9003bb86d8ea16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce7bb7a9-180a-4acf-8ab0-c48c06679df0", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "621c009ed00d18df6baabb3f9c1cf248e71922800927ed79f47d2303c7a1baf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a9fbaa8-f505-4125-b6b9-aa697f8e4b09", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "af4d5b47b1ac8b54ee4e6689ae93529a5b158cca8f0e542560acd5ff4ab7d31e", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "start_char_idx": 385, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a9fbaa8-f505-4125-b6b9-aa697f8e4b09": {"__data__": {"id_": "9a9fbaa8-f505-4125-b6b9-aa697f8e4b09", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd198f88-d159-45e9-9821-c88681c39a87", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ec1e8c46f068fabec4f4d0e3fed5e95ca15600a9df9e051ad7b5fdc0023e7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58ad214b-c37b-4aae-9480-27541a1413e7", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96384e097521a6c6d5dae2569e09f89559773e6bf41e39428ae765f8ea8dc8fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6be4fa7-bcae-45bc-a61f-481f2c8d5687", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "903764a0dbe74137ee09aab015e1ca012e20fcf38749c69c4f4360902439a285", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6be4fa7-bcae-45bc-a61f-481f2c8d5687": {"__data__": {"id_": "b6be4fa7-bcae-45bc-a61f-481f2c8d5687", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd198f88-d159-45e9-9821-c88681c39a87", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ec1e8c46f068fabec4f4d0e3fed5e95ca15600a9df9e051ad7b5fdc0023e7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a9fbaa8-f505-4125-b6b9-aa697f8e4b09", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80714610affc8f273a4412e2ae103944a5187146321b4c6bc258c85aa4cea49e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f723193e-0af3-4c4b-854c-147a08cf6425", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22"}, "hash": "21ecc3be5e93b53c3b0aab6ed9ba9764ca47230c830293878cac15d1a198ba7c", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 16, "end_char_idx": 852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f723193e-0af3-4c4b-854c-147a08cf6425": {"__data__": {"id_": "f723193e-0af3-4c4b-854c-147a08cf6425", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd198f88-d159-45e9-9821-c88681c39a87", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ec1e8c46f068fabec4f4d0e3fed5e95ca15600a9df9e051ad7b5fdc0023e7d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6be4fa7-bcae-45bc-a61f-481f2c8d5687", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31371be38089c74a70648cda288bea645b08089d6d305c0aac0bff1e8c2e539a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30e55dd6-9506-4d1c-a89d-5cfc31543137", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23", "original_text": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23"}, "hash": "eb45e8e339a69754e4ad4f70820df3aac42522f28fcdd4b7448928bed3f23d39", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "start_char_idx": 852, "end_char_idx": 937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30e55dd6-9506-4d1c-a89d-5cfc31543137": {"__data__": {"id_": "30e55dd6-9506-4d1c-a89d-5cfc31543137", "embedding": null, "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23", "original_text": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23", "page_label": "23", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bca54e88-b0ed-4801-8b53-81c24cf54653", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b1b6037d9544b16ef099cda93de9c99967cf2c8e809d01f0a3e6fb963754d0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f723193e-0af3-4c4b-854c-147a08cf6425", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb6958f61a74896dc494cdaba3cab618e70c6def908d5a9b4d567b57789acf01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97add506-dddf-474d-95e0-ec1a2cfb1d03", "node_type": "1", "metadata": {"window": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24", "original_text": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24"}, "hash": "1e8d5c156e907eb93982cb3dbb40c6ff19f5119f9ccd250b2e4d539e6deb655d", "class_name": "RelatedNodeInfo"}}, "text": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23", "start_char_idx": 0, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97add506-dddf-474d-95e0-ec1a2cfb1d03": {"__data__": {"id_": "97add506-dddf-474d-95e0-ec1a2cfb1d03", "embedding": null, "metadata": {"window": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24", "original_text": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24", "page_label": "24", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70c46885-d0c7-4811-9a6b-6bffb9724193", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f22e65a430cccf81d87f1cea3d57c513f1340508f78788c524847a66cb4083f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30e55dd6-9506-4d1c-a89d-5cfc31543137", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23", "original_text": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23", "page_label": "23", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc99feb411e08788dd6f0aef6fe0e55b03a0342fc9897ad47a7b643f54ea4729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b199cbea-a9f4-4a1c-8d86-a50ea8a8f97e", "node_type": "1", "metadata": {"window": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25", "original_text": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25"}, "hash": "650bad178ce4bd79efe7b11f62443f84e7631cca96d26f2de0c473b30fc13db8", "class_name": "RelatedNodeInfo"}}, "text": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24", "start_char_idx": 0, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b199cbea-a9f4-4a1c-8d86-a50ea8a8f97e": {"__data__": {"id_": "b199cbea-a9f4-4a1c-8d86-a50ea8a8f97e", "embedding": null, "metadata": {"window": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25", "original_text": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25", "page_label": "25", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a78e43b3-387a-4394-9d6d-d884c4293b00", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ce5ddf1bdf8658bb946a68410131cd50b1803a484b893bf15ea1bee57154202", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97add506-dddf-474d-95e0-ec1a2cfb1d03", "node_type": "1", "metadata": {"window": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24", "original_text": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24", "page_label": "24", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "440b864aadea0c72943dff488c57758dbf4b650bafad1266f042b11c3c4f6650", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeed0154-ced6-424c-995d-5ddaf9936346", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n"}, "hash": "742b68639a1c32cf637aee7d0a3ac4c595ed7bb6dd1bb9857784354e7838752e", "class_name": "RelatedNodeInfo"}}, "text": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25", "start_char_idx": 0, "end_char_idx": 1374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeed0154-ced6-424c-995d-5ddaf9936346": {"__data__": {"id_": "eeed0154-ced6-424c-995d-5ddaf9936346", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b199cbea-a9f4-4a1c-8d86-a50ea8a8f97e", "node_type": "1", "metadata": {"window": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25", "original_text": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25", "page_label": "25", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30898367f3ff77d3f6aaa2960b7d729f51e039d35a724a3166e1c2e8715b9a35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "066b29a3-d340-4488-bbfd-ef7c7d89aab1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "5044d7ffd0fea49755fc650e661e5a8d5fed8df819f369b62c9b307e1148e23e", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n", "start_char_idx": 0, "end_char_idx": 228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "066b29a3-d340-4488-bbfd-ef7c7d89aab1": {"__data__": {"id_": "066b29a3-d340-4488-bbfd-ef7c7d89aab1", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeed0154-ced6-424c-995d-5ddaf9936346", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfe03da5359ef439e05e05bb9ae6bb5e93a0687279534d63dcb59e54ba89a6cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af05938a-4412-4054-b7f7-4e9ce289fd22", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "4ea85e566416a7e873593e5f8747e47ea9272b70e17b7da059e650f00cb8e17e", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 228, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af05938a-4412-4054-b7f7-4e9ce289fd22": {"__data__": {"id_": "af05938a-4412-4054-b7f7-4e9ce289fd22", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "066b29a3-d340-4488-bbfd-ef7c7d89aab1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60bd24ea274bda9afd4e0cc0190dd17caabfe7d47b2385f7e0058ec4b5bb4e3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0372218-5f0a-43ae-b391-45eb9872fb9c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "b47fb88d7012f0b315f7ad1a227ea5f3fe06bca0e55bd5505d32a7c4ebc6b8aa", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1007, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0372218-5f0a-43ae-b391-45eb9872fb9c": {"__data__": {"id_": "e0372218-5f0a-43ae-b391-45eb9872fb9c", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af05938a-4412-4054-b7f7-4e9ce289fd22", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a93b5375cb41bfae75e9c729910c08419c723e125dac7e8d7d10f6f0610bc916", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbcf49ca-2ac2-4d1d-bdb6-ed9cb946600e", "node_type": "1", "metadata": {"window": "2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "e554aa49e7557fcbe2f016705a5952a71d0bb7bc4fe7c25700b84bf645e318b2", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1122, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbcf49ca-2ac2-4d1d-bdb6-ed9cb946600e": {"__data__": {"id_": "dbcf49ca-2ac2-4d1d-bdb6-ed9cb946600e", "embedding": null, "metadata": {"window": "2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0372218-5f0a-43ae-b391-45eb9872fb9c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "179e04abba10723a7c257017d58f7ace03b0e1cdb27d427e4d9254ddb9f31d95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c0a0cf8-52f3-4d35-a0f9-3d7f85b9b5eb", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "b6487424bb155a13682e5cb89e3445ae787135f574ffdc4179a040da640341a5", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1262, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c0a0cf8-52f3-4d35-a0f9-3d7f85b9b5eb": {"__data__": {"id_": "7c0a0cf8-52f3-4d35-a0f9-3d7f85b9b5eb", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbcf49ca-2ac2-4d1d-bdb6-ed9cb946600e", "node_type": "1", "metadata": {"window": "2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19af4473f6af7f9be234984d049126184291990087ac615bb1b3ba4b1f6bdeef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae4f1d22-e999-4dde-8da5-31aa7bfdd038", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "2f0fef6990f98be807276cb99b00476c6eb92507d830368a6953afd41e95aaff", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 1381, "end_char_idx": 1600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae4f1d22-e999-4dde-8da5-31aa7bfdd038": {"__data__": {"id_": "ae4f1d22-e999-4dde-8da5-31aa7bfdd038", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c0a0cf8-52f3-4d35-a0f9-3d7f85b9b5eb", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3059ddbffe14c15e9b89d89c17c2804ddd293d48ac18d65c8feb91eb30f7aaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3bfdfe5-83bd-48bf-b808-3d0fdb16a9e0", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "080a26bedf91489b5d53417f85631c4dcdaaa7e1bd7791fd6151c8221be8bfc7", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1600, "end_char_idx": 1782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3bfdfe5-83bd-48bf-b808-3d0fdb16a9e0": {"__data__": {"id_": "c3bfdfe5-83bd-48bf-b808-3d0fdb16a9e0", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae4f1d22-e999-4dde-8da5-31aa7bfdd038", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbd9eb35dd09c7ef9212d56c3eccdc47224178ee4888cdbc93c38dc3583a1f0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3573c5d-c86b-4552-9cee-2d244b81992d", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). "}, "hash": "313aa761fe8d4bd57e2484b230f0a7387a8fec849e2998a8ff9a1ced3cb6a8ea", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1782, "end_char_idx": 2063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3573c5d-c86b-4552-9cee-2d244b81992d": {"__data__": {"id_": "e3573c5d-c86b-4552-9cee-2d244b81992d", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3bfdfe5-83bd-48bf-b808-3d0fdb16a9e0", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d988bf2e00b4b7ddb4d4a09c793bebd28d3faf53cc0a4d74e4964fe677dff15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38ee4568-2a8c-4a8e-9f45-603626d2bc35", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. "}, "hash": "eebc071b9e63ad794626ca6b07b3e3be2f226cc71dcae6fac1ecf332d0e8c604", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "start_char_idx": 2063, "end_char_idx": 2387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38ee4568-2a8c-4a8e-9f45-603626d2bc35": {"__data__": {"id_": "38ee4568-2a8c-4a8e-9f45-603626d2bc35", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3573c5d-c86b-4552-9cee-2d244b81992d", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e626d24051bebc8c2bf301edb68de8e7465528b35c522189fdb3c5f1990904b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fde6cd25-3e80-4a7e-9769-86fb792a6a81", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "bb47293aabe021a6ab00e39c362ceafab254dd16d7da71d6bdf62041fc25fcf6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 2387, "end_char_idx": 2472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fde6cd25-3e80-4a7e-9769-86fb792a6a81": {"__data__": {"id_": "fde6cd25-3e80-4a7e-9769-86fb792a6a81", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38ee4568-2a8c-4a8e-9f45-603626d2bc35", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7923e286dfc80c460cdecb9f6ecd65efa1620e8f33e4b0f7f455f2d82618959", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf451dd7-3a8f-4105-8127-2c6e1b1bd58f", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. "}, "hash": "189ab01f0956fad358b498e9c81228c1803d61c215f1b48f58176ff4cb6a27ae", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 2472, "end_char_idx": 2629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf451dd7-3a8f-4105-8127-2c6e1b1bd58f": {"__data__": {"id_": "bf451dd7-3a8f-4105-8127-2c6e1b1bd58f", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fde6cd25-3e80-4a7e-9769-86fb792a6a81", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db2e374dade3cd4e42a38eabe98403e12fb5873d1c8eb7e6468620de2559a5b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a62ed26-2b74-47f1-a9e1-f658a9baf57b", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "5b7cd72cca8dfafe7c79085c9a33780147d293db0951575c4d208e0c60d3166b", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "start_char_idx": 2629, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a62ed26-2b74-47f1-a9e1-f658a9baf57b": {"__data__": {"id_": "9a62ed26-2b74-47f1-a9e1-f658a9baf57b", "embedding": null, "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf451dd7-3a8f-4105-8127-2c6e1b1bd58f", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35147d57cb02cf250ef6c6e5eeedbd00ef85d8f891b8f0c978065b563da29ac6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f2906c6-cbe6-4c26-8a5c-9c366383713c", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "LIFO expense (credit)\n26"}, "hash": "b67a11a645335518b121219a78c5d96dde00de7b7cc0bb67a728bb7ffa306334", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 2831, "end_char_idx": 3127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f2906c6-cbe6-4c26-8a5c-9c366383713c": {"__data__": {"id_": "5f2906c6-cbe6-4c26-8a5c-9c366383713c", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "LIFO expense (credit)\n26", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "983de150-ea96-4f85-8bcd-ed58dd552e45", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "946cafebf3feaa43967c80d30631e3f90308c6e0409ec1eb01361a37beb88294", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a62ed26-2b74-47f1-a9e1-f658a9baf57b", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6db6f1c8e42b33b6677b964198ab61b81b214ca315ba953fe11739a953bfe946", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42ecfccc-ac51-4321-b5c1-568409c02e78", "node_type": "1", "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies. ", "original_text": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n"}, "hash": "e4c401220887ec63cc75781b4c2d0c71a681a172f6e48bbc7a4a631adfb373f5", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit)\n26", "start_char_idx": 3127, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42ecfccc-ac51-4321-b5c1-568409c02e78": {"__data__": {"id_": "42ecfccc-ac51-4321-b5c1-568409c02e78", "embedding": null, "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies. ", "original_text": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f2906c6-cbe6-4c26-8a5c-9c366383713c", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\n26", "original_text": "LIFO expense (credit)\n26", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a247bd2bb0f186ca00786a357fd1b1538259fd75ded1cb3dd5a42a8d11b413c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6cb1bed-d046-4ce5-91d0-ed8c0950951c", "node_type": "1", "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets. "}, "hash": "a2aa40ccceecd77edcf3296afcb39a26af05ae6c379030f12b3f3ac7f321b025", "class_name": "RelatedNodeInfo"}}, "text": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "start_char_idx": 0, "end_char_idx": 160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6cb1bed-d046-4ce5-91d0-ed8c0950951c": {"__data__": {"id_": "e6cb1bed-d046-4ce5-91d0-ed8c0950951c", "embedding": null, "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42ecfccc-ac51-4321-b5c1-568409c02e78", "node_type": "1", "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies. ", "original_text": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "724b3efffd303d71b3e4008fb9c0dd92a4fa9712ee092826458efae9ef0be4b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b3aba64-ecf5-4df0-8c38-d52ad831f93a", "node_type": "1", "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue. "}, "hash": "7492b8eba12268efd308c3622c9e9061a0901b845cb2be46a24b80e93ea8ad8d", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets. ", "start_char_idx": 160, "end_char_idx": 436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b3aba64-ecf5-4df0-8c38-d52ad831f93a": {"__data__": {"id_": "5b3aba64-ecf5-4df0-8c38-d52ad831f93a", "embedding": null, "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6cb1bed-d046-4ce5-91d0-ed8c0950951c", "node_type": "1", "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "624fbe65939eda29ba94f906ebb7799b822d123821607b9bad98d91e51b1ab95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3b21f29-1267-4df3-8be7-24377e08df43", "node_type": "1", "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies. "}, "hash": "58b5b2b9c648aa65ed9bba8630c663a74778f385820d41b3607b6f29aafca025", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue. ", "start_char_idx": 436, "end_char_idx": 532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3b21f29-1267-4df3-8be7-24377e08df43": {"__data__": {"id_": "f3b21f29-1267-4df3-8be7-24377e08df43", "embedding": null, "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b3aba64-ecf5-4df0-8c38-d52ad831f93a", "node_type": "1", "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaeb34bb6173b2035a5264dcad8dd9e9f5d24b874013242864a29254fc195e64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "003178f7-47b5-4585-b7c2-99973fe1b8ed", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring. "}, "hash": "e4f9f614e998e60f114e38125bf8fae0e633ce2fd68b0c06d1b5453ad5368a5a", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies. ", "start_char_idx": 532, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "003178f7-47b5-4585-b7c2-99973fe1b8ed": {"__data__": {"id_": "003178f7-47b5-4585-b7c2-99973fe1b8ed", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3b21f29-1267-4df3-8be7-24377e08df43", "node_type": "1", "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "182486066666b0f002ca127a89a327363c3913159bc8a44d4b1d3aff9902f2ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f58e092-4bce-4d30-aae7-fb007091fb4b", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n"}, "hash": "12e6f77e1242b2548d31ac8e10d283400f438eb2be7dbe0ac6b9f537ba94c566", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring. ", "start_char_idx": 693, "end_char_idx": 805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f58e092-4bce-4d30-aae7-fb007091fb4b": {"__data__": {"id_": "0f58e092-4bce-4d30-aae7-fb007091fb4b", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "003178f7-47b5-4585-b7c2-99973fe1b8ed", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d1ac723aa828144e4dd9ca9cbe5b55bca024daa5665e93ef478737185130f6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39790d1f-5f27-4266-a3f4-b9aca06a6bcc", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "1aea93c9da0b78547886f3d10693a335a440f9ba4b9a3d82976fe613ef72e2df", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n", "start_char_idx": 805, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39790d1f-5f27-4266-a3f4-b9aca06a6bcc": {"__data__": {"id_": "39790d1f-5f27-4266-a3f4-b9aca06a6bcc", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f58e092-4bce-4d30-aae7-fb007091fb4b", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e88aa23e1e7db62d531803a0aaed2311e727ba13216522148f37ca8dbf9427ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "404433a7-4c42-4366-87df-55262b303f19", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "3b5ddaffff113431473d8ddb25ab79b850c246ea262d2e69505022b9695adc14", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 1107, "end_char_idx": 1356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "404433a7-4c42-4366-87df-55262b303f19": {"__data__": {"id_": "404433a7-4c42-4366-87df-55262b303f19", "embedding": null, "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39790d1f-5f27-4266-a3f4-b9aca06a6bcc", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76d6a13708d2a50bc37567282a5b00530236df8ccf5b4e3c60de9d767d5de7c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79a6881b-9db1-417f-bca6-50d7dd3c8a95", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "813960fa90fea7a404ea830e6ec8024fcd972a557212c84511d021c97e70265e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 1356, "end_char_idx": 1449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79a6881b-9db1-417f-bca6-50d7dd3c8a95": {"__data__": {"id_": "79a6881b-9db1-417f-bca6-50d7dd3c8a95", "embedding": null, "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "404433a7-4c42-4366-87df-55262b303f19", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable\nand/or non-recurring business restructuring.  We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d25efc6c34cade66d8056ac72f13e6849cfe3b6057937ecdf2aec6642fb4a295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0cbcf8f-53e0-4e73-97c2-68d957d69c71", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "2e5bd21f79b9ebfee4a7443309fd6a683259db49f29d56633e2851eb05a9c59e", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 1449, "end_char_idx": 1696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0cbcf8f-53e0-4e73-97c2-68d957d69c71": {"__data__": {"id_": "d0cbcf8f-53e0-4e73-97c2-68d957d69c71", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79a6881b-9db1-417f-bca6-50d7dd3c8a95", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, goodwill\nimpairment, and the impairment of assets that are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature because we believe these exclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4b728121277e733b5fb0f66bf4dc2cf5935ae3ace89e84b2d96009b21be7002", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "985ce36d-c2d2-4572-84b1-06e75c608228", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring. "}, "hash": "0008b0f4f5164f102acea159b1fcf0dc88755db5b682604e5d3f8569bc548cc6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 1696, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "985ce36d-c2d2-4572-84b1-06e75c608228": {"__data__": {"id_": "985ce36d-c2d2-4572-84b1-06e75c608228", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0cbcf8f-53e0-4e73-97c2-68d957d69c71", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45df81758aa49a7d13b9018bab2c4909bf1c9fbc6caccaf25ad4d8b0651f081a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "105bddc1-d9e9-454b-aa3b-39da03d600c8", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n"}, "hash": "778531436c476a8912fe548db5cb5e6daf3f525476205d6915b15db24973fa2e", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring. ", "start_char_idx": 1901, "end_char_idx": 2185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "105bddc1-d9e9-454b-aa3b-39da03d600c8": {"__data__": {"id_": "105bddc1-d9e9-454b-aa3b-39da03d600c8", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "985ce36d-c2d2-4572-84b1-06e75c608228", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27c44a21a528c17f0b22d390f8ed16d2183081c7364f942948e0dbaa0ebed158", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcdbc5f5-bc70-4c9c-a434-449afb43eded", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "957fbce895b87d13014260759f5c2590bc11bd4de25de393e829d1b7e47f99cf", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "start_char_idx": 2185, "end_char_idx": 2350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcdbc5f5-bc70-4c9c-a434-449afb43eded": {"__data__": {"id_": "dcdbc5f5-bc70-4c9c-a434-449afb43eded", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "105bddc1-d9e9-454b-aa3b-39da03d600c8", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9120ddce202cf97779bd240ed00a9cfa8cb4e25cfe1884f7e1fbe66c5baeb449", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29f88ae1-45df-4949-83e5-993ed9425dd1", "node_type": "1", "metadata": {"window": "In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "dd90877d1ccfe57e7f4cc00b5e98f56883152ef6c433b38f85c90ab58b2b6474", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 2350, "end_char_idx": 2547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29f88ae1-45df-4949-83e5-993ed9425dd1": {"__data__": {"id_": "29f88ae1-45df-4949-83e5-993ed9425dd1", "embedding": null, "metadata": {"window": "In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcdbc5f5-bc70-4c9c-a434-449afb43eded", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1246075be796ae4a1ab76299988fc165b9730a08e96a8b9dee9f298f7f16b95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "868f11d1-4f25-4349-834a-b5b315d75718", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "cba5fa6046807436953928cfe45c7de23097c1b39e86893ab44a1b3883d9e4e3", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 2547, "end_char_idx": 2819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "868f11d1-4f25-4349-834a-b5b315d75718": {"__data__": {"id_": "868f11d1-4f25-4349-834a-b5b315d75718", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29f88ae1-45df-4949-83e5-993ed9425dd1", "node_type": "1", "metadata": {"window": "In addition, the gain (loss) on the\nsale of businesses and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax reform\nare excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and non-\nrecurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01a4ee910cc41f6ed1f39345de5ba8ea1b01f236b1ed9dd776a3373a6c601fe8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fb51fea-c351-4875-ae86-7d33a9e7969f", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021. "}, "hash": "db1d01b8878b0f49b4ff0284e94e46cce8227e0bb1415e03d0de72b590c7e418", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 2819, "end_char_idx": 3057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fb51fea-c351-4875-ae86-7d33a9e7969f": {"__data__": {"id_": "3fb51fea-c351-4875-ae86-7d33a9e7969f", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "868f11d1-4f25-4349-834a-b5b315d75718", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d62053b412cfe14969db58771e28e34563f4b9a18f0d450a2ecc221400ec2f86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5aaea41b-981a-45e4-81cc-476fb6b9b35d", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021. "}, "hash": "33884c6bf21daaa7a347fb49625df6b2f5062e84be8b7c49a6b82562240bf0de", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021. ", "start_char_idx": 3057, "end_char_idx": 3391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5aaea41b-981a-45e4-81cc-476fb6b9b35d": {"__data__": {"id_": "5aaea41b-981a-45e4-81cc-476fb6b9b35d", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fb51fea-c351-4875-ae86-7d33a9e7969f", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "292faaab692c646c770243775c66c112bdefed766e71498deb6328042ca64431", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "012b94d7-b545-4e2f-8924-1461379f939a", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "51ca942f876bad0a94778ac5c15868bb46b463acdbe4772e5152f4419b5a2604", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021. ", "start_char_idx": 3391, "end_char_idx": 3731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "012b94d7-b545-4e2f-8924-1461379f939a": {"__data__": {"id_": "012b94d7-b545-4e2f-8924-1461379f939a", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aaea41b-981a-45e4-81cc-476fb6b9b35d", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "493d9e26e90f1e822361662eceaf577976bae6cd4e497d2baca0ea554afd3e98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06673be3-ff98-42cc-86eb-3931de30f08f", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. "}, "hash": "9270c2b4ababc47e91a051729cb06c4486781b6290e7794d03562d329301ede3", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 3731, "end_char_idx": 3975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06673be3-ff98-42cc-86eb-3931de30f08f": {"__data__": {"id_": "06673be3-ff98-42cc-86eb-3931de30f08f", "embedding": null, "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "012b94d7-b545-4e2f-8924-1461379f939a", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b99b3f3bbbef35a06924885bf923c36b4ae18becf3d4bbd602f299e1918f1881", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ec10203-c1df-4ca2-9534-66ff0798bc7f", "node_type": "1", "metadata": {"window": "Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n"}, "hash": "b8ed6aea579e62ce7e0ddd39c3fd9ba7523ae755f8e3ac2bf395c5e77f5a6a37", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "start_char_idx": 3975, "end_char_idx": 4189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ec10203-c1df-4ca2-9534-66ff0798bc7f": {"__data__": {"id_": "1ec10203-c1df-4ca2-9534-66ff0798bc7f", "embedding": null, "metadata": {"window": "Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06673be3-ff98-42cc-86eb-3931de30f08f", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months\nended June 30, 2022 and the income tax deduction recognized in connection with the permanent shutdown of PharMEDium\nare also excluded from adjusted income tax expense for the nine months ended June 30, 2021.  Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8a431713268a736ca55f2bb55c54731c98f81de5d1ccaadcf351b6dfccf4f8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "441ff1e8-9040-4768-84a9-ec493db5eb75", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. "}, "hash": "b3f3fdb183f6b17e7a9005f82496352a06084654c4c4823377c903d0329e8df1", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "start_char_idx": 4189, "end_char_idx": 4360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "441ff1e8-9040-4768-84a9-ec493db5eb75": {"__data__": {"id_": "441ff1e8-9040-4768-84a9-ec493db5eb75", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ec10203-c1df-4ca2-9534-66ff0798bc7f", "node_type": "1", "metadata": {"window": "Further, certain expenses\nrelating to tax reform in Switzerland are excluded from adjusted income tax expense for the three and nine months ended\nJune 30, 2022, and certain expenses relating to tax reform in Switzerland and the United Kingdom are excluded from adjusted\nincome tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e199950367eceee7e21617a15c49693ad8497c778d5cbee4229446e91d7927b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a51028a-cbe3-4204-8726-bbf5386d1d2d", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "ad3b5fcdaef219a309b456614948fccecec0e9960cea0ec4e4bdb6e6449f7f49", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "start_char_idx": 4360, "end_char_idx": 4545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a51028a-cbe3-4204-8726-bbf5386d1d2d": {"__data__": {"id_": "7a51028a-cbe3-4204-8726-bbf5386d1d2d", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "441ff1e8-9040-4768-84a9-ec493db5eb75", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf334f34cdecd818c1d5159f0404333a789eebfae08b21ad80359447a7f38ab3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78574e59-df2a-4a41-bd91-bf0d29d1bd41", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items. "}, "hash": "6bdf593f381a87f39298d03f4cc11d8661cb32bc4e1ce2c2db11d92381d2ed67", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 4545, "end_char_idx": 4789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78574e59-df2a-4a41-bd91-bf0d29d1bd41": {"__data__": {"id_": "78574e59-df2a-4a41-bd91-bf0d29d1bd41", "embedding": null, "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a51028a-cbe3-4204-8726-bbf5386d1d2d", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "576493405174ba980ee12026e0a4725d8ab9aa6c37f29f1bc13b632157e9a4da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2f19a98-2126-4664-ae47-577f77e3862e", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "In addition, the per share impact of certain discrete tax\n27"}, "hash": "a02dd8506f6b6783c765d42424670166fcafcf20d20f459b8aa72d1524748992", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 4789, "end_char_idx": 5356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2f19a98-2126-4664-ae47-577f77e3862e": {"__data__": {"id_": "c2f19a98-2126-4664-ae47-577f77e3862e", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "In addition, the per share impact of certain discrete tax\n27", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659a45def2262c45d6c54803ed3eb300050613a31939167e528c3258e39de83f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78574e59-df2a-4a41-bd91-bf0d29d1bd41", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items. ", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "876b62b97b2ee9235122bc228ea126620b0fb7d72e78e4e720d442a1961254d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0498d21e-f0d8-4c1c-9922-997ee07380fb", "node_type": "1", "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share. ", "original_text": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share. "}, "hash": "b37cbce5ba8c07ad283cfc19c5f5b3b74b4a847a0599050ed96bcb5cf8f8efac", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of certain discrete tax\n27", "start_char_idx": 5356, "end_char_idx": 5416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0498d21e-f0d8-4c1c-9922-997ee07380fb": {"__data__": {"id_": "0498d21e-f0d8-4c1c-9922-997ee07380fb", "embedding": null, "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share. ", "original_text": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2f19a98-2126-4664-ae47-577f77e3862e", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; employee severance, litigation, and other; goodwill impairment; impairment of assets; gain\non sale of businesses; and the loss on the currency remeasurement related to Swiss tax reform, in each case net of the tax\neffect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete tax\n27", "original_text": "In addition, the per share impact of certain discrete tax\n27", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c233cd181b0a7ad9cbe87b36bf092b93060a1aeb14cc4891e95696320f5a5d6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bf96be3-cc8b-4fad-a8de-e19d54a4b87e", "node_type": "1", "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "original_text": "Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021. "}, "hash": "c39244b85cc821561d53f648f27f00e0a94053d270592457085e99a3ad7f0890", "class_name": "RelatedNodeInfo"}}, "text": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share. ", "start_char_idx": 0, "end_char_idx": 316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bf96be3-cc8b-4fad-a8de-e19d54a4b87e": {"__data__": {"id_": "0bf96be3-cc8b-4fad-a8de-e19d54a4b87e", "embedding": null, "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "original_text": "Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0498d21e-f0d8-4c1c-9922-997ee07380fb", "node_type": "1", "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share. ", "original_text": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4896f92a0209ded19ab5faaec984584a904e846cbce01dccf836f781c9b3fe8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9568524e-3c39-4a11-a444-1cb5c42bac48", "node_type": "1", "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. "}, "hash": "36e4ea56814ded276e97aa48eeeaccc66abd4756577079bc979204b42724d6d6", "class_name": "RelatedNodeInfo"}}, "text": "Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021. ", "start_char_idx": 316, "end_char_idx": 730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9568524e-3c39-4a11-a444-1cb5c42bac48": {"__data__": {"id_": "9568524e-3c39-4a11-a444-1cb5c42bac48", "embedding": null, "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bf96be3-cc8b-4fad-a8de-e19d54a4b87e", "node_type": "1", "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "original_text": "Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b82ccd610f010729455efd19618d247f9df309f8d2331966867d3d4e19ad7bcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06093286-67e4-411c-8302-e60aeb868b50", "node_type": "1", "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "original_text": "The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share. "}, "hash": "9419eab2f5bfa01950638c5a5fe3c5598cf035a51f8cef1b6b3dc9360ac8e4b9", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "start_char_idx": 730, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06093286-67e4-411c-8302-e60aeb868b50": {"__data__": {"id_": "06093286-67e4-411c-8302-e60aeb868b50", "embedding": null, "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "original_text": "The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9568524e-3c39-4a11-a444-1cb5c42bac48", "node_type": "1", "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fca07857323d03868851c03dbf9451a69cf0cff4d4a433f7fc06c62bfad4913b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19723a54-d622-4490-9f20-71a3e01ba1ae", "node_type": "1", "metadata": {"window": "Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. "}, "hash": "b213730ce4e11189f8bd2c2637395c98bf7296c2ed7ef1a1ca1359824d575e50", "class_name": "RelatedNodeInfo"}}, "text": "The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share. ", "start_char_idx": 1084, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19723a54-d622-4490-9f20-71a3e01ba1ae": {"__data__": {"id_": "19723a54-d622-4490-9f20-71a3e01ba1ae", "embedding": null, "metadata": {"window": "Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06093286-67e4-411c-8302-e60aeb868b50", "node_type": "1", "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "original_text": "The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a6ca94ef8beac6838788f7fce234a0070ff858dd99a8c907eae3c5dc26ca431", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "915a53af-1a9f-473b-8d16-a3754195b293", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. "}, "hash": "db7b1efd85f592a56206dcef4750cbb3e2b7e18db5294fbb4a36d6602519c18a", "class_name": "RelatedNodeInfo"}}, "text": "The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "start_char_idx": 1175, "end_char_idx": 1478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "915a53af-1a9f-473b-8d16-a3754195b293": {"__data__": {"id_": "915a53af-1a9f-473b-8d16-a3754195b293", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19723a54-d622-4490-9f20-71a3e01ba1ae", "node_type": "1", "metadata": {"window": "Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "096dc6d3c0cf9d108d2f7c9f532e851c6e02e82f6cc0bae9a91582d80bacf148", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "388f355c-5288-4149-9022-5f2b7c26838c", "node_type": "1", "metadata": {"window": "The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow. ", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n"}, "hash": "2c7cc91a4d5d79c1d2f4f8f7cac3f892c9f40539f9cb8ca9c5728cf929b3247b", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "start_char_idx": 1478, "end_char_idx": 1728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "388f355c-5288-4149-9022-5f2b7c26838c": {"__data__": {"id_": "388f355c-5288-4149-9022-5f2b7c26838c", "embedding": null, "metadata": {"window": "The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow. ", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "915a53af-1a9f-473b-8d16-a3754195b293", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db51a53d8c6af3f537e3214c4b6c968beb066a8eaa5f437a37fa138ab5e799bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f405c70-921b-43ce-922d-6b5c64717cf5", "node_type": "1", "metadata": {"window": "The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "507faf35b7667ef2efeaa8ea41633a08b600373aac980c7f4e034380a852755d", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "start_char_idx": 1728, "end_char_idx": 2044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f405c70-921b-43ce-922d-6b5c64717cf5": {"__data__": {"id_": "5f405c70-921b-43ce-922d-6b5c64717cf5", "embedding": null, "metadata": {"window": "The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "388f355c-5288-4149-9022-5f2b7c26838c", "node_type": "1", "metadata": {"window": "The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share.  The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow. ", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2b73917cfd658de0797f8233d5879043320088fa5a619115099ae5667a43632", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f3fb2ba-ad96-457a-9c29-969d5b6c794c", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. "}, "hash": "70b0d9cf36410ba481a28dd522a559be4b16cba1379a3266174a3db49d0d606a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 2044, "end_char_idx": 2317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f3fb2ba-ad96-457a-9c29-969d5b6c794c": {"__data__": {"id_": "6f3fb2ba-ad96-457a-9c29-969d5b6c794c", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f405c70-921b-43ce-922d-6b5c64717cf5", "node_type": "1", "metadata": {"window": "The guidance for this metric\nexcludes the same or similar items as those that are excluded from the historical non-GAAP financial measure, as well as\nsignificant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c35acc973636acdfa6a007bd67f9dc7781ac37ef0409e36d55b857891f76bd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83f2d32f-88bb-4910-bbf6-67d9a098a88b", "node_type": "1", "metadata": {"window": "For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow. "}, "hash": "d6244480cff7b81bca04c1095f36f5b1fbd8145ae108b7ff4c4589858319213b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "start_char_idx": 2317, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83f2d32f-88bb-4910-bbf6-67d9a098a88b": {"__data__": {"id_": "83f2d32f-88bb-4910-bbf6-67d9a098a88b", "embedding": null, "metadata": {"window": "For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f3fb2ba-ad96-457a-9c29-969d5b6c794c", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for diluted\nearnings per share because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc75f7ef7d691c750c5eb9e7310ce4271e8591feb28dd0aaf1f276d7c7066f82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bda9448-25cd-406a-89c3-bdc78f12c2b7", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n"}, "hash": "5aec0dc01542c86760e01b51c1e8836ac8568beac368295e94ef2baa7c748b6a", "class_name": "RelatedNodeInfo"}}, "text": "The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow. ", "start_char_idx": 2555, "end_char_idx": 2647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bda9448-25cd-406a-89c3-bdc78f12c2b7": {"__data__": {"id_": "3bda9448-25cd-406a-89c3-bdc78f12c2b7", "embedding": null, "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83f2d32f-88bb-4910-bbf6-67d9a098a88b", "node_type": "1", "metadata": {"window": "For example, LIFO expense (credit) is largely dependent upon the future\ninflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related\nintangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24e37d1845f1b589c242f7a545a9ceb02f019ac9736042d7ed53e3d7518a522d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85c4fb61-a143-47f3-b315-6806ad90f81c", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28"}, "hash": "cfa7172c2cafa0541d5c53727a973940d4346e58f1ba99329732930d084bb14f", "class_name": "RelatedNodeInfo"}}, "text": "The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n", "start_char_idx": 2647, "end_char_idx": 2945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85c4fb61-a143-47f3-b315-6806ad90f81c": {"__data__": {"id_": "85c4fb61-a143-47f3-b315-6806ad90f81c", "embedding": null, "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6576f10b-ddf9-4842-b900-87ada1a103d3", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cc5baa4552f946d2f34298e8d41fffe896ca30db9dfa8fdce00522b5c961d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bda9448-25cd-406a-89c3-bdc78f12c2b7", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company has updated its non-GAAP fiscal year 2022 guidance for adjusted free cash flow.  The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company does\nnot provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and\nunfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n\u00a0\n", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42c89005544e8b8a8d1b51f4675b581d9fe0539cf18aa49c1c00500e57f06ed0", "class_name": "RelatedNodeInfo"}}, "text": "Bennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "start_char_idx": 2945, "end_char_idx": 3095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"f1376409-62d5-4a48-bfc2-f6919d3130da": {"doc_hash": "bde513f5f03c169d53af79467988893981b03fc63df188a8a668ac4f9e9b6e3e", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "a903647e-f527-4bce-acb1-29f0dee53783": {"doc_hash": "34f2536f60cdadf4d509487625fbfdf724ddbf0f76a9c35189d8f76e9a30e106", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "60912c69-6218-41c7-aaf3-002514baea26": {"doc_hash": "d42e830e59c6d223d45eb13fb0429bfc3e12b850f89cab795f63932add441686", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "36c74af9-a578-4373-aced-70467b2edbec": {"doc_hash": "d3750184e2b481caa6acfee8fbda7f922986d54a350e2c78376bff90c4599c8e", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "5a2cc351-a57d-4ace-b88a-e1338051ea30": {"doc_hash": "c308696e350b3f148d79a48fccf3d25e36ff9330a24bf56b61de762467d59073", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "d4ed20b7-50a5-4f89-84a4-0185ecb2625c": {"doc_hash": "7a535997eed95f90ca67c34545a6d0d3ce2994e0a83ed50869f517eefbff67ae", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "1fd20d5f-1621-4b4f-ab57-b11a3cac7397": {"doc_hash": "d2bed505b58bce6c30217f19f920b4d9029c1152cdaf72c46a2ae9a6467971e2", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "47cf6cb5-c6f5-43cd-8b92-0b06693083bc": {"doc_hash": "8f3960369c347f79c3d3d26d5dae03106a49c2c695a9fdf7a20aec8da3715707", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "4b71f098-9369-4e32-adb7-7fc2796626d0": {"doc_hash": "0cd35f6cf7dbf3f40a12e9b207df51e7cee90c071b388f109e04c407eeac5193", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "48107d5d-81f2-4dd2-aca4-2c5face58097": {"doc_hash": "41c75cf67dfb86e661bdd8ec4f6e413647e77a0d2095826f4e7c8c602e0d5f18", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "61c8d977-2276-40ca-bd05-0259ac3251de": {"doc_hash": "6ebe6be2adb9f1b7096a5c15b520d4caae1912819ccfd669f9897e1749495f38", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "ac2b8d21-8cde-47c0-a84c-dc396cbd16e9": {"doc_hash": "1478e834886ca6368a2acbc5526cf518c1a18933be11f63daf0b001ba47c7098", "ref_doc_id": "ff4cdd16-733d-4b11-9860-47e4042b79c5"}, "e888d6ae-a6bb-4743-93c1-6276b456ccdd": {"doc_hash": "1f1638a68417de2c6004a6daa195964a893230234846b1762500c84b3d5f4666", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "41ff12a5-d804-4c9d-be01-ce7aa020028e": {"doc_hash": "ac0adee00beec0accea4babc505b8f730fac2ef256c92384b4de83973707c8ac", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "6284bb7b-7d00-4181-a24b-53bb61ef5f5f": {"doc_hash": "e936985b74d590979fb8e5320e78a63c2fd75942695100f203cc9b35970daaae", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "53658c5a-d2f3-4a5b-b1fb-9679c4025082": {"doc_hash": "18a6a043ba5dd2abc078039ba50b37507e1cb88438d0891434815dd427ca6d1f", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "bfcdce41-9dda-4320-8705-cf5abbce8edb": {"doc_hash": "4b55918f055981c3bfde0469f55ee51a0fa1d62f4e9672a309537bd160b59f1b", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "026cf758-3c32-4623-b161-cbd12a658a87": {"doc_hash": "c8aa9be1440ae25d1894516f2bae451890e1f68ff461bcbd74bf6adc43ad0c58", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "453c436f-ab52-46fd-acaa-72487c0b22a0": {"doc_hash": "19abf7239b9794c1321b558f5c5881317a55c333d455a5e12f53dfed0af6fbdb", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "ab055769-4aac-4a42-b35d-24bd2dc85394": {"doc_hash": "9d8e4cc7fe386165f5c80eb5394a1adb97e1f562196b68e9bb2fee5939755b34", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "a2849634-6cfc-496b-ae6e-02babf2f21ba": {"doc_hash": "72cea1231e741b1b03708c735f5992613e189c5cb7ac59bb868cdf58d6b7c58c", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "ad9ac889-dab6-432a-b1ac-74209b10ca80": {"doc_hash": "56a72628d385b9c8d44ea0304cfab83e6c9855ed283a91c05ebb6164f54d529a", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "3f3151ec-24eb-4b48-a92e-b7651dfe3ec3": {"doc_hash": "8ed362c407f2bb5c9cbe308585541bb770a7b3b7023047f38ecd62356db4eb82", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "bb448d88-0bfe-4a8c-ace7-c53ec5794d6c": {"doc_hash": "b1be11af99de2a3836f2bc7ace36c8ce061563841b95977f468ae7c3c47bb530", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "e832744a-6f2c-4019-b8b9-20ec54fa0ebe": {"doc_hash": "e0e01e6698032cf70e97bd58067dba2dbec6b7228f9f81d1bb43ba02167c7426", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "68291281-5c35-4128-85b2-a17d0934b946": {"doc_hash": "87524065136e1deb4a25b7acdff19c137e45896dd8986e6d50da68c7927eca51", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "26bc811a-7026-4400-85a6-49bb30a1b111": {"doc_hash": "383165ae9ebc33e337a1d4a2df0109c03c074d08cb914fb7cfaa923c1b9b660f", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "89665b11-691c-4dc1-b5fe-c6a9d954a976": {"doc_hash": "c6da582ee10b67967abda4e6ea3302dde473d0f328fc08768a405f4f8b9c0d4d", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "dbc1f0f2-87bf-45d1-92e3-b6c25d8e6759": {"doc_hash": "0b354bd4ce9b39d575f990be104e6808d2086f51389c7c6bfa84acb7bc1361fe", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "c1b99932-ef6d-45e5-8b63-c8fb74f3069b": {"doc_hash": "8c481fd30fba371877a92811b858a0f0057777267d6621b015a2f4a4392486cb", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "f30c214d-8715-4fd1-b5b2-32a5fdd0cb57": {"doc_hash": "52126c3a02bcf0d4d686aaf65e8eb898bd60a9455302cd73f73e9cd6ba312950", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "afc2ab63-0334-4ad8-95ba-59f438f4d763": {"doc_hash": "a775a8bffb7c5061f2b30bb055f2e7dbfba6070a7afc28c0bfe22a6ce76711bf", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "b5f87745-10df-4b61-bbdf-8a119c272e0b": {"doc_hash": "ce48fa67efc0921e5e3cc98e29f691b953d97a5434c7fcb3fa84111aff1d47c2", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "c0e9cf2b-31b9-4fa3-ac11-d5c47ebb6ff5": {"doc_hash": "80bbdd5fea2901b946c874afff14d82be461c1c94efb8e9294ad808ae07101b6", "ref_doc_id": "376fbe2b-0bab-4a72-810d-ddbfb5356b26"}, "5f0672f0-3098-4286-bfea-e83b05852650": {"doc_hash": "5d80e134da6c21982906a1e334454e3952149425eb33186c61ffaa15860c6e19", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "ceb99d52-6419-4e57-ba68-225ee03f6aaf": {"doc_hash": "c15496beb1c821e242c761722d110ca79f60c0ac40e45d66dd8b0ed692d2344f", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "37684366-b73f-49d9-bf83-60a6a1850c90": {"doc_hash": "791546d58385ceda91966f750233fd53a1d831244f825fa0d2ce7d38da806ee4", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "7d85016d-8324-4a10-83f1-75f35fdfc26d": {"doc_hash": "57ddfc36f08c7b19d03f321d77ed640ad14aacd9a4111b48a8429ab818093d8b", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "bd105971-9c67-4a0b-b6c9-731cc9778848": {"doc_hash": "8c9fa184d0104a870dabd5d4b673feffe5125ca11b3eac30fd65493da1a8e9ca", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "35b584be-a08e-4e1a-b89c-13be314137a2": {"doc_hash": "67dd63015c809dbca3b60b8b747cbcc57f517cec8ec09fe605c5434409c466e4", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "0dfe9750-da1b-4f1b-9f88-34f9a0ef8ce8": {"doc_hash": "c13c171cc939c31a3b51f9d2d3990388d4b98dd18ad0f549b14834296ae3bb87", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "c1c52f43-6050-4893-9762-a8b80ec363a5": {"doc_hash": "c79e780452b104a4bbd4078b8bd21b159e564bf592230fab3bac18890975b333", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "e6967086-0a0f-4889-b94f-965752571813": {"doc_hash": "5dd85bf31d9a52e4d9bfe4c9936b1599024c59ea06420cf8e1c9e3bec7953072", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "83ffc80c-32e5-4814-a942-4c0f028fe911": {"doc_hash": "3839bd2f6df1ce15990db18194249d31b22fa8b73b6bc88bf6d05e3da4f936db", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "05c78100-06e7-43c1-8383-399e0107d7c7": {"doc_hash": "e4f72d17287224b3ec73adf5cded0841846a22a08147781aaa2929d31d9968fa", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "0ad8e704-2f6a-40b9-a3a0-aeeb49aa144d": {"doc_hash": "0eadc64d8fb5d82266c30887e4fa91eedcb4e13bec2fd5bda05ebfd4b3ab1bbf", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "aa08710d-7155-4945-a2fc-a3c0e30d3f86": {"doc_hash": "83da7eb96d90e87d8009d433e6e16e83342bf1492b15ec72ae04622ea7470c47", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "c9cd7057-3830-421b-9499-4bda9d0b41b5": {"doc_hash": "c278648d383317957b124b3be2d1f2058c8793db7c64ff4d669fa66a5ebfb51a", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "03431f43-51f6-4445-9055-219e8dcb6ad3": {"doc_hash": "36dec1499366013413b0202e975c85d39dc5fd6cf175e7442cbc4eb2168ef4a3", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "174beec3-145f-404a-b5c9-6eabafe33511": {"doc_hash": "c51c439c95a3d51cbf3760c952a74712d77749ea531b44803a24e0ece387bb59", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "ad340b6c-b061-4935-bc86-a27b06084a62": {"doc_hash": "5524033dba1fc1f29295e308e070d5368d7fbace0636ecac214773eccbf0ec30", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "4c39e2ab-7ca2-4a78-91e3-152f68894c1a": {"doc_hash": "9cd1faaebcc47897dbc7e2e94049292f7947160d95b1c78c433e615fbdeeba1f", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "6f4a0df9-f463-465c-892d-29edaef39f69": {"doc_hash": "282bcf81be6f52c951fddbf67a86757935573cbdf3a6de0c6e5b5660716d2f06", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "12b534bb-64fb-4f1a-96be-682487c02960": {"doc_hash": "3da82c7f160f3142b7e6820d1e6911624a424cc0dde8264703facc55a163a807", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "37279452-189a-4e1f-a239-c94bae076420": {"doc_hash": "bbb8066d5e20f5767300026ce89f8a556a12569f2bb879163421081f10cae0b3", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "b06cca55-88f4-4b89-bccb-b2cefe12cff8": {"doc_hash": "fc33370db9b615e196623c7f7296f20ca8c8a356fb7a3bb6b020fbde906f0b20", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "3a9b8daf-a385-4d71-965a-92f1c870696b": {"doc_hash": "f85ca7f524f15ee2fb61ee425a1a8df4a29220a7d2138ff505062f159872ff38", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "2163abfd-09ef-414d-afdb-3ed680a8241d": {"doc_hash": "c86da15a45021b83c9bb0907f64db6d1cb7f6013bc663ae8615fb3e4143d68c1", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "29736fdf-b1aa-4321-861b-f30a5bb9fab2": {"doc_hash": "90625fd7b40e549b9dcc070071b0f8e6681fe65c3b9ac04a38fd315e04cb339e", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "2cf609ca-0ddd-4662-8bad-5cbae2fbd242": {"doc_hash": "f9313817c6dafdfd5e1964ccd5eadb182ca92ef4f38a623e8938577eabc8bcd9", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "f4ed3bf8-7f3e-47c3-a8d9-0da01d862bc2": {"doc_hash": "d0905ff3a1963a2a96747a4506733fa859099c75f39c9c2c71705206c1c453b4", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "44c5ff7e-cbcc-4e5c-9a0f-8678b05416ab": {"doc_hash": "9371c3ccc69c3c6ea56490b6a231b353d8ad1d0b39b2607b3f414ee3f465bd71", "ref_doc_id": "305780ff-10c5-4cf3-8d3c-ca45b5215d34"}, "a8332c56-a46c-46a2-8bc7-ae1f1eeb96f4": {"doc_hash": "c79d86df9021aab21b3176a656ba4001f0b24b9eb834321f96539f9f5572777f", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "b7d34fd3-6d9d-403d-ab75-e455ab7cbea3": {"doc_hash": "82979d95d3bf767042d75c03e97f45ee50e36d3329e59b34036acef671e463f7", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "d408751e-1b7a-45ce-aa3d-b805b9abfd12": {"doc_hash": "f04140b267c0ca2b86a717d8bc5fcdb820b7c2955e862ad4c9a8dcafcbc1fbcf", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "c225d553-0c54-4cfc-83c1-a97258fe9a75": {"doc_hash": "2fc375161fa71be80a2864d5e9126347a4392f211bc2cffdc954bf6331c8c306", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "2a46fb5d-8310-4c76-83db-808ef8816903": {"doc_hash": "5d214f8991424e1bb0e9a769b7d0674c100dda5b32b0de8185c954b40ae8bff4", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "292163f3-b5a9-415d-b50f-6516aa61c094": {"doc_hash": "871d0a0f85381b3c1acda986825ae9e7589e3aeb3c91a5125731ce6f6093fdd8", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "578fc715-f349-48a8-89dc-a6971caf9f2f": {"doc_hash": "6eb7fc95cc8fdbab35c883c4639dcf5fe6dd06de395b0130da5efff1381f6e9c", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "8226e07a-5fad-4ee5-8037-e65d960b6b41": {"doc_hash": "3f564d2bba3694704eb07ee122d353305fa3ea12e528d87bc7d748dcf1f1e01e", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "26ed6df1-1717-4c66-9cea-99238cb91550": {"doc_hash": "3866a171b796b2ab4f030a9cdf1953c5daad7247af29d86dd29f0f688302a42f", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "83f0561c-41fc-4a97-844d-9d1d9a0f6120": {"doc_hash": "13ca54a1af817ebb65205a84229b33c2ea44b38accaaf2614c1038b6a19e8085", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "7acd524a-c0fc-45fb-a0cf-4d2247a721a6": {"doc_hash": "d8d5b064013e96aa843501747acf7b5ab7d7bba2f2d41fca4af3efea32c14aad", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "b090702d-78fa-4c66-b308-fdb9159ce81b": {"doc_hash": "ad717ec26d5149208c24b7b33f8343bf96bdbb6876ed54edda6a370ed6a3dd0d", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "9a957d5d-1ee8-4ceb-8a3e-0ff1cad1d85b": {"doc_hash": "80bf5545919ae58cfe287cb96babed93753cc61550fa03fe07720d4f654eddb4", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "b7e65ac2-ab26-4797-8bd5-5716faf4ea54": {"doc_hash": "34ad10d03c4851e7253f95cbb99b21fd62778005286a767d86e900a5d42dc6ab", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "723a026b-862c-4e5f-9098-14cb27942489": {"doc_hash": "aab0b71c140193c2df4ab1ea2630d6fa7ccc55fcf354fca74a23ade8bd9bddb5", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "ae7b22b6-3df5-4524-af1c-3ce55b56adcb": {"doc_hash": "5a3ea76ae5b9154f38e63f4013e3591363498ff397c6bc9cb50e9bfefacac7a8", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "9fe54f1e-e522-4464-be44-992ca879dca6": {"doc_hash": "63bbd77b2205823153c4b28cd56796c0ab63b9ed7cf9d19502111f99ec85c1bb", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "b41d7d83-bdde-4857-8edf-d357cdf76a02": {"doc_hash": "216c660839190204c9ba5327a34d9c6db2da7373117b3046c8d0f695c03cd715", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "4214caaf-5ee9-409a-a291-9048b867dcf0": {"doc_hash": "023046fdff550ad1981b933d63f59378d18eb6963b2ba378041557cd193b77ae", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "ff7a88b4-b4ca-4062-a6e6-b19261e05b42": {"doc_hash": "caf59df40167590a298d1d776139fcec10bf482348a9250e0ed36502e519a7f9", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "52a5274b-c82d-4995-b2cd-811955bd85a9": {"doc_hash": "6a7c35fb84e86ab482a0f654d8fcef08181a1d69ac2bf5c00b8e8e9f2b129e71", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "ee48edc2-528c-46ca-b3d2-0b3aca3b1fed": {"doc_hash": "7d9e4fcfb3dc0a39169ba22dbc0f9fe94d4370e01c4f2469d61c8897226eacfc", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "060e63ca-ac8b-47db-b45b-88c819093634": {"doc_hash": "af1f5139f10b87a6b1610c6872c55413eb598586e98ee592df3a346e0cbd4318", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "4b63f17d-8772-4c9f-be18-bc966e1cadd9": {"doc_hash": "4435489abe0abeb0cf71d491c219d6d4caf8fb047393c9a354b7c177f544af0f", "ref_doc_id": "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2"}, "6df9099b-4a07-4077-86c9-41286fc8e6ba": {"doc_hash": "e81a7b53630e629e978c8c0968ef67fad0ab32b6ea3d5afc9da354ace74744ad", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "0c58afb8-fa1a-45db-a71a-484d7cfac58e": {"doc_hash": "79f5bf2606af362a0a331fd43bfbe26943d40058026d431a7c17e9a3f1506629", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "1347ac50-3e34-4b24-bc62-7448a98a0062": {"doc_hash": "61be83d42d0b5eacb46319cd7622bb9ccc6b51a47f1f12387e5e3e10ca01a12a", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "13288cc8-18be-4e39-99c2-e5a0d251bc43": {"doc_hash": "5c4594beca94c1b8a225321d3cbe39fcdae8ed09f194a87fdc3383513fc48ee0", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "71737c57-3d01-4825-977b-bfafb1b04d9f": {"doc_hash": "a6e31ccbf1c1cdefbf8e2f782f9736aefda02c4d81865de7a601101b9236ead8", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "232cdd59-b151-4df7-af7e-f1bb37c81e77": {"doc_hash": "3216142c0c96d1d8672002dd99f88b53d7cbf0af47ce5b748f3a861170364ec8", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "24bffac4-e532-4bc5-ad73-ccd8c3df529c": {"doc_hash": "e7c66d035725bb2b5f0c7c604b8c4a472c7df61b57aef50abe9af998b07e3149", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "ecb7c3f7-a18a-4c52-a165-084fc372dd61": {"doc_hash": "17863f97116c94d8e73bf9a9fa653c90788f855988c187842855e918abfd8178", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "62ca346f-aa6a-4099-ba96-fd93f6d87c1e": {"doc_hash": "7bf700774bd0196e4e98a34fabecbce1566bed530e8b5a2210b5a2d936ef988e", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "c81d5fd8-cb3c-44ed-add8-83c3e5e5c2c2": {"doc_hash": "aadf74eccdaef17e166c913491436ba45d90f404a73342ad2ffebb98b444d3dd", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "4cde92c4-9043-4e46-9b76-1e8f06ed57b9": {"doc_hash": "804a767d1f9fd95899dd2e69f1f425e3fc7cedf98f47c6739047bbcf2d9cf508", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "f81c59c4-e1af-4a6a-8335-1b3949685daf": {"doc_hash": "262e4ed52680bfb3305635cc9ef9bea712fc395b0c5c7bf0e1deb10f53e81771", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "133dfc7b-2ebe-4c3c-883a-c6b203e08c03": {"doc_hash": "add5ec89313fa2333039bf7fc558dbf0b03d5f4fd5ca245d000cbf589dcb1e11", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "7fe3470c-84e5-4389-828a-09a5da90eaf9": {"doc_hash": "f7215cba655b86256713e7a8426c9c9d4c4785e2b1bd7dfeb39f189b2b3db96e", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "6dddf706-c501-43d6-af04-d05cf2b4ccc1": {"doc_hash": "56a327a24a7ea0c4d3d8dad7826b7d9ddf5a6b21f05e5825b177107a874f4d67", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "ed13e6f2-fb77-4a97-a673-a43605c5ed5e": {"doc_hash": "ca877572d164d226d15daaaebfd27888f4d1ad71daa22eed9a72bc445aeeb62a", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "67daff0f-83b9-4a8c-ab22-c177cf9552d5": {"doc_hash": "35766e52c798ac432895d025329ac650c35c50111523e141d3d83a1185a5d851", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "9b52e2b9-2310-4f24-a554-fd5889ad1f9f": {"doc_hash": "10568bb534ccc17d665a88eeae4317772ad252b8c7431ed9c9bd4b5f4a1dc5c9", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "3b985de3-9c7c-45c7-8d43-34c8da777df2": {"doc_hash": "4b4155a1d66370c61b3d0d4e1282826c0d69e2536858b98f5fdc4e77c1e7e668", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "4be52beb-db88-46c1-9b18-47449ef7a60a": {"doc_hash": "e49e004c4c9c8698f83fcebdaf52947dc4f4422eae3b12f7aaf68624732e4a6d", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "d887cd66-efe0-40ed-8222-8072021950a4": {"doc_hash": "316861550a6520af45bb9ec2d501d3612e733e0fab7e4e3b60b10024aa5ec3e7", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "1b5dca8b-ee1a-492e-96cd-233251be8b5a": {"doc_hash": "0ccafca8cfce10d80d079335e5e6c802d1408f2efced9d15503f284825289946", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "00f14fcb-6fd7-4be8-a811-f9baf5582b39": {"doc_hash": "9bd48b7a72400832808ca1b139818326ab761d894cd81e9030c98b3526cf1f2b", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "1590fccf-45e7-4cd9-9179-3c75103a0728": {"doc_hash": "5ab4ad4ee3f3a52b80a0052d739432c90c2eafabf76dfd266625182117bd3d3a", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "1360ac08-61bb-4232-8011-c5384836bd47": {"doc_hash": "83304ba33acd07d9e879c707db084985c6050f9365022f8d2b31bedcf989a1b0", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "3b730e2f-c1e9-40ab-a9b3-95887ce8dd92": {"doc_hash": "46830ecb51bb3a40d6f4fde2e4c906d3f31409d78648dffaa2792eb447ef76d1", "ref_doc_id": "17c1b134-bef7-4067-9464-18c8c23ac74f"}, "0f15d240-5bdf-4c76-972c-71e71a9afc96": {"doc_hash": "d95a863fb44dde3c514c41428d02fb7e1a03432970ffe665941f71d7f54acfe6", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "8822e284-b228-41bd-b36a-925751260669": {"doc_hash": "550ce7e33a80c77f9a49e0816ec36dba1fadface34f95a61f9b0c42526480dce", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "8e6645ab-30e2-4254-9f7a-0b6c9de809ee": {"doc_hash": "03f21df3ac4baa138332f1997f9bd594d4c52bc789b0256ca41135c749a759f2", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "59d898ac-1ea9-479a-bf65-d9c7da5420be": {"doc_hash": "8e7952ec11adbd2a6340dbe62635442994755b22ecd9353c0547cc86cde222fc", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "66078c83-a361-4718-b80a-2a92b1bb6b22": {"doc_hash": "7693df8ce3c998bb5ac5f6121d494371cc40ccef2f2975cf4b27eec11f2bc772", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "4e4eadab-b898-4d05-a960-a118843eefed": {"doc_hash": "a11e85aaf0e3ab5f484f767a042d43fece09d75742f239541ec08edadfa1d1e8", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "0b33de3b-72bb-4245-a36b-0545170d4207": {"doc_hash": "8a1d49b6ac0844faa34f94218b9425da9e3f694e85a50159591ab7f01df534a0", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "be8c30f9-7588-4c81-bdc5-68687052d4df": {"doc_hash": "cdf5860d3b7e548bc5cf31331ecaf0707bbf15db00054d797cf85fef5bd0c4e7", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "53f1b40c-91c2-40b5-9a72-4ca4eb021b0a": {"doc_hash": "7db9ee6c285a7c6cb4896f88988cb58aac635679ca6ab4f9f7fd2d490371f2aa", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "ce2b1630-9eec-4681-95dd-9f6d5b1e0335": {"doc_hash": "4615387d0b37aef36516995dee51889f4c5da5a911bc449cfd1c03d847569a7f", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "6a47a0ee-7a9d-43bb-86b1-2056aff1e51c": {"doc_hash": "c122b8efb0f4f346808c6c4e354a656e90a8f72c67a6b79ddc1972bb3132ce88", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "b1287924-bff3-4b71-90b3-2a9966fae016": {"doc_hash": "09a9d7692377e4db9e1b06ff914ae2b58357358a9a0f4cbf66481c51d9c7ea51", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "433ed539-4ad9-4a50-a677-3ea08191666e": {"doc_hash": "6a4ba2ceb23ad082262fca8dbea98000b8cb4660466a8a88a1308019464df3e2", "ref_doc_id": "bf2c7821-db0b-4d56-abe5-64be52ea41f3"}, "8ef64117-75f7-4454-b719-13774022523e": {"doc_hash": "095ec099a703ddf5cb3de256c9acf1536753d76dfab6e91803fb381d7022d435", "ref_doc_id": "b47b6f6a-7bf4-4739-8ffd-267bc91011b4"}, "a27c0bb2-5d3d-48b1-a6ea-6ee16e567af0": {"doc_hash": "34bafcc215343bfdcb69ad607695ad9a86fbf8de66c2cf25948ffc0cfceed704", "ref_doc_id": "b47b6f6a-7bf4-4739-8ffd-267bc91011b4"}, "975c835c-efa7-4a9c-811f-1105f4fbc6bd": {"doc_hash": "b1425433726f39033809745e0e95448ee928c4720fc0fb88a35c6c06ef904448", "ref_doc_id": "b47b6f6a-7bf4-4739-8ffd-267bc91011b4"}, "d9b46e1f-2f14-46da-9021-8547a79f1994": {"doc_hash": "3c809e05d79013b479139bef6a174e9cde311be4a0fef9948d1660d159268414", "ref_doc_id": "b47b6f6a-7bf4-4739-8ffd-267bc91011b4"}, "2b41c37c-6950-46d8-a7f4-18c06f0a6455": {"doc_hash": "067462251e4e755739539e0b17015c50d90237d44d43cb486dc1816809610ae6", "ref_doc_id": "bfca8351-6e90-402f-8ae5-18e43836680c"}, "5db8d93c-97fa-4d62-9f89-748fb8722730": {"doc_hash": "ffeed3b7e212e1fe00e8d830b3abd830e3a8f90eda8b970b416d885b66848718", "ref_doc_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45"}, "256a1601-3baa-448a-98b1-42bcef1a8782": {"doc_hash": "f747c657762dfa2ec985e45ce05039d2a55531f0f5b716a00cfb9828fb18f640", "ref_doc_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45"}, "9b93dcb9-0b97-4d92-8041-8c7023b40fed": {"doc_hash": "72be3dfa8265c071901c2e0bf6f52eabfb7a8fc7904102da27c9c89e8c61abbb", "ref_doc_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45"}, "8e96a0e3-d536-4e4c-a80a-58d1a6e50e11": {"doc_hash": "9b745316385b66e7455d3b179e32bb0ebb78de914d0b2e9e8ed1171f2b5306cc", "ref_doc_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45"}, "e0893809-3817-4952-87e1-c81b9066baa9": {"doc_hash": "7cb347a4c5ddf89b2e867bc9502e7604788061006de0ff1a05615f1bad2afcf0", "ref_doc_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45"}, "a64ebf5f-4fc1-434b-9e45-800ddecccf1c": {"doc_hash": "a914d28fa779a4a83a56e771f3378437fd082ab66fd491b53cf2e0a0e90c3a78", "ref_doc_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45"}, "54de995a-d95a-406a-b821-92ce3ff90ced": {"doc_hash": "9d87453ac7f9eccef6f4f9fde7edd6c4a9cc4074b39633fc1c2e6598dfdc85f7", "ref_doc_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45"}, "aac47b6c-fa75-408d-8c47-9c5b15c10fef": {"doc_hash": "123cb6b5a79e870f2f126991908abc4bbb63f6b5ca37548790db551e9dc7ff3f", "ref_doc_id": "b09e67c7-31c6-425d-ac9f-4ba73c08ba45"}, "57c396bc-c7a4-43b9-b433-38aa0533f82d": {"doc_hash": "9aa1859c1c0dbe459fed775cbaab3076b9cd51c8680b7af1a3e4c8282a89b1ea", "ref_doc_id": "3105b0d4-8518-4336-9440-5ee0a82312a9"}, "bf5fe614-f3e2-456b-b6d3-15e98f2bb1df": {"doc_hash": "e024fbd996a6004ce0eb213effceea47d8ac6751806de87b149e586875b72eff", "ref_doc_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8"}, "d72eebe5-b86a-495a-807a-a9847dc030bd": {"doc_hash": "587eec0aab106641c2a9bf3ee6c31d11e18088d005f3078a42c5a0f5870cae14", "ref_doc_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8"}, "3d2833ba-cde8-47c9-b298-8f3065e22dc4": {"doc_hash": "525040abda328f59fbf44ff5c57b232d51e4ebbbb3c8d555e4e6baa5b363da18", "ref_doc_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8"}, "e2ee3d02-14ee-4381-a5f0-4b5e0e6e01f9": {"doc_hash": "834f0042b12f182186a0a2e82ded4e269d1fb181a27e25a328c24c2f900c38e0", "ref_doc_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8"}, "50ecd62d-972e-4d44-b180-7139553b4717": {"doc_hash": "fdf21032ddd721b61640d20db99b10876c46d61228bf65d9784cbff092d50c88", "ref_doc_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8"}, "01c0cb71-bbe4-471b-9366-0f2c85ea78bf": {"doc_hash": "29742b8c9bc4a56b91917dfa7b75ccf2c8c09eb3a2da9f5d110e595d2384fe0b", "ref_doc_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8"}, "9d3ffaa2-a63e-4ef0-ab90-d6c54c32fad8": {"doc_hash": "50398ff5f6e88c7dba70c9c1f74b40fc9c7498ce447976c87bdb4ad511c20d85", "ref_doc_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8"}, "ccf6cb6a-9a37-4daf-b330-625fa5e0d2a2": {"doc_hash": "ce1df2392cec4db1c87094c962048eeae37a2f3e74b5b952e56c19c29f558122", "ref_doc_id": "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8"}, "a9d88532-40c3-48f9-a9f4-b11318586b04": {"doc_hash": "a52dbae91115cfa034eb93aba39779eb9c1e2ebd3e2decc735225ee905d6edbb", "ref_doc_id": "b429cd82-4359-4aed-a8ea-b0f48fba2b9b"}, "67721d3e-a1c2-431b-aa5d-ac761113e92e": {"doc_hash": "4835f81eca151f33d891d3bf58b6b047d913287450b6a270a9b9218cc5eae413", "ref_doc_id": "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b"}, "72904d5c-b15c-4faa-b0f4-d7f7f438bec8": {"doc_hash": "4b15c4eb96a4383f01ad21a9ef8f3f8b446437d649e9b497cdcc784670864895", "ref_doc_id": "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b"}, "0d5b461a-3271-4d97-935c-a471129c273a": {"doc_hash": "ac59c956a7437c50621061ec6603379e3269d8dbb2ea39b4fad88f1fa365e38f", "ref_doc_id": "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b"}, "e6b4313c-fbc1-4662-b7ea-6a716d9536a3": {"doc_hash": "9330692397b1c430f20e62d540d93ae4854ef384498336b208503b57c78d61e8", "ref_doc_id": "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b"}, "8d230fa4-278a-4ee2-a56f-1b0eee309acc": {"doc_hash": "d746b8400efa93980446874a93b6fd4e22c4d71b11c1e8009dccaafb1815e700", "ref_doc_id": "2804764e-0d08-458a-b941-ec3b619cb0ba"}, "48714758-3b4d-420c-a446-7b1d469f7352": {"doc_hash": "efd9c82f74aafb19b16a34a2413f06e4138c8124decc8a9398c2ef6dfe88214b", "ref_doc_id": "2804764e-0d08-458a-b941-ec3b619cb0ba"}, "11b1a9e1-10c4-448e-aca2-50a203f3643b": {"doc_hash": "8375d4a08e7932aabcbd1aa9e864ceccfc7faccd8a52b973571740a47d9d8717", "ref_doc_id": "2804764e-0d08-458a-b941-ec3b619cb0ba"}, "74ab59e6-c45c-44e8-9883-ff2d66c406f6": {"doc_hash": "53ba3b0976e8f4180671bbc88b84a7006f6c63f23a78aa2430654654a4a46b23", "ref_doc_id": "bd9c2d22-daf1-4438-92c9-2c5e663f9a3f"}, "943cd21a-56ab-4d4e-a5fe-460dfd36b099": {"doc_hash": "40f8af3815dae8797779d50e63c9fbf59a75ebda79eef780fc89adb03930171e", "ref_doc_id": "bd9c2d22-daf1-4438-92c9-2c5e663f9a3f"}, "c405952f-34bc-4b6b-923c-c25fa9a2cf50": {"doc_hash": "6fc44f2125c28a57dda2afbabe2bc6a20f5dc43e6b0853a6701348d928a551d1", "ref_doc_id": "b3be76cb-f655-46f6-be0f-bc2b34951518"}, "57c985b6-049c-49ba-9dbd-9df197aabd9d": {"doc_hash": "3f69fc0f2e7283c4bb0dd69645a2dfd40056693f6a6f5392a714131a3359ea45", "ref_doc_id": "b3be76cb-f655-46f6-be0f-bc2b34951518"}, "e7c622d3-98d4-4b5b-8496-d934757d4524": {"doc_hash": "87c8010fcc93c677c01a003a65b57a75881320af480c8cf504c27249c36e945e", "ref_doc_id": "73efb85c-f47a-44ee-bd17-6ce84ee08a14"}, "9987be0f-695b-4e3c-81c0-2330f8489afe": {"doc_hash": "2a135621245bd3fc8c3f16db47e179ac347a1b188a5688ad7d144803ff93d9d5", "ref_doc_id": "73efb85c-f47a-44ee-bd17-6ce84ee08a14"}, "660f6b69-2822-4b5a-a541-a5660695f751": {"doc_hash": "9c7b496a75465e842a840e9dadb752582f7d44e49cd611f355b3166b2e967e81", "ref_doc_id": "73efb85c-f47a-44ee-bd17-6ce84ee08a14"}, "7061d1a0-97af-4bd1-b23a-9cacf5cad9b1": {"doc_hash": "25007871f9f2bdf6c0f05a4f055fe30a82494f7b3d8f21a649979841a45e5914", "ref_doc_id": "73efb85c-f47a-44ee-bd17-6ce84ee08a14"}, "b10782ed-de35-411d-acb5-49df0f9d0d92": {"doc_hash": "6470aecc4ae06e3ee6eab377db7f6a77a36f8ea802a1bdbedcf8cf789d6f505d", "ref_doc_id": "9829c99f-a04e-407c-9935-6fec97bb62ea"}, "980461ff-52e3-493c-9a8c-dc68adaf1289": {"doc_hash": "a335d74ac3d71b56d4e7baa396e3a1ce8726797906e7f4aa5a74bf8fb348d812", "ref_doc_id": "9829c99f-a04e-407c-9935-6fec97bb62ea"}, "62d566a0-688d-4083-a6b1-02004be6a552": {"doc_hash": "6145bddfdec5fce8f55e1c81466da7b3c44cd5527aaea491ad346c932d5608f6", "ref_doc_id": "9829c99f-a04e-407c-9935-6fec97bb62ea"}, "c437a22c-6975-4875-bfd4-cc9bc1b88740": {"doc_hash": "fa775eb2564bb8a886251f6940bf490bd8a255770e3128f08acc797d86ff2682", "ref_doc_id": "9829c99f-a04e-407c-9935-6fec97bb62ea"}, "0b45935b-531f-42ae-940b-d1870c64919a": {"doc_hash": "5baaabd385287713579e7c79f95f758b36ec8845ea03539d10f6f522f40b7e13", "ref_doc_id": "26fe9012-9886-4bfe-9e07-2a2d8815347e"}, "b454b7d8-fdeb-4ba8-9816-c8bf24f16355": {"doc_hash": "084fe957029471df74cfccb3026561a9890b16057c8deb219cf52cc794beaa6a", "ref_doc_id": "26fe9012-9886-4bfe-9e07-2a2d8815347e"}, "7159f84b-434e-4b21-8543-0e12ccccd01f": {"doc_hash": "07a43157aeb50f7fa23430e523e4b56346eb35ece2036e6ee6df2a9f563672f0", "ref_doc_id": "26fe9012-9886-4bfe-9e07-2a2d8815347e"}, "681b15af-3529-4336-8be3-32ef122ac854": {"doc_hash": "51b3f2af3870fbd5e5844d8a6e28f46b9db4684a7a627b35575a4fe9cef6e792", "ref_doc_id": "f3836303-9cf4-4bc8-a48e-9d167c85aa93"}, "a7b28925-b5d8-4ed5-bd2f-43e332697f3b": {"doc_hash": "82daada52475e3d52d96528004b0d94c926d0c75286d80ff6df1c340eb7099c4", "ref_doc_id": "f3836303-9cf4-4bc8-a48e-9d167c85aa93"}, "c8f8efb0-67ec-4957-a87f-c7144aac9a1d": {"doc_hash": "c9056a0e0e97bb5b9cbae436cadbc17b14ee6a3242cf66cee286733717830064", "ref_doc_id": "f3836303-9cf4-4bc8-a48e-9d167c85aa93"}, "43e64f46-ac7f-486d-a95f-54f81f6f95fe": {"doc_hash": "90229528ec83587fdd838f99a70ae00154822e3edb3874556e750f5ff3b02c29", "ref_doc_id": "c7ee99bb-dccc-489b-8b3e-724db5cfd5e8"}, "ce7bb7a9-180a-4acf-8ab0-c48c06679df0": {"doc_hash": "621c009ed00d18df6baabb3f9c1cf248e71922800927ed79f47d2303c7a1baf2", "ref_doc_id": "c7ee99bb-dccc-489b-8b3e-724db5cfd5e8"}, "58ad214b-c37b-4aae-9480-27541a1413e7": {"doc_hash": "96384e097521a6c6d5dae2569e09f89559773e6bf41e39428ae765f8ea8dc8fa", "ref_doc_id": "c7ee99bb-dccc-489b-8b3e-724db5cfd5e8"}, "9a9fbaa8-f505-4125-b6b9-aa697f8e4b09": {"doc_hash": "80714610affc8f273a4412e2ae103944a5187146321b4c6bc258c85aa4cea49e", "ref_doc_id": "fd198f88-d159-45e9-9821-c88681c39a87"}, "b6be4fa7-bcae-45bc-a61f-481f2c8d5687": {"doc_hash": "31371be38089c74a70648cda288bea645b08089d6d305c0aac0bff1e8c2e539a", "ref_doc_id": "fd198f88-d159-45e9-9821-c88681c39a87"}, "f723193e-0af3-4c4b-854c-147a08cf6425": {"doc_hash": "eb6958f61a74896dc494cdaba3cab618e70c6def908d5a9b4d567b57789acf01", "ref_doc_id": "fd198f88-d159-45e9-9821-c88681c39a87"}, "30e55dd6-9506-4d1c-a89d-5cfc31543137": {"doc_hash": "fc99feb411e08788dd6f0aef6fe0e55b03a0342fc9897ad47a7b643f54ea4729", "ref_doc_id": "bca54e88-b0ed-4801-8b53-81c24cf54653"}, "97add506-dddf-474d-95e0-ec1a2cfb1d03": {"doc_hash": "440b864aadea0c72943dff488c57758dbf4b650bafad1266f042b11c3c4f6650", "ref_doc_id": "70c46885-d0c7-4811-9a6b-6bffb9724193"}, "b199cbea-a9f4-4a1c-8d86-a50ea8a8f97e": {"doc_hash": "30898367f3ff77d3f6aaa2960b7d729f51e039d35a724a3166e1c2e8715b9a35", "ref_doc_id": "a78e43b3-387a-4394-9d6d-d884c4293b00"}, "eeed0154-ced6-424c-995d-5ddaf9936346": {"doc_hash": "cfe03da5359ef439e05e05bb9ae6bb5e93a0687279534d63dcb59e54ba89a6cf", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "066b29a3-d340-4488-bbfd-ef7c7d89aab1": {"doc_hash": "60bd24ea274bda9afd4e0cc0190dd17caabfe7d47b2385f7e0058ec4b5bb4e3b", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "af05938a-4412-4054-b7f7-4e9ce289fd22": {"doc_hash": "a93b5375cb41bfae75e9c729910c08419c723e125dac7e8d7d10f6f0610bc916", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "e0372218-5f0a-43ae-b391-45eb9872fb9c": {"doc_hash": "179e04abba10723a7c257017d58f7ace03b0e1cdb27d427e4d9254ddb9f31d95", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "dbcf49ca-2ac2-4d1d-bdb6-ed9cb946600e": {"doc_hash": "19af4473f6af7f9be234984d049126184291990087ac615bb1b3ba4b1f6bdeef", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "7c0a0cf8-52f3-4d35-a0f9-3d7f85b9b5eb": {"doc_hash": "d3059ddbffe14c15e9b89d89c17c2804ddd293d48ac18d65c8feb91eb30f7aaa", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "ae4f1d22-e999-4dde-8da5-31aa7bfdd038": {"doc_hash": "fbd9eb35dd09c7ef9212d56c3eccdc47224178ee4888cdbc93c38dc3583a1f0c", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "c3bfdfe5-83bd-48bf-b808-3d0fdb16a9e0": {"doc_hash": "7d988bf2e00b4b7ddb4d4a09c793bebd28d3faf53cc0a4d74e4964fe677dff15", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "e3573c5d-c86b-4552-9cee-2d244b81992d": {"doc_hash": "e626d24051bebc8c2bf301edb68de8e7465528b35c522189fdb3c5f1990904b7", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "38ee4568-2a8c-4a8e-9f45-603626d2bc35": {"doc_hash": "e7923e286dfc80c460cdecb9f6ecd65efa1620e8f33e4b0f7f455f2d82618959", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "fde6cd25-3e80-4a7e-9769-86fb792a6a81": {"doc_hash": "db2e374dade3cd4e42a38eabe98403e12fb5873d1c8eb7e6468620de2559a5b4", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "bf451dd7-3a8f-4105-8127-2c6e1b1bd58f": {"doc_hash": "35147d57cb02cf250ef6c6e5eeedbd00ef85d8f891b8f0c978065b563da29ac6", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "9a62ed26-2b74-47f1-a9e1-f658a9baf57b": {"doc_hash": "6db6f1c8e42b33b6677b964198ab61b81b214ca315ba953fe11739a953bfe946", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "5f2906c6-cbe6-4c26-8a5c-9c366383713c": {"doc_hash": "a247bd2bb0f186ca00786a357fd1b1538259fd75ded1cb3dd5a42a8d11b413c2", "ref_doc_id": "983de150-ea96-4f85-8bcd-ed58dd552e45"}, "42ecfccc-ac51-4321-b5c1-568409c02e78": {"doc_hash": "724b3efffd303d71b3e4008fb9c0dd92a4fa9712ee092826458efae9ef0be4b6", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "e6cb1bed-d046-4ce5-91d0-ed8c0950951c": {"doc_hash": "624fbe65939eda29ba94f906ebb7799b822d123821607b9bad98d91e51b1ab95", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "5b3aba64-ecf5-4df0-8c38-d52ad831f93a": {"doc_hash": "eaeb34bb6173b2035a5264dcad8dd9e9f5d24b874013242864a29254fc195e64", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "f3b21f29-1267-4df3-8be7-24377e08df43": {"doc_hash": "182486066666b0f002ca127a89a327363c3913159bc8a44d4b1d3aff9902f2ea", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "003178f7-47b5-4585-b7c2-99973fe1b8ed": {"doc_hash": "0d1ac723aa828144e4dd9ca9cbe5b55bca024daa5665e93ef478737185130f6a", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "0f58e092-4bce-4d30-aae7-fb007091fb4b": {"doc_hash": "e88aa23e1e7db62d531803a0aaed2311e727ba13216522148f37ca8dbf9427ee", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "39790d1f-5f27-4266-a3f4-b9aca06a6bcc": {"doc_hash": "76d6a13708d2a50bc37567282a5b00530236df8ccf5b4e3c60de9d767d5de7c1", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "404433a7-4c42-4366-87df-55262b303f19": {"doc_hash": "d25efc6c34cade66d8056ac72f13e6849cfe3b6057937ecdf2aec6642fb4a295", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "79a6881b-9db1-417f-bca6-50d7dd3c8a95": {"doc_hash": "d4b728121277e733b5fb0f66bf4dc2cf5935ae3ace89e84b2d96009b21be7002", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "d0cbcf8f-53e0-4e73-97c2-68d957d69c71": {"doc_hash": "45df81758aa49a7d13b9018bab2c4909bf1c9fbc6caccaf25ad4d8b0651f081a", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "985ce36d-c2d2-4572-84b1-06e75c608228": {"doc_hash": "27c44a21a528c17f0b22d390f8ed16d2183081c7364f942948e0dbaa0ebed158", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "105bddc1-d9e9-454b-aa3b-39da03d600c8": {"doc_hash": "9120ddce202cf97779bd240ed00a9cfa8cb4e25cfe1884f7e1fbe66c5baeb449", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "dcdbc5f5-bc70-4c9c-a434-449afb43eded": {"doc_hash": "d1246075be796ae4a1ab76299988fc165b9730a08e96a8b9dee9f298f7f16b95", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "29f88ae1-45df-4949-83e5-993ed9425dd1": {"doc_hash": "01a4ee910cc41f6ed1f39345de5ba8ea1b01f236b1ed9dd776a3373a6c601fe8", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "868f11d1-4f25-4349-834a-b5b315d75718": {"doc_hash": "d62053b412cfe14969db58771e28e34563f4b9a18f0d450a2ecc221400ec2f86", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "3fb51fea-c351-4875-ae86-7d33a9e7969f": {"doc_hash": "292faaab692c646c770243775c66c112bdefed766e71498deb6328042ca64431", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "5aaea41b-981a-45e4-81cc-476fb6b9b35d": {"doc_hash": "493d9e26e90f1e822361662eceaf577976bae6cd4e497d2baca0ea554afd3e98", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "012b94d7-b545-4e2f-8924-1461379f939a": {"doc_hash": "b99b3f3bbbef35a06924885bf923c36b4ae18becf3d4bbd602f299e1918f1881", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "06673be3-ff98-42cc-86eb-3931de30f08f": {"doc_hash": "f8a431713268a736ca55f2bb55c54731c98f81de5d1ccaadcf351b6dfccf4f8c", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "1ec10203-c1df-4ca2-9534-66ff0798bc7f": {"doc_hash": "4e199950367eceee7e21617a15c49693ad8497c778d5cbee4229446e91d7927b", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "441ff1e8-9040-4768-84a9-ec493db5eb75": {"doc_hash": "cf334f34cdecd818c1d5159f0404333a789eebfae08b21ad80359447a7f38ab3", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "7a51028a-cbe3-4204-8726-bbf5386d1d2d": {"doc_hash": "576493405174ba980ee12026e0a4725d8ab9aa6c37f29f1bc13b632157e9a4da", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "78574e59-df2a-4a41-bd91-bf0d29d1bd41": {"doc_hash": "876b62b97b2ee9235122bc228ea126620b0fb7d72e78e4e720d442a1961254d6", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "c2f19a98-2126-4664-ae47-577f77e3862e": {"doc_hash": "c233cd181b0a7ad9cbe87b36bf092b93060a1aeb14cc4891e95696320f5a5d6c", "ref_doc_id": "ba8e296c-2fc1-42e3-91c6-e09d4308e68b"}, "0498d21e-f0d8-4c1c-9922-997ee07380fb": {"doc_hash": "4896f92a0209ded19ab5faaec984584a904e846cbce01dccf836f781c9b3fe8d", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "0bf96be3-cc8b-4fad-a8de-e19d54a4b87e": {"doc_hash": "b82ccd610f010729455efd19618d247f9df309f8d2331966867d3d4e19ad7bcb", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "9568524e-3c39-4a11-a444-1cb5c42bac48": {"doc_hash": "fca07857323d03868851c03dbf9451a69cf0cff4d4a433f7fc06c62bfad4913b", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "06093286-67e4-411c-8302-e60aeb868b50": {"doc_hash": "7a6ca94ef8beac6838788f7fce234a0070ff858dd99a8c907eae3c5dc26ca431", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "19723a54-d622-4490-9f20-71a3e01ba1ae": {"doc_hash": "096dc6d3c0cf9d108d2f7c9f532e851c6e02e82f6cc0bae9a91582d80bacf148", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "915a53af-1a9f-473b-8d16-a3754195b293": {"doc_hash": "db51a53d8c6af3f537e3214c4b6c968beb066a8eaa5f437a37fa138ab5e799bc", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "388f355c-5288-4149-9022-5f2b7c26838c": {"doc_hash": "c2b73917cfd658de0797f8233d5879043320088fa5a619115099ae5667a43632", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "5f405c70-921b-43ce-922d-6b5c64717cf5": {"doc_hash": "5c35acc973636acdfa6a007bd67f9dc7781ac37ef0409e36d55b857891f76bd6", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "6f3fb2ba-ad96-457a-9c29-969d5b6c794c": {"doc_hash": "bc75f7ef7d691c750c5eb9e7310ce4271e8591feb28dd0aaf1f276d7c7066f82", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "83f2d32f-88bb-4910-bbf6-67d9a098a88b": {"doc_hash": "24e37d1845f1b589c242f7a545a9ceb02f019ac9736042d7ed53e3d7518a522d", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "3bda9448-25cd-406a-89c3-bdc78f12c2b7": {"doc_hash": "42c89005544e8b8a8d1b51f4675b581d9fe0539cf18aa49c1c00500e57f06ed0", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}, "85c4fb61-a143-47f3-b315-6806ad90f81c": {"doc_hash": "30391032053889089d69ac845bf4443439cf62e0b4a4d3c89398a2e5a4c19f3a", "ref_doc_id": "6576f10b-ddf9-4842-b900-87ada1a103d3"}}, "docstore/ref_doc_info": {"ff4cdd16-733d-4b11-9860-47e4042b79c5": {"node_ids": ["f1376409-62d5-4a48-bfc2-f6919d3130da", "a903647e-f527-4bce-acb1-29f0dee53783", "60912c69-6218-41c7-aaf3-002514baea26", "36c74af9-a578-4373-aced-70467b2edbec", "5a2cc351-a57d-4ace-b88a-e1338051ea30", "d4ed20b7-50a5-4f89-84a4-0185ecb2625c", "1fd20d5f-1621-4b4f-ab57-b11a3cac7397", "47cf6cb5-c6f5-43cd-8b92-0b06693083bc", "4b71f098-9369-4e32-adb7-7fc2796626d0", "48107d5d-81f2-4dd2-aca4-2c5face58097", "61c8d977-2276-40ca-bd05-0259ac3251de", "ac2b8d21-8cde-47c0-a84c-dc396cbd16e9"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to\n$1.40 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n21.3 percent to $2.62 in the fiscal third quarter from $2.16 in the prior year quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Thir d Quar ter Results\n8/3/2022\nRevenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 \n Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nthird quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "376fbe2b-0bab-4a72-810d-ddbfb5356b26": {"node_ids": ["e888d6ae-a6bb-4743-93c1-6276b456ccdd", "41ff12a5-d804-4c9d-be01-ce7aa020028e", "6284bb7b-7d00-4181-a24b-53bb61ef5f5f", "53658c5a-d2f3-4a5b-b1fb-9679c4025082", "bfcdce41-9dda-4320-8705-cf5abbce8edb", "026cf758-3c32-4623-b161-cbd12a658a87", "453c436f-ab52-46fd-acaa-72487c0b22a0", "ab055769-4aac-4a42-b35d-24bd2dc85394", "a2849634-6cfc-496b-ae6e-02babf2f21ba", "ad9ac889-dab6-432a-b1ac-74209b10ca80", "3f3151ec-24eb-4b48-a92e-b7651dfe3ec3", "bb448d88-0bfe-4a8c-ace7-c53ec5794d6c", "e832744a-6f2c-4019-b8b9-20ec54fa0ebe", "68291281-5c35-4128-85b2-a17d0934b946", "26bc811a-7026-4400-85a6-49bb30a1b111", "89665b11-691c-4dc1-b5fe-c6a9d954a976", "dbc1f0f2-87bf-45d1-92e3-b6c25d8e6759", "c1b99932-ef6d-45e5-8b63-c8fb74f3069b", "f30c214d-8715-4fd1-b5b2-32a5fdd0cb57", "afc2ab63-0334-4ad8-95ba-59f438f4d763", "b5f87745-10df-4b61-bbdf-8a119c272e0b", "c0e9cf2b-31b9-4fa3-ac11-d5c47ebb6ff5"], "metadata": {"window": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2022, revenue was $60.1 billion, up 12.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 120.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 6.0 percent increase in U.S. ", "original_text": "Dilut ed Earnings P er Shar e $1.92 $2.62\nDilut ed Shar es Outstanding 211.7M 211.7M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "305780ff-10c5-4cf3-8d3c-ca45b5215d34": {"node_ids": ["5f0672f0-3098-4286-bfea-e83b05852650", "ceb99d52-6419-4e57-ba68-225ee03f6aaf", "37684366-b73f-49d9-bf83-60a6a1850c90", "7d85016d-8324-4a10-83f1-75f35fdfc26d", "bd105971-9c67-4a0b-b6c9-731cc9778848", "35b584be-a08e-4e1a-b89c-13be314137a2", "0dfe9750-da1b-4f1b-9f88-34f9a0ef8ce8", "c1c52f43-6050-4893-9762-a8b80ec363a5", "e6967086-0a0f-4889-b94f-965752571813", "83ffc80c-32e5-4814-a942-4c0f028fe911", "05c78100-06e7-43c1-8383-399e0107d7c7", "0ad8e704-2f6a-40b9-a3a0-aeeb49aa144d", "aa08710d-7155-4945-a2fc-a3c0e30d3f86", "c9cd7057-3830-421b-9499-4bda9d0b41b5", "03431f43-51f6-4445-9055-219e8dcb6ad3", "174beec3-145f-404a-b5c9-6eabafe33511", "ad340b6c-b061-4935-bc86-a27b06084a62", "4c39e2ab-7ca2-4a78-91e3-152f68894c1a", "6f4a0df9-f463-465c-892d-29edaef39f69", "12b534bb-64fb-4f1a-96be-682487c02960", "37279452-189a-4e1f-a239-c94bae076420", "b06cca55-88f4-4b89-bccb-b2cefe12cff8", "3a9b8daf-a385-4d71-965a-92f1c870696b", "2163abfd-09ef-414d-afdb-3ed680a8241d", "29736fdf-b1aa-4321-861b-f30a5bb9fab2", "2cf609ca-0ddd-4662-8bad-5cbae2fbd242", "f4ed3bf8-7f3e-47c3-a8d9-0da01d862bc2", "44c5ff7e-cbcc-4e5c-9a0f-8678b05416ab"], "metadata": {"window": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the third quarter of fiscal 2022 was $2.1 billion, a 27.0 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions. ", "original_text": "$60.1 billion, up 12.5 percent compared to the same quarter in the previous fiscal year, reflecting a 120.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\nHealthcare, and a 6.0 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e1e2cc46-20a8-4ef4-a0e0-f27559b2c6e2": {"node_ids": ["a8332c56-a46c-46a2-8bc7-ae1f1eeb96f4", "b7d34fd3-6d9d-403d-ab75-e455ab7cbea3", "d408751e-1b7a-45ce-aa3d-b805b9abfd12", "c225d553-0c54-4cfc-83c1-a97258fe9a75", "2a46fb5d-8310-4c76-83db-808ef8816903", "292163f3-b5a9-415d-b50f-6516aa61c094", "578fc715-f349-48a8-89dc-a6971caf9f2f", "8226e07a-5fad-4ee5-8037-e65d960b6b41", "26ed6df1-1717-4c66-9cea-99238cb91550", "83f0561c-41fc-4a97-844d-9d1d9a0f6120", "7acd524a-c0fc-45fb-a0cf-4d2247a721a6", "b090702d-78fa-4c66-b308-fdb9159ce81b", "9a957d5d-1ee8-4ceb-8a3e-0ff1cad1d85b", "b7e65ac2-ab26-4797-8bd5-5716faf4ea54", "723a026b-862c-4e5f-9098-14cb27942489", "ae7b22b6-3df5-4524-af1c-3ce55b56adcb", "9fe54f1e-e522-4464-be44-992ca879dca6", "b41d7d83-bdde-4857-8edf-d357cdf76a02", "4214caaf-5ee9-409a-a291-9048b867dcf0", "ff7a88b4-b4ca-4062-a6e6-b19261e05b42", "52a5274b-c82d-4995-b2cd-811955bd85a9", "ee48edc2-528c-46ca-b3d2-0b3aca3b1fed", "060e63ca-ac8b-47db-b45b-88c819093634", "4b63f17d-8772-4c9f-be18-bc966e1cadd9"], "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating income in\nthe third quarter of fiscal 2022 was $176.3 million, an increase of 74.8 percent, primarily due to the June 2021 acquisition of Alliance\nHealthcare and strong operating performance at World Courier.\n Recent Comp any Highlights & Milest ones\nOn June 1, 2022, AmerisourceBergen hosted an investor day event during which management discussed the company's\npurpose, strategic imperatives, ESG commitments and long-term financial growth outlook.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it was ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.7 billion in the third quarter of fiscal 2022, an increase from the previous fiscal\nyear\u2019s third quarter of 120.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "17c1b134-bef7-4067-9464-18c8c23ac74f": {"node_ids": ["6df9099b-4a07-4077-86c9-41286fc8e6ba", "0c58afb8-fa1a-45db-a71a-484d7cfac58e", "1347ac50-3e34-4b24-bc62-7448a98a0062", "13288cc8-18be-4e39-99c2-e5a0d251bc43", "71737c57-3d01-4825-977b-bfafb1b04d9f", "232cdd59-b151-4df7-af7e-f1bb37c81e77", "24bffac4-e532-4bc5-ad73-ccd8c3df529c", "ecb7c3f7-a18a-4c52-a165-084fc372dd61", "62ca346f-aa6a-4099-ba96-fd93f6d87c1e", "c81d5fd8-cb3c-44ed-add8-83c3e5e5c2c2", "4cde92c4-9043-4e46-9b76-1e8f06ed57b9", "f81c59c4-e1af-4a6a-8335-1b3949685daf", "133dfc7b-2ebe-4c3c-883a-c6b203e08c03", "7fe3470c-84e5-4389-828a-09a5da90eaf9", "6dddf706-c501-43d6-af04-d05cf2b4ccc1", "ed13e6f2-fb77-4a97-a673-a43605c5ed5e", "67daff0f-83b9-4a8c-ab22-c177cf9552d5", "9b52e2b9-2310-4f24-a554-fd5889ad1f9f", "3b985de3-9c7c-45c7-8d43-34c8da777df2", "4be52beb-db88-46c1-9b18-47449ef7a60a", "d887cd66-efe0-40ed-8222-8072021950a4", "1b5dca8b-ee1a-492e-96cd-233251be8b5a", "00f14fcb-6fd7-4be8-a811-f9baf5582b39", "1590fccf-45e7-4cd9-9179-3c75103a0728", "1360ac08-61bb-4232-8011-c5384836bd47", "3b730e2f-c1e9-40ab-a9b3-95887ce8dd92"], "metadata": {"window": "U.S.  Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to\n10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion;\nWeighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the\nprevious range of approximately 212 million shares;\nAdjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0\nbillion to $2.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable August 29, 2022, to\nstockholders of record at the close of business on August 15, 2022.\n", "original_text": "U.S. ", "page_label": "5", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bf2c7821-db0b-4d56-abe5-64be52ea41f3": {"node_ids": ["0f15d240-5bdf-4c76-972c-71e71a9afc96", "8822e284-b228-41bd-b36a-925751260669", "8e6645ab-30e2-4254-9f7a-0b6c9de809ee", "59d898ac-1ea9-479a-bf65-d9c7da5420be", "66078c83-a361-4718-b80a-2a92b1bb6b22", "4e4eadab-b898-4d05-a960-a118843eefed", "0b33de3b-72bb-4245-a36b-0545170d4207", "be8c30f9-7588-4c81-bdc5-68687052d4df", "53f1b40c-91c2-40b5-9a72-4ca4eb021b0a", "ce2b1630-9eec-4681-95dd-9f6d5b1e0335", "6a47a0ee-7a9d-43bb-86b1-2056aff1e51c", "b1287924-bff3-4b71-90b3-2a9966fae016", "433ed539-4ad9-4a50-a677-3ea08191666e"], "metadata": {"window": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Baird Healthcare Conference, September 13, 2022; and\nMorgan Stanley Healthcare Conference, September 14, 2022.\n", "page_label": "6", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b47b6f6a-7bf4-4739-8ffd-267bc91011b4": {"node_ids": ["8ef64117-75f7-4454-b719-13774022523e", "a27c0bb2-5d3d-48b1-a6ea-6ee16e567af0", "975c835c-efa7-4a9c-811f-1105f4fbc6bd", "d9b46e1f-2f14-46da-9021-8547a79f1994"], "metadata": {"window": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n June 30, 2022 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n June 30, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$60,064,601 \u00a0\u00a0\u00a0 \u00a0$53,405,695 \u00a0\u00a0\u00a0 \u00a012.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a058,049,232 \u00a0\u00a0\u00a0 \u00a0\u00a051,517,489 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,015,369 \u00a0\u00a03.36% \u00a0\u00a01,888,206 \u00a0\u00a03.54% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,212,152 \u00a0\u00a02.02% \u00a0\u00a0913,414 \u00a0\u00a01.71% \u00a032.7%\nDepreciation and amortization \u00a0\u00a0172,114 \u00a0\u00a00.29% \u00a0\u00a0127,101 \u00a0\u00a00.24% \u00a035.4%\n7", "original_text": "positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions and increases in inflation in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "7", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bfca8351-6e90-402f-8ae5-18e43836680c": {"node_ids": ["2b41c37c-6950-46d8-a7f4-18c06f0a6455"], "metadata": {"window": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8", "original_text": "Employee severance, litigation, and other 2 \u00a0\u00a067,870 \u00a0\u00a0\u00a0 \u00a0\u00a0226,964 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,528,072 \u00a0\u00a02.54% \u00a0\u00a01,267,479 \u00a0\u00a02.37% \u00a020.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0487,297 \u00a0\u00a00.81% \u00a0\u00a0620,727 \u00a0\u00a01.16% \u00a0(21.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0\u00a0(41,888 )\u00a0\u00a0 \u00a0\u00a0(4,141 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,862 \u00a0\u00a0\u00a0 \u00a0\u00a051,338 \u00a0\u00a0\u00a0 \u00a03.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0476,323 \u00a0\u00a00.79% \u00a0\u00a0573,530 \u00a0\u00a01.07% \u00a0(16.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0113,120 \u00a0\u00a0\u00a0 \u00a0\u00a0278,082 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0363,203 \u00a0\u00a00.60% \u00a0\u00a0295,448 \u00a0\u00a00.55% \u00a022.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a043,761 \u00a0\u00a0\u00a0 \u00a0\u00a0(3,326 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$406,964 \u00a0\u00a00.68% \u00a0$292,122 \u00a0\u00a00.55% \u00a039.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.95 \u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a037.3%\nDiluted \u00a0$1.92 \u00a0\u00a0\u00a0 \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a037.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,885 \u00a0\u00a0\u00a0 \u00a0\u00a0206,156 \u00a0\u00a0\u00a0 \u00a01.3%\nDiluted \u00a0\u00a0211,738 \u00a0\u00a0\u00a0 \u00a0\u00a0208,912 \u00a0\u00a0\u00a0 \u00a01.4%\n8", "page_label": "8", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b09e67c7-31c6-425d-ac9f-4ba73c08ba45": {"node_ids": ["5db8d93c-97fa-4d62-9f89-748fb8722730", "256a1601-3baa-448a-98b1-42bcef1a8782", "9b93dcb9-0b97-4d92-8041-8c7023b40fed", "8e96a0e3-d536-4e4c-a80a-58d1a6e50e11", "e0893809-3817-4952-87e1-c81b9066baa9", "a64ebf5f-4fc1-434b-9e45-800ddecccf1c", "54de995a-d95a-406a-b821-92ce3ff90ced", "aac47b6c-fa75-408d-8c47-9c5b15c10fef"], "metadata": {"window": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022.  Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation\nsettlements in the three months ended June 30, 2021.\n\u00a0\u00a0\n 2\u00a0Consists of $3.9 million of employee severance, $23.4 million of legal fees in connection with opioid lawsuits and\ninvestigations, and $40.5 million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the three months ended June 30, 2022.  Consists of $6.7 million of\nemployee severance, a $124.3\u00a0million legal accrual related to opioid settlements, $28.9 million of litigation costs related to\nlegal fees in connection with opioid lawsuits and investigations, and $67.0 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nthree months ended June 30, 2021.\n\u00a0\u00a0\n", "original_text": "________________________________________\n1\u00a0Includes Turkey foreign exchange remeasurement expense of $27.6 million and a $23.1 million LIFO expense in the three\nmonths ended June 30, 2022. ", "page_label": "9", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3105b0d4-8518-4336-9440-5ee0a82312a9": {"node_ids": ["57c396bc-c7a4-43b9-b433-38aa0533f82d"], "metadata": {"window": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "Operating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a03,585,500 \u00a0\u00a02.02% \u00a0\u00a02,378,563 \u00a0\u00a01.53% \u00a050.7%\nDepreciation and amortization \u00a0\u00a0523,333 \u00a0\u00a00.29% \u00a0\u00a0327,451 \u00a0\u00a00.21% \u00a059.8%\nEmployee severance, litigation, and other 2 \u00a0\u00a0209,234 \u00a0\u00a0\u00a0 \u00a0\u00a0375,501 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 3 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a04,398,949 \u00a0\u00a02.48% \u00a0\u00a03,081,515 \u00a0\u00a01.99% \u00a042.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,911,859 \u00a0\u00a01.08% \u00a0\u00a01,792,302 \u00a0\u00a01.16% \u00a06.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  4 \u00a0\u00a0(48,008 )\u00a0\u00a0 \u00a0\u00a04,901 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0159,150 \u00a0\u00a0\u00a0 \u00a0\u00a0119,478 \u00a0\u00a0\u00a0 \u00a033.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,800,717 \u00a0\u00a01.01% \u00a0\u00a01,667,923 \u00a0\u00a01.08% \u00a08.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0432,853 \u00a0\u00a0\u00a0 \u00a0\u00a0559,763 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,367,864 \u00a0\u00a00.77% \u00a0\u00a01,108,160 \u00a0\u00a00.71% \u00a023.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling interests \u00a0\u00a036,219 \u00a0\u00a0\u00a0 \u00a0\u00a0(5,926 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,404,083 \u00a0\u00a00.79% \u00a0$1,102,234 \u00a0\u00a00.71% \u00a027.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$6.72 \u00a0\u00a0\u00a0 \u00a0$5.37 \u00a0\u00a0\u00a0 \u00a025.1%\nDiluted \u00a0$6.63 \u00a0\u00a0\u00a0 \u00a0$5.31 \u00a0\u00a0\u00a0 \u00a024.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "21bddd12-ad18-45d0-91b6-eb83d8a4f0b8": {"node_ids": ["bf5fe614-f3e2-456b-b6d3-15e98f2bb1df", "d72eebe5-b86a-495a-807a-a9847dc030bd", "3d2833ba-cde8-47c9-b298-8f3065e22dc4", "e2ee3d02-14ee-4381-a5f0-4b5e0e6e01f9", "50ecd62d-972e-4d44-b180-7139553b4717", "01c0cb71-bbe4-471b-9366-0f2c85ea78bf", "9d3ffaa2-a63e-4ef0-ab90-d6c54c32fad8", "ccf6cb6a-9a37-4daf-b330-625fa5e0d2a2"], "metadata": {"window": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022.  Includes a $160.6 million LIFO credit and a\n$147.4 million gain from antitrust litigation settlements in the nine months ended June 30, 2021.\n\u00a0\n 2\u00a0Consists of $10.5 million of employee severance, a $36.6 million legal accrual related to opioid litigation settlements, $71.6\nmillion of legal fees in connection with opioid lawsuits and investigations, and $90.5 million of other costs in connection with\nacquisition-related deal and integration activities, business transformation efforts, and other restructuring initiatives in the\nnine months ended June 30, 2022.  Consists of $6.7 million of employee severance, a $141.4\u00a0million legal accrual related to\nopioid settlements, $85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations,\nand $141.5\u00a0million of other costs in connection with acquisition-related deal and integration activities, business\ntransformation efforts, and other restructuring initiatives in the nine months ended June 30, 2021.\n\u00a0\n", "original_text": "Weighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,895 \u00a0\u00a0\u00a0 \u00a0\u00a0205,255 \u00a0\u00a0\u00a0 \u00a01.8%\nDiluted \u00a0\u00a0211,633 \u00a0\u00a0\u00a0 \u00a0\u00a0207,679 \u00a0\u00a0\u00a0 \u00a01.9%\n________________________________________\n1\u00a0Includes a $37.7 million LIFO credit, Turkey foreign exchange remeasurement expense of $27.6 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the nine months ended June 30, 2022. ", "page_label": "11", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b429cd82-4359-4aed-a8ea-b0f48fba2b9b": {"node_ids": ["a9d88532-40c3-48f9-a9f4-b11318586b04"], "metadata": {"window": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12", "original_text": "GAAP \u00a0$2,015,369 \u00a0\u00a0$1,528,072 \u00a0\u00a0$487,297 \u00a0\u00a0$476,323 \u00a0\u00a0$113,120 \u00a0\u00a0$43,761 \u00a0\u00a0$406,964 \u00a0\u00a0$1.92 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a060 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO\nexpense \u00a0\u00a023,070 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a023,070 \u00a0\u00a0\u00a04,142 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,928 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(74,408 )\u00a0\u00a074,408 \u00a0\u00a0\u00a074,408 \u00a0\u00a0\u00a024,894 \u00a0\u00a0\u00a0(538 )\u00a0\u00a048,976 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(67,870 )\u00a0\u00a067,870 \u00a0\u00a0\u00a067,870 \u00a0\u00a0\u00a021,439 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,431 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,886 \u00a0\u00a0\u00a0(8,954 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a017,840 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,066,057 \u00a0\u00a0$1,309,858 \u00a0\u00a0$756,199 \u00a0\u00a0$699,943 \u00a0\u00a0$141,388 \u00a0\u00a0$(3,781 )\u00a0$554,774 \u00a0\u00a0$2.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\n12", "page_label": "12", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "46c1e8cb-99c3-4b85-be2f-4fe7043ada3b": {"node_ids": ["67721d3e-a1c2-431b-aa5d-ac761113e92e", "72904d5c-b15c-4faa-b0f4-d7f7f438bec8", "0d5b461a-3271-4d97-935c-a471129c273a", "e6b4313c-fbc1-4662-b7ea-6a716d9536a3"], "metadata": {"window": "Non-GAAP\n% change\nvs.  prior\nyear \u00a027.0% \u00a031.5% \u00a019.9% \u00a021.3% \u00a016.6% \u00a0\u00a0 \u00a022.8% \u00a021.3% \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.36% \u00a03.44%\nOperating expenses \u00a02.54% \u00a02.18%\nOperating income \u00a00.81% \u00a01.26%\n________________________________________\n1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income Befor e \n Income T axes \u00a0Income T ax \nExpense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\n13", "original_text": "Non-GAAP\n% change\nvs. ", "page_label": "13", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2804764e-0d08-458a-b941-ec3b619cb0ba": {"node_ids": ["8d230fa4-278a-4ee2-a56f-1b0eee309acc", "48714758-3b4d-420c-a446-7b1d469f7352", "11b1a9e1-10c4-448e-aca2-50a203f3643b"], "metadata": {"window": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n 14", "original_text": "litigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(113,920 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(113,920 )\u00a0\u00a0(113,920 )\u00a0\u00a0(6,692 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(107,228 )\u00a0\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,282 )\u00a0\u00a044,282 \u00a0\u00a0\u00a044,282 \u00a0\u00a0\u00a0(4,355 )\u00a0\u00a0(890 )\u00a0\u00a047,747 \u00a0\u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(226,964 )\u00a0\u00a0226,964 \u00a0\u00a0\u00a0226,964 \u00a0\u00a0\u00a06,034 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0220,930 \u00a0\u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,243 )\u00a0\u00a0(136,588 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0130,345 \u00a0\u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.54% \u00a03.05%\nOperating expenses \u00a02.37% \u00a01.87%\nOperating income \u00a01.16% \u00a01.18%\n________________________________________\n1\u00a0Includes $127.6\u00a0million of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 UK\u00a0 tax\u00a0 reform,\u00a0 $9.0\u00a0million\u00a0 of\u00a0 expense\u00a0 relating\u00a0 to\u00a0 Swiss\u00a0 tax\u00a0 reform,\u00a0\nand $6.2\u00a0million\u00a0 of\u00a0 income\u00a0 on\u00a0 the\u00a0 currency remeasurement of the related deferred tax assets, which is recorded within\nOther (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n", "page_label": "14", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bd9c2d22-daf1-4438-92c9-2c5e663f9a3f": {"node_ids": ["74ab59e6-c45c-44e8-9883-ff2d66c406f6", "943cd21a-56ab-4d4e-a5fe-460dfd36b099"], "metadata": {"window": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income T axes\u00a0Income T ax \nExpense \u00a0Net Loss \n (Income) \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \nto ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$6,310,808 \u00a0\u00a0$4,398,949 \u00a0\u00a0$1,911,859 \u00a0\u00a0$1,800,717 \u00a0\u00a0$432,853 \u00a0\u00a0$36,219 \u00a0\u00a0$1,404,083 \u00a0\u00a0$6.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(487 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,348 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey\nhighly\ninflationary\nimpact \u00a0\u00a027,618 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a027,618 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a033,423 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(37,668 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,668 )\u00a0\u00a0(37,668 )\u00a0\u00a0(10,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(27,668 )\u00a0\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(231,866 )\u00a0\u00a0231,866 \u00a0\u00a0\u00a0231,866 \u00a0\u00a0\u00a061,555 \u00a0\u00a0\u00a0(4,092 )\u00a0\u00a0166,219 \u00a0\u00a0\u00a00.79 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(209,234 )\u00a0\u00a0209,234 \u00a0\u00a0\u00a0209,234 \u00a0\u00a0\u00a045,836 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0163,398 \u00a0\u00a0\u00a00.77 \u00a0\u00a0\n15", "original_text": "\u00a0\u00a0Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b3be76cb-f655-46f6-be0f-bc2b34951518": {"node_ids": ["c405952f-34bc-4b6b-923c-c25fa9a2cf50", "57c985b6-049c-49ba-9dbd-9df197aabd9d"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a038.0 %\u00a0\u00a048.4 %\u00a0\u00a023.9 %\u00a0\u00a023.6 %\u00a0\u00a019.0 %\u00a0\u00a0 \u00a0\u00a025.0 %\u00a0\u00a022.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.56% \u00a03.55%\nOperating expenses \u00a02.48% \u00a02.19%\nOperating income \u00a01.08% \u00a01.37%\n________________________________________\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale\nof\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(59,973 )\u00a0\u00a0(13,193 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,780 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,316 \u00a0\u00a0\u00a0(26,158 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,474 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$6,298,923 \u00a0\u00a0$3,876,967 \u00a0\u00a0$2,421,956 \u00a0\u00a0$2,262,962 \u00a0\u00a0$471,427 \u00a0\u00a0$(8,037 )\u00a0$1,783,498 \u00a0\u00a0$8.43 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "16", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "73efb85c-f47a-44ee-bd17-6ce84ee08a14": {"node_ids": ["e7c622d3-98d4-4b5b-8496-d934757d4524", "9987be0f-695b-4e3c-81c0-2330f8489afe", "660f6b69-2822-4b5a-a541-a5660695f751", "7061d1a0-97af-4bd1-b23a-9cacf5cad9b1"], "metadata": {"window": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross\u00a0Pr ofit\u00a0\u00a0Operating \n Expenses \u00a0\u00a0\u00a0Operating \nIncome \u00a0\u00a0Income Befor e \nIncome T axes \u00a0Income T ax \nExpense \u00a0\u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests\u00a0 \u00a0Net Income \n Attributable \nto ABC \u00a0 \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(147,432 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(147,432 )\u00a0\u00a0(147,432 )\u00a0\u00a0(15,266 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(132,166 )\u00a0\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(160,565 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(160,565 )\u00a0\u00a0(160,565 )\u00a0\u00a0(16,625 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(143,940 )\u00a0\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(94,289 )\u00a0\u00a094,289 \u00a0\u00a0\u00a094,289 \u00a0\u00a0\u00a03,043 \u00a0\u00a0\u00a0(1,764 )\u00a0\u00a089,482 \u00a0\u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\n17", "original_text": "1\u00a0Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax\nassets, which is recorded within Other (Income) Loss, Net.\n\u00a0\u00a0\u00a0\n", "page_label": "17", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9829c99f-a04e-407c-9935-6fec97bb62ea": {"node_ids": ["b10782ed-de35-411d-acb5-49df0f9d0d92", "980461ff-52e3-493c-9a8c-dc68adaf1289", "62d566a0-688d-4083-a6b1-02004be6a552", "c437a22c-6975-4875-bfd4-cc9bc1b88740"], "metadata": {"window": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n 2\u00a0Includes $127.6\u00a0million of expense relating to UK tax reform, $64.0\u00a0million of expense relating to Swiss tax reform, and a\n$1.1\u00a0million loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income)\nLoss, Net.\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n18", "original_text": "and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(375,501 )\u00a0\u00a0375,501 \u00a0\u00a0\u00a0375,501 \u00a0\u00a0\u00a036,502 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0338,999 \u00a0\u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a01,086 \u00a0\u00a0\u00a0(191,607 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0192,693 \u00a0\u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1\u00a0Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n\u00a0\u00a0\u00a0\n", "page_label": "18", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "26fe9012-9886-4bfe-9e07-2a2d8815347e": {"node_ids": ["0b45935b-531f-42ae-940b-d1870c64919a", "b454b7d8-fdeb-4ba8-9816-c8bf24f16355", "7159f84b-434e-4b21-8543-0e12ccccd01f"], "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$53,389,345 \u00a0\u00a0$50,375,842 \u00a0\u00a06.0%\nInternational Healthcare Solutions \u00a0\u00a06,676,726 \u00a0\u00a0\u00a03,030,769 \u00a0\u00a0120.3%\nIntersegment eliminations \u00a0\u00a0(1,470 )\u00a0\u00a0(916 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$60,064,601 \u00a0\u00a0$53,405,695 \u00a0\u00a012.5%\n\u00a0 \u00a0Three Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$579,927 \u00a0\u00a0$529,790 \u00a0\u00a09.5%\nInternational Healthcare Solutions \u00a0\u00a0176,272 \u00a0\u00a0\u00a0100,831 \u00a0\u00a074.8%\nTotal segment operating income \u00a0\u00a0756,199 \u00a0\u00a0\u00a0630,621 \u00a0\u00a019.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(23,070 )\u00a0\u00a0113,920 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(74,408 )\u00a0\u00a0(44,282 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(67,870 )\u00a0\u00a0(226,964 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$487,297 \u00a0\u00a0$620,727 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f3836303-9cf4-4bc8-a48e-9d167c85aa93": {"node_ids": ["681b15af-3529-4336-8be3-32ef122ac854", "a7b28925-b5d8-4ed5-bd2f-43e332697f3b", "c8f8efb0-67ec-4957-a87f-c7144aac9a1d"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.49 %\u00a0\u00a02.44 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.40 %\u00a0\u00a01.38 %\u00a0\u00a0\nOperating income \u00a0\u00a01.09 %\u00a0\u00a01.05 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.05 %\u00a0\u00a013.20 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.41 %\u00a0\u00a09.87 %\u00a0\u00a0\nOperating income \u00a0\u00a02.64 %\u00a0\u00a03.33 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.36 %\u00a0\u00a03.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.54 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a00.81 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.05 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.18 %\u00a0\u00a01.87 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.26 %\u00a0\u00a01.18 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c7ee99bb-dccc-489b-8b3e-724db5cfd5e8": {"node_ids": ["43e64f46-ac7f-486d-a95f-54f81f6f95fe", "ce7bb7a9-180a-4acf-8ab0-c48c06679df0", "58ad214b-c37b-4aae-9480-27541a1413e7"], "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$157,311,755 \u00a0\u00a0$150,114,010 \u00a0\u00a04.8%\nInternational Healthcare Solutions \u00a0\u00a020,104,199 \u00a0\u00a0\u00a04,964,112 \u00a0\u00a0305.0%\nIntersegment eliminations \u00a0\u00a0(3,097 )\u00a0\u00a0(1,700 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$177,412,857 \u00a0\u00a0$155,076,422 \u00a0\u00a014.4%\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,878,556 \u00a0\u00a0$1,750,432 \u00a0\u00a07.3%\nInternational Healthcare Solutions \u00a0\u00a0543,400 \u00a0\u00a0\u00a0203,663 \u00a0\u00a0166.8%\nTotal segment operating income \u00a0\u00a02,421,956 \u00a0\u00a0\u00a01,954,095 \u00a0\u00a023.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0147,432 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a037,668 \u00a0\u00a0\u00a0160,565 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(27,618 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(231,866 )\u00a0\u00a0(94,289 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(209,234 )\u00a0\u00a0(375,501 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,911,859 \u00a0\u00a0$1,792,302 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n21", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fd198f88-d159-45e9-9821-c88681c39a87": {"node_ids": ["9a9fbaa8-f505-4125-b6b9-aa697f8e4b09", "b6be4fa7-bcae-45bc-a61f-481f2c8d5687", "f723193e-0af3-4c4b-854c-147a08cf6425"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.59 %\u00a0\u00a02.52 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.35 %\u00a0\u00a0\nOperating income \u00a0\u00a01.19 %\u00a0\u00a01.17 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.09 %\u00a0\u00a015.81 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a011.71 %\u00a0\u00a0\nOperating income \u00a0\u00a02.70 %\u00a0\u00a04.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.56 %\u00a0\u00a03.14 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.48 %\u00a0\u00a01.99 %\u00a0\u00a0\nOperating income \u00a0\u00a01.08 %\u00a0\u00a01.16 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.55 %\u00a0\u00a02.94 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.68 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.37 %\u00a0\u00a01.26 %\u00a0\u00a0\n\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n22", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "22", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bca54e88-b0ed-4801-8b53-81c24cf54653": {"node_ids": ["30e55dd6-9506-4d1c-a89d-5cfc31543137"], "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23", "original_text": "(unaudited)\n\u00a0\n\u00a0 June 30, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,034,233 \u00a0$2,547,142\nAccounts receivable, net \u00a018,624,104 \u00a0\u00a018,167,175\nInventories \u00a015,823,360 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,565,883 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0696,946 \u00a0\u00a01,448,383\nTotal current assets \u00a039,744,526 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,104,765 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,240,098 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0252,379 \u00a0\u00a0290,791\nOther long-term assets \u00a01,831,862 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,173,630 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $39,305,668 \u00a0$38,009,954\nOther current liabilities \u00a02,427,076 \u00a0\u00a03,048,474\nShort-term debt \u00a01,421,566 \u00a0\u00a0300,213\n23", "page_label": "23", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "70c46885-d0c7-4811-9a6b-6bffb9724193": {"node_ids": ["97add506-dddf-474d-95e0-ec1a2cfb1d03"], "metadata": {"window": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24", "original_text": "Total current liabilities \u00a043,154,310 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,640,131 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0306,356 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,612,325 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,033,018 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,909,626 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0517,864 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,173,630 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Nine Months Ended June 30,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,367,864 \u00a0\u00a0$1,108,160 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0704,628 \u00a0\u00a0\u00a0599,953 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and\ndivestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,550,962 )\u00a0\u00a0(116,845 )\nInventories \u00a0(712,849 )\u00a0\u00a0(594,708 )\n24", "page_label": "24", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a78e43b3-387a-4394-9d6d-d884c4293b00": {"node_ids": ["b199cbea-a9f4-4a1c-8d86-a50ea8a8f97e"], "metadata": {"window": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25", "original_text": "Accounts payable \u00a02,074,612 \u00a0\u00a0\u00a0242,419 \u00a0\nOther, net \u00a0(344,675 )\u00a0\u00a0417,790 \u00a0\nNet cash provided by operating activities \u00a01,538,618 \u00a0\u00a0\u00a01,656,769 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(322,732 )\u00a0\u00a0(273,407 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0(5,536,717 )\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0258,082 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a0(4,899 )\u00a0\u00a02,516 \u00a0\nNet cash used in investing activities \u00a0(193,707 )\u00a0\u00a0(5,970,228 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(576,303 )\u00a0\u00a02,620,315 \u00a0\nPurchases of common stock  1 \u00a0(248,422 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a083,954 \u00a0\u00a0\u00a0164,297 \u00a0\nCash dividends on common stock \u00a0(295,239 )\u00a0\u00a0(274,041 )\nOther, net \u00a0(43,309 )\u00a0\u00a0(30,965 )\nNet cash (used in) provided by financing activities \u00a0(1,079,319 )\u00a0\u00a02,397,456 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(33,056 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified\nwithin assets held for sale \u00a0232,536 \u00a0\u00a0\u00a0(1,916,003 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0\u2014 \u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0231,926 \u00a0\u00a0\u00a0(1,916,003 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n25", "page_label": "25", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "983de150-ea96-4f85-8bcd-ed58dd552e45": {"node_ids": ["eeed0154-ced6-424c-995d-5ddaf9936346", "066b29a3-d340-4488-bbfd-ef7c7d89aab1", "af05938a-4412-4054-b7f7-4e9ce289fd22", "e0372218-5f0a-43ae-b391-45eb9872fb9c", "dbcf49ca-2ac2-4d1d-bdb6-ed9cb946600e", "7c0a0cf8-52f3-4d35-a0f9-3d7f85b9b5eb", "ae4f1d22-e999-4dde-8da5-31aa7bfdd038", "c3bfdfe5-83bd-48bf-b808-3d0fdb16a9e0", "e3573c5d-c86b-4552-9cee-2d244b81992d", "38ee4568-2a8c-4a8e-9f45-603626d2bc35", "fde6cd25-3e80-4a7e-9769-86fb792a6a81", "bf451dd7-3a8f-4105-8127-2c6e1b1bd58f", "9a62ed26-2b74-47f1-a9e1-f658a9baf57b", "5f2906c6-cbe6-4c26-8a5c-9c366383713c"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n 2\u00a0The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0June 30, \n 2022 \u00a0September 30,\n2021 \u00a0June 30, \n 2021 \u00a0September 30,\n2020\nCash and cash equivalents \u00a0$3,034,233 \u00a0$2,547,142 \u00a0$2,553,217 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0207,722 \u00a0\u00a0462,986 \u00a0\u00a0128,526 \u00a0\u00a0\u2014\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,099 \u00a0\u00a060,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,302,054 \u00a0$3,070,128 \u00a0$2,681,743 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $3,302,054 \u00a0\u00a0$2,681,743 \u00a0\n________________________________________\n1\u00a0Additional purchases made in June 2022 totaling $11.7 million cash settled in July 2022.\n", "page_label": "26", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ba8e296c-2fc1-42e3-91c6-e09d4308e68b": {"node_ids": ["42ecfccc-ac51-4321-b5c1-568409c02e78", "e6cb1bed-d046-4ce5-91d0-ed8c0950951c", "5b3aba64-ecf5-4df0-8c38-d52ad831f93a", "f3b21f29-1267-4df3-8be7-24377e08df43", "003178f7-47b5-4585-b7c2-99973fe1b8ed", "0f58e092-4bce-4d30-aae7-fb007091fb4b", "39790d1f-5f27-4266-a3f4-b9aca06a6bcc", "404433a7-4c42-4366-87df-55262b303f19", "79a6881b-9db1-417f-bca6-50d7dd3c8a95", "d0cbcf8f-53e0-4e73-97c2-68d957d69c71", "985ce36d-c2d2-4572-84b1-06e75c608228", "105bddc1-d9e9-454b-aa3b-39da03d600c8", "dcdbc5f5-bc70-4c9c-a434-449afb43eded", "29f88ae1-45df-4949-83e5-993ed9425dd1", "868f11d1-4f25-4349-834a-b5b315d75718", "3fb51fea-c351-4875-ae86-7d33a9e7969f", "5aaea41b-981a-45e4-81cc-476fb6b9b35d", "012b94d7-b545-4e2f-8924-1461379f939a", "06673be3-ff98-42cc-86eb-3931de30f08f", "1ec10203-c1df-4ca2-9534-66ff0798bc7f", "441ff1e8-9040-4768-84a9-ec493db5eb75", "7a51028a-cbe3-4204-8726-bbf5386d1d2d", "78574e59-df2a-4a41-bd91-bf0d29d1bd41", "c2f19a98-2126-4664-ae47-577f77e3862e"], "metadata": {"window": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, goodwill\nimpairment and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total\nrevenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the\noperating performance of the acquired companies. ", "original_text": "is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "27", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6576f10b-ddf9-4842-b900-87ada1a103d3": {"node_ids": ["0498d21e-f0d8-4c1c-9922-997ee07380fb", "0bf96be3-cc8b-4fad-a8de-e19d54a4b87e", "9568524e-3c39-4a11-a444-1cb5c42bac48", "06093286-67e4-411c-8302-e60aeb868b50", "19723a54-d622-4490-9f20-71a3e01ba1ae", "915a53af-1a9f-473b-8d16-a3754195b293", "388f355c-5288-4149-9022-5f2b7c26838c", "5f405c70-921b-43ce-922d-6b5c64717cf5", "6f3fb2ba-ad96-457a-9c29-969d5b6c794c", "83f2d32f-88bb-4910-bbf6-67d9a098a88b", "3bda9448-25cd-406a-89c3-bdc78f12c2b7", "85c4fb61-a143-47f3-b315-6806ad90f81c"], "metadata": {"window": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share.  Further, the per share impact of certain expenses\nrelating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share for the three and nine\nmonths ended June 30, 2022, and the per share impact of certain expenses relating to tax reform in Switzerland and the\nUnited Kingdom are also excluded from adjusted diluted earnings per share for the three and nine months ended June 30,\n2021.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share\nimpact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing\noperating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.  The\nCompany updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share. ", "original_text": "expense (benefits) primarily attributable to foreign valuation allowance adjustments for the nine months ended June 30, 2022\nand the income tax deduction recognized in connection with the permanent shutdown of PharMEDium for the nine months\nended June 30, 2021 are excluded from adjusted diluted earnings per share. ", "page_label": "28", "file_name": "CEN-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 234790, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}